Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and Cancer of Gastrointestinal Tract

imatinib mesylate has been researched along with Cancer of Gastrointestinal Tract in 641 studies

Research

Studies (641)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's188 (29.33)29.6817
2010's351 (54.76)24.3611
2020's102 (15.91)2.80

Authors

AuthorsStudies
Cai, Y; Cao, WT; Deng, YH; Ding, MM; Hu, HB; Ling, JY; Shi, LS; Wang, H; Wang, HM; Xie, XY; Yang, ZF; Zhang, JW; Zhao, YD1
Donmez, T; Gul, MO; Ozkara, S; Subasi, IE; Sunamak, O1
Arribas, J; Barretina, J; Carles, J; de Álava, E; Demetri, GD; Esteve, A; Fletcher, JA; García-Valverde, A; Gómez-Peregrina, D; Gut, M; Maurel, J; Olivares-Rivas, I; Pilco-Janeta, DF; Rosell, J; Rubió-Casadevall, J; Sayols, S; Serrano, C; Valverde, C1
Akçakaya, P; Bränström, R; Caramuta, S; Gangaev, A; Huang, WK; Larsson, C; Lui, WO; Shi, H; Yeh, CN; Zeljic, K1
Adesunkanmi, AO; Lawal, AO; Mustapha, B; Ndegbu, CU; Odunafolabi, TA; Olasehinde, O; Olorunsola, IS1
Mu, J; Sun, H; Sun, P; Sun, X; Zhao, Z1
Bruns, CJ; Fuchs, HF; Ghadimi, M; Schmidt, T1
Arima, J; Inomata, Y; Lee, SW; Shima, T; Takabe, K; Taniguchi, K; Tokumaru, Y; Uchiyama, K; Yoshida, K1
Devine, C; Ganeshan, D; Segaran, N; Wang, MX1
Cai, K; Chen, J; Du, X; Guo, L; Huang, L; Jiang, J; Jiang, X; Li, H; Lin, G; Liu, T; Peng, H; Tang, J; Ye, Y; Zhang, W1
Huang, PH; Jones, RL; Napolitano, A; Smith, MJ; Thway, K1
Bauer, S; Serrano, C1
Bruland, ØS; Fauske, L; Hompland, I; Wærstad, PH1
Antonescu, CR; Berger, MF; Biniakewitz, MD; Camacho, N; Chen, Y; Chi, P; Crago, AM; D'Angelo, SP; Dickson, MA; Francis, JH; Gounder, MM; Hwang, S; Kelly, CM; Keohan, ML; Lee, CJ; Martindale, M; Movva, S; Nacev, BA; Phelan, HT; Qin, LX; Rosenbaum, E; Singer, S; Tap, WD; Thornton, KA1
Basaran, A; Kurt, F; Ozlu, O; Yazar, BC1
Cao, H; Huang, C; Huang, P; Li, Q; Ma, X; Ni, B; Shen, Y; Tu, L; Wang, M; Xia, X; Yang, L; Zhang, Z; Zhao, E; Zhao, W; Zhu, C; Zhuang, C1
Burge, M; Chantrill, L; Desai, J; Foo, T; Goldstein, D; Karapetis, CS; Nagrial, A; Pavlakis, N; Price, TJ; Roy, AC; Segelov, E; Shapiro, J; Tebbutt, N; Yip, D; Zalcberg, J1
Borruso, L; D'Jamirze, A; Kotecha, K; Mittal, A; Samra, JS; Sharma, V1
Ahr, K; Senchak, J; von Mehren, M1
Artigas-Raventós, V; Asencio-Pascual, JM; Cantín-Blázquez, S; Fernández-Hernández, JA; García-Granero, E; García-Somacarrera, E; González-López, JA; Mendiola, M; Serrano, C; Varo-Pérez, E1
DeMatteo, RP; Schaefer, IM; Serrano, C1
Ali, AA; Amankulor, NM; Duensing, A; Kaczorowski, A; Lee, DM; Liu, C; Liu, L; Patil, SS; Presutti, LD; Rao, AV; Rausch, JL; Schneider, F; Shuda, M; Sun, A; Trent, PT1
Cho, H; Hirota, S; Kagimura, T; Kitagawa, Y; Komatsu, Y; Kondo, M; Kurokawa, Y; Nakahara, Y; Nishida, T; Ozaka, M; Sato, S1
Italiano, A1
Alves, GV; DE-Antoni, NM; Everling, EM; Grezzana-Filho, TJM; Isbert, BBM; Marchet, D1
Goggin, C; Huang, P; Jones, RL; Mahalingam, P; Napolitano, A; Smith, MJ; Stansfeld, A; Thway, K1
Bachet, JB; Mas, L1
He, X; Mu, M; Yin, Y; Zhang, H1
Chang, CF; Chen, JS; Chou, WC; Huang, WK; Wang, SY; Wu, CE; Yeh, CN1
Chen, Y; Dong, X; Huang, T; Mi, D; Shi, S; Wang, Q; Xiao, H; Zhang, H; Zhang, R1
Bozic, B; Jaros, D; Sebesta, C1
Chen, LT; Higashi, T; Huang, RY; Ichinose, Y; Nishida, T; Tsai, HJ; Yang, YH1
Heinrich, MC; Khosroyani, HM; Klug, LR1
Constantinidou, A; Jones, RL; Kucharczyk, MA; Sargsyan, A1
Blum, A; Brandstetter, S; Buchstaller, HP; Busch, M; Dorsch, D; Esdar, C; Glaser, N; Grädler, U; Linde, N; Petersson, C; Ruff, A; Schieferstein, H; Sherbetjian, E1
Del Prado, P; Feng, WA; Mazraani, M; Zeineddin, S1
Doi, T; Naito, Y; Nishida, T2
Cao, B; Li, J; Wang, B; Weng, Z; Xu, Z; Zhao, Y; Zhou, X1
Duyster, J; Follo, M; Illert, AL; Jilg, S; Jolic, M; Jost, PJ; Peschel, C; Philipp, U; Rassner, M; Scherer, F; von Bubnoff, N; Waldeck, S; Wehrle, J1
Bleckman, RF; Desar, IME; Gelderblom, H; Hollander, DD; IJzerman, NS; Mohammadi, M; Oosten, AW; Reyners, AKL; Steeghs, N1
Hu, K; Shu, M; Wang, X; Zhang, H1
Call, J; Evans, D; Garland, M; Hughes, TJ; Kaur, S; Knox, P; Lim, PT; Luedke, M; Rothschild, S; Scherzer, NJ; Tordella, C; Trent, J; Wojtkowiak, J1
Bai, R; Cao, X; Fan, Z; Li, S; Liang, N; Liu, A; Sun, J; Tian, J; Wang, M; Xiao, K; Yu, Y; Zhang, L; Zhang, S; Zhao, H; Zhao, S; Zhou, L1
Aasen, T; Angelini, S; Benuzzi, E; Coschina, E; Di Vito, A; Gorini, F; Hrelia, P; Monesmith, S; Morroni, F; Ravegnini, G; Serrano, C1
Hao, CY; Jia, WW; Li, CP; Liu, DN; Wang, HY; Wu, JH1
Hao, Y; Jia, J; Jiang, Q; Li, C; Liu, W; Lou, Z; Ma, X; Tao, K; Wang, T; Zeng, X; Zhang, P; Zhang, R; Zhao, F1
Jones, RL; Symcox, M1
Aploks, K; Da Dong, X; Dong, M; Gu, KW; Miller, K; Murdande, S; Rahimi-Ardabily, A; Zhang, B1
Feng, YD; Qiu, C; Yang, X1
Barysauskas, CM; Demetri, GD; Fletcher, JA; George, S; Kuang, Y; Leal, A; Mariño-Enríquez, A; Morgan, JA; Paweletz, CP; Phallen, J; Serrano, C; Triplett, O; Velculescu, VE; Wagner, AJ1
Bonvalot, S; Casali, P; Gronchi, A; Hohenberger, P; Litiere, S; Olungu, C; Rutkowski, P; Stoeckle, E; van Coevorden, F; Wardelmann, E1
Doi, T; Komatsu, Y; Kurokawa, Y; Naito, Y; Nishida, T; Ohkubo, S; Ozaka, M; Sawaki, A; Takahashi, T1
Barone, C; Bauer, S; Castellana, R; Crippa, S; Delgado Perez, JR; Fumagalli, E; Le Cesne, A; Melichar, B; Papai, Z; Prausova, J; Pustowka, A; Quiering, C; Reichardt, P; Schlemmer, M1
Beck, M; Chae, H; Kang, YK; Ma, J; Ryu, MH1
Adegoke, OO; Egbo, OH; Ogun, GO; Rahman, A1
Aickara, DJ; McBride, J; Morrison, B; Romanelli, P1
Achour, H; Bauer, S; Blay, JY; Choucair, K; Gelderblom, H; George, S; Heinrich, MC; Mehren, MV; Nemunaitis, J; Ruiz-Soto, R; Schöffski, P; Zalcberg, J1
Du, J; Han, Q; Liu, Y; Wang, R; Wang, S; Wang, SY; Xu, HT; Yang, P1
Chong, TH; Dong, Z; Guan, B; Peng, J; Sun, P; Wang, C; Yang, J1
Chai, L; Chen, J; Fletcher, JA; Huang, M; Li, X; Mariño-Enríquez, A; Ou, WB; Qiu, H; Quan, Y; Wu, Y; Yang, W; Zhu, C; Zhu, J1
Doki, Y; Fujimoto, M; Hirota, S; Ishida, T; Koh, M; Kurokawa, Y; Makino, T; Miyazaki, Y; Mori, M; Naka, T; Nakagawa, F; Nakajima, K; Nishida, T; Nishigaki, T; Obata, Y; Ohkawara, T; Ohkubo, S; Saito, Y; Serada, S; Sugase, T; Takahashi, T; Tanaka, K; Yamasaki, M1
Hirano, H; Hirota, S; Iwamoto, H; Katayanagi, S; Katsumata, K; Kawachi, S; Makuuchi, Y; Osakabe, H; Sumi, T; Tsuchida, A; Yokoyama, T1
Aida, A; Aigul, G; Elena, S; Firyuza, B; Ilmira, N; Ilshat, M; Natalia, A; Pavel, D; Refat, K; Sergei, B; Vera, G1
Han, Y; McLeod, HL; Nelson, RS; Tao, K; Wang, Y; Xiang, H; Yuan, Y; Zhang, M; Zhang, P; Zhou, H1
Ma, Z; Mu, J; Sun, P1
Hakim, N; Rehman, H; Saif, MW; Seetharamu, N; Sugarman, R1
Cai, Z; Fu, W; Pu, L; Shen, C; Wang, J; Wang, Y; Yin, X; Yin, Y; Zhang, B1
Aimone, P; Benson, C; Brandt, U; Doi, T; Gelderblom, H; George, S; Hertle, S; Jones, RL; Le Cesne, A; Leahy, M; Renouf, DJ; Schӧffski, P; Valverde Morales, C1
Aida, T; Miyazawa, K; Miyoshi, T; Ogasawara, T; Sato, S; Shiobara, M; Suda, K; Wakatsuki, K; Yamazaki, K; Yoshioka, S1
Guan, W; Shi, X; Tao, T; Wang, F; Wang, M; Wang, X; Xia, X; Yu, H1
Hasegawa, M; Ieta, K; Ishida-Yamamoto, A; Ishikawa, O; Shibusawa, K; Shimizu, A; Tamura, A1
Blay, JY; Bonvalot, S; Broto, JM; Casali, PG; Duffaud, F; Fumagalli, E; Gelderblom, HJ; Goldstein, D; Gronchi, A; Hohenberger, P; Italiano, A; Judson, IR; Kopp, HG; Kotasek, D; Le Cesne, A; Litière, S; Marréaud, S; Penel, N; Poveda Velasco, A; Rutkowski, P; Smithers, M; van Coevorden, F; Wardelmann, E; Zaffaroni, F1
Chen, W; Dong, Y; Huang, J; Jiang, S; Li, J; Li, Z; Liu, H; Sun, L; Wang, G; Wang, X; Yu, S1
Cai, GQ; Liao, GQ; Liu, HL; Liu, S; Liu, WH; Qi, J; Ren, F; Shi, W1
Accurso, V; Badalamenti, G; Bronte, E; Di Lisi, D; Macaione, F; Novo, G; Novo, S; Rinaldi, G; Russo, A; Siragusa, S1
Fujimoto, Y; Okada, T; Ueno, T; Uraoka, M; Yamamura, M1
Akamatsu, H; Furukawa, K; Imasato, M; Kado, T; Kishi, K; Mikamori, M; Ohtsuka, M; Saito, T; Suzuki, Y; Tanemura, M1
Al-Batran, SE; Alvegård, T; Bauer, S; Cameron, S; Eriksson, M; Hermes, B; Hohenberger, P; Jaakkola, P; Joensuu, H; Jost, PJ; Junnila, J; Kallio, R; Lindner, LH; Nilsson, B; Reichardt, A; Reichardt, P; Schütte, J; Sundby Hall, K; Wardelmann, E1
Ali, N; Benson, C; Blay, JY; Cousin, S; Dileo, P; Gelderblom, H; Italiano, A; Kasper, B; Kopeckova, K; LeCesne, A; Litiere, S; Marreaud, S; Menge, F; Mir, O; Nzokirantevye, A; Papai, Z; Schöffski, P; Vanden Bempt, I; Wardelmann, E; Wozniak, A; Zaffaroni, F1
Huang, W; Li, J; Li, X; Qiu, F; Wu, X; Yao, G; Zhang, J; Zhu, S1
Gennatas, S; Huang, P; Jones, RL; Smrke, A1
Dhillon, S1
Gheysen, M; Lehnert, S; Schöffski, P; Vanden Bempt, I; Vander Borght, S; Vanslembrouck, R1
Comandini, D; Damiani, A; Damiano, G; Grassi, M; Martelli, V; Prelaj, A; Rebuzzi, SE1
Beijnen, JH; Groenland, SL; Huitema, ADR; IJzerman, NS; Kerst, M; Koenen, AM; Rosing, H; Steeghs, N; van der Graaf, WTA1
Keung, EZ; Raut, CP; Rutkowski, P1
Copur, MS; Cushman-Vokoun, AM; Delaney, A; Lauer, S; Padussis, J; Talmon, GA; Wedel, W1
Anadkat, MJ; Chen, DY; Lewis, HA; Picus, J; Rosman, IS1
He, YL; Zhang, XH1
Gao, XD; Shen, KT; Sun, JY1
Kim, BJ; Kim, HJ; Kim, HS; Kim, JG; Park, JM; Park, JY1
Antonescu, CR; Balachandran, VP; Cavnar, MJ; Curtin, C; DeMatteo, RP; Gönen, M; Seier, K; Singer, S; Tap, WD1
Gomes, A; Mankoski, R; Miller, A; Nellesen, D; Norregaard, C; Proudman, D; Sullivan, E1
Gelderblom, H; Mohammadi, M1
Abe, O; Amemiya, S; Baba, A; Fujita, N; Gonoi, W; Hagiwara, A; Kawahara, T; Kurokawa, M; Kurokawa, R; Nakai, Y; Ota, Y; Yamaguchi, H1
Chi, P; Gutierrez Sainz, L; Kelly, CM1
Erfurt-Berge, C; Ronicke, M1
Blay, JY; Casali, PG; Duffaud, F; Fumagalli, E; Gelderblom, H; Goldstein, D; Gronchi, A; Hartmann, JT; Hohenberger, P; Italiano, A; Judson, IR; Kotasek, D; Le Cesne, A; Litière, S; Marréaud, S; Martin-Broto, J; Penel, N; Rutkowski, P; Velasco, AP; Wardelmann, E; Zalcberg, JR1
Akamaru, Y; Doki, Y; Eguchi, H; Kimura, Y; Koh, M; Kurokawa, Y; Makino, T; Miyazaki, Y; Motoori, M; Nakajima, K; Nishida, T; Takahashi, T; Tanaka, K; Wada, N; Yamasaki, M1
Al Hallak, MN; Al-Share, B; Alloghbi, A; Azmi, A; Kim, SH; Mohammad, RM; Philip, PA; Shields, AF; Uddin, H1
Billingsley, KG; Corless, CL; Heinrich, MC; Mayo, SC; Sheppard, BC; Sutton, TL; Walker, BS2
Ali Abuderman, AW; M Aldakheel, F1
Al-Bahrani, B; Al-Maqrashi, Z; Al-Moundhri, M; Al-Sawafi, Y; Burney, IA; Kumar, S; Lakhtakia, R; Mehdi, I; Qureshi, A; Taqi, KM1
Che, K; Gupta, A; Ma, S; Pobbati, AV; Rubin, BP1
Doki, Y; Eguchi, H; Ishida, T; Kimura, Y; Kurokawa, Y; Makino, T; Miyazaki, Y; Motoori, M; Nakahara, Y; Nakajima, K; Nishida, T; Ohnishi, H; Saito, T; Sato, S; Takahashi, T; Takeno, A; Tanaka, K; Tsuboyama, T; Yamamoto, K; Yamasaki, M; Yamashita, K1
Liu, Y; Sun, W; Wang, H; Ye, S; Zhu, G1
Cubedo, R; García Del Muro, X; López-Guerrero, JA; Martín-Broto, J; Martínez, V; Poveda, A; Romero, I; Serrano, C; Valverde, C1
Chang, J; Draexler, K; Madin-Warburton, M; Ngai, C; Pitcher, A; Tamoschus, D1
Blay, JY; Casali, PG; Fumagalli, E; Gronchi, A; Grünwald, V; Hogendoorn, P; Italiano, A; Judson, IR; Kerst, JM; Kotasek, D; Le Cesne, A; Leyvraz, S; Lindner, LH; Litière, S; Marreaud, S; Pousa, AL; Reichardt, P; Rutkowski, P; Schöffski, P; Sleijfer, S; van der Graaf, W; Verweij, J; Zalcberg, J1
Baniak, N; Lee, L; Young, S; Yu, D; Zhou, C1
Diepstraten, J; Gelderblom, H; Kouwen, S; Posthuma, WF; Swen, JJ; van Lammeren, D; Verboom, MC; Visser, L; Wilms, EB1
Chen, J; Chen, Z; Shen, C; Tang, S; Yang, J; Yao, Y; Yin, X; Yin, Y; Zhang, B1
Kykalos, S; Machairas, N; Sotiropoulos, GC; Stamopoulos, P1
Antonescu, C; Balachandran, VP; Bertagnolli, MM; DeMatteo, RP; Fairweather, M; Li, GZ; Raut, CP; Singer, S; Tap, W1
Carles, J; García-Valverde, A; George, S; Morales-Barrera, R; Olivares, D; Serrano, C; Suárez, C; Valverde, C1
Chen, XM; Huang, M; Qiu, HB; Sun, XW; Wang, XD; Yang, LF; Yuan, XH; Zhou, XJ; Zhou, ZW; Zhuang, W1
Burger, D; Colbers, A; Desar, IME; Gelderblom, H; Kweekel, DM; Lubberman, FJE; van der Graaf, WTA; van Erp, N; Wilmer, CM1
Cao, Z; Chen, W; Eilers, G; Fletcher, JA; He, Q; Kuang, Y; Li, HL; Meng, F; Ou, WB; Qiu, HB; Sheng, Q; Tu, Y; Wang, Y; Wu, Y; Zhang, R; Zhu, M1
Felisiak-Golabek, A; Kowalik, A; Lasota, J; Miettinen, M; Wang, ZF; Zięba, S1
Adenis, A; Barone, C; Bauer, S; Blay, JY; Bouché, O; Camozzi, M; Castellana, R; Comandone, A; Crippa, S; Del Muro, XG; Fumagalli, E; Grignani, G; Italiano, A; Joensuu, H; Le Cesne, A; Martin-Broto, J; Pousa, AL; Valverde, C; Weiss, C1
Boonstra, PA; Desar, I; Farag, S; Gelderblom, H; Geus-Oei, LF; Grunhagen, D; Reyners, AKL; Steeghs, N; van Coevorden, F; van der Graaf, WT1
Binia, S; Diumenjo, M; Fader, E; García, B; Ibarra, J; Sola, A1
Bovée, JVMG; Gelderblom, H; Guchelaar, HJ; Kloth, JSL; Mathijssen, RHJ; Reyners, AKL; Sleijfer, S; Steeghs, N; Swen, JJ; van der Straaten, T; Verboom, MC1
Aguilar, JG; Antonescu, CR; Balachandran, VP; Cavnar, MJ; DeMatteo, RP; Guillem, JG; Keohan, M; Nash, GM; Paty, PB; Singer, S; Tap, WD; Temple, L; Wang, L; Weiser, MR1
Benson, C; Chou, AJ; Magnan, H; Rutkowski, P1
Fan, LQ; Hao, YJ; Jia, N; Li, B; Li, Y; Liang, H; Liang, XB; Liu, Y; Ma, ZX; Shi, YN; Tan, BB; Wang, D; Wang, LL; Wang, LP; Wang, ZH; Zhang, L; Zhang, ZD; Zhao, Q; Zhao, XF1
Antonescu, CR; Balachandran, VP; Bowler, TG; Cross, JR; DeMatteo, RP; Liu, M; Loo, JK; Medina, BD; Moral, AJ; Param, NJ; Rossi, F; Vitiello, GA; Zeng, S; Zhang, JQ; Zhao, JN1
Doki, Y; Kurokawa, Y; Makino, T; Miyazaki, Y; Mori, M; Nakajima, K; Saito, Y; Takahashi, T; Takiguchi, S; Tanaka, K; Yamasaki, M1
Iwamatsu, K; Kimura, A; Kogure, N; Kuwano, H; Nakazawa, N; Ogata, K; Suzuki, M; Ubukata, Y; Yanai, M; Yanoma, T1
Ahmadou, I; Bah, A; Dembélé, BT; Diakité, I; Diallo, G; Dicko, MY; Kanté, L; Konaté, M; Koné, T; Togo, A; Traoré, A; Yoro Sidibé, B1
Cabezas–Palacios, MN; Fernández–Ruiz, M; Rodríguez–Zarco, E; Tato–Varela, S1
Büttner, R; Eriksson, M; Hartmann, W; Huss, S; Ihle, MA; Jeske, W; Joensuu, H; Merkelbach-Bruse, S; Reichardt, P; Schildhaus, HU; Sihto, H; Sundby Hall, K; Wardelmann, E1
Feng, JX; He, JP1
Astolfi, A; Biasco, G; Brandi, G; Castellani, G; do Valle, IF; Fiorentino, M; Gatto, L; Heinrich, MC; Indio, V; Nannini, M; Pantaleo, MA; Patterson, J; Remondini, D; Santini, D; Saponara, M; Tarantino, G; Urbini, M; von Mehren, M1
Bertagnolli, MM; Cavnar, MJ; DeMatteo, RP; Fairweather, M; Li, GZ; Raut, CP1
Bylina, E; Czarnecka, AM; Klimczak, A; Lugowska, I; Osuch, C; Rutkowski, P; Streb, J; Teterycz, P1
Boichuk, S; Dunaev, P; Galembikova, A; Mustafin, I; Valeeva, E1
Baker, LH; Bolejack, V; Chow, WA; Choy, E; Chugh, R; D'Amato, G; Forscher, CA; Ganjoo, KN; Loeb, DM; Okuno, S; Patel, S; Priebat, DA; Reinke, DK; Rushing, DA; Samuels, B; Schuetze, SM; Staddon, AP; Thomas, DG; von Mehren, M1
Collie, GW; Gunaratnam, M; Neidle, S; Parkinson, GN; Reszka, AP; Todd, AK1
Ainsua-Enrich, E; Arango, D; Arribas, J; Bazzocco, S; García-Valverde, A; Macaya, I; Martin, M; Navinés-Ferrer, A; Rodrigues, P; Sayós, J; Serrano, C; Serrano-Candelas, E1
Reichardt, P2
do Carmo, LL; Mendonça, LG; Yung, AA1
Dong, P; Li, F; Liu, S; Lv, W; Pan, L; Shu, Y; Yang, Z1
Gronchi, A; Tattersall, HL1
Gao, J; Li, J; Li, Y; Shen, L; Wu, X; Xu, W1
Chen, WS; Chen, YJ; Juan, CK; Yang, CS1
Ali, NS; Aloma, A; Aslam, MH; Hachem, H; Inayat, F; Saif, MW; Song, F1
Antonescu, CR; Chi, P; D'Angelo, SP; DeMatteo, RP; Dickson, MA; Francis, JH; Gounder, MM; Heinemann, MH; Hwang, S; Kelly, CM; Keohan, ML; Mcfadyen, C; Qin, LX; Shoushtari, AN; Singer, S; Sjoberg, A; Tap, WD1
Cai, W; Cao, J; Chen, H; Chen, Z; He, F; Hu, H; Li, W; Wang, Q; Wei, F; Wei, J; Yang, P; Yang, Z; Zhang, T; Zhong, J1
Arribas, J; Carles, J; Díaz-Beveridge, R; Durán, J; Estival, A; García-Del-Muro, X; Hernández-Losa, J; Hindi, N; Jiménez, L; Landolfi, S; Lavernia, J; Manzano, A; Martínez-Marín, V; Pajares, I; Pericay, C; Rubió-Casadevall, J; Safont, MJ; Sebio, A; Serrano, C; Valverde, C; Vicente-Baz, D; Vivancos, A1
Åhlén, J; Akçakaya, P; Berglund, E; Bränström, R; Gangaev, A; Ghaderi, M; Hajeri, P; Huang, WK; Larsson, C; Lee, L; Lui, WO; Zeljic, K1
Canbay, A; Franck, C; Franke, S; Haybaeck, J; Rosania, R; Venerito, M1
Berner, JM; Bjerkehagen, B; Boye, K; Bruland, ØS; Hall, KS; Hompland, I; Hølmebakk, T; Poulsen, JP; Revheim, ME; Stoldt, S; Wiedswang, AM1
Boichuk, S; Dunaev, P; Galembikova, A; Khromova, N; Kopnin, P; Micheeva, E; Novikova, M; Valeeva, E1
Araujo, DM; DeMatteo, RP; Espat, NJ; Maki, RG; Purkayastha, DD; Raut, CP; Trent, J; Williams, TF1
Bi, X; Cai, J; Chen, Q; Huang, Z; Li, C; Li, Z; Yang, H; Zhang, Y; Zhao, H; Zhao, J; Zhou, J1
Bjerkehagen, B; Boye, K; Hompland, I; Hølmebakk, T; Stoldt, S1
Kou, Y; Wang, Q; Yang, R1
Andersen, JL; Armstrong, SA; Bradner, JE; Chipashvili, O; Demetri, GD; Hagan, T; Hemming, ML; Lawlor, MA; Raut, CP; Scott, TG; Sicinska, E1
Baek, D; Christensen, P; Jung, M; Karakas, C; Ro, JY1
Boonstra, PA; Gietema, JA; Reyners, AKL; Schuuring, E; Ter Elst, A; Tibbesma, M1
Beck, M; Chae, H; Kang, YK; Kim, BS; Kim, CW; Kim, JH; Kim, KH; Na, H; Ryu, MH; Yoo, C; Yoo, MW; Yook, JH1
Gelderblom, H; Guchelaar, HJ; Kloth, JSL; Mathijssen, RHJ; Reyners, AKL; Sleijfer, S; Steeghs, N; Swen, JJ; Verboom, MC1
Cui, Y; Huang, Y; Li, Z; Song, Y; Wang, Y; Wu, X; Xia, L; Yi, M; Zhao, R; Zhou, Y; Zhuang, W1
Altimari, A; Astolfi, A; Casadio, R; Castellucci, P; Ceccarelli, C; De Leo, A; Di Scioscio, V; Fanti, S; Gatto, L; Gruppioni, E; Indio, V; Martelli, PL; Nannini, M; Pantaleo, MA; Pession, A; Ravegnini, G; Santini, D; Saponara, M; Tarantino, G; Urbini, M1
Bauer, S; Czaplinski, JT; Demetri, GD; Eilers, G; Fletcher, JA; George, S; Heinrich, MC; Ketzer, J; Mannan, AM; Mariño-Enríquez, A; McKinley, A; Presnell, A; Raut, CP; Rubin, BP; Serrano, C; Sicinska, E; Tao, DL; Yu, C; Zhu, M1
Akita, H; Asanuma, H; Hamamoto, Y; Ishida, T; Jinzaki, M; Kameyama, K; Kitaoka, S; Morita, S; Oya, M; Shinoda, K; Takahashi, R; Tamaki, S; Yoshida, T1
Bellera, CA; Blay, JY; Boidot, R; Bompas, E; Bouche, O; Duffaud, F; Esnaud, T; Geneste, D; Ghiringhelli, F; Isambert, N; Italiano, A; Le Loarer, F; Lucchesi, C; Mir, O; Penel, N; Toulmonde, M1
Boichuk, S; Dunaev, P; Galembikova, A; Khromova, N; Kopnin, P; Micheeva, E; Novikova, M1
Beck, MY; Kang, YK; Kim, JJ; Ma, JE; Ryu, MH; Yoo, C1
Barisella, M; Casali, PG; Colombo, C; Fiore, M; Frezza, AM; Fumagalli, E; Gronchi, A; Morosi, C; Radaelli, S; Tirotta, F1
Khoshnood, A1
Desar, IME; Kievit, W; van Erp, NP; Zuidema, S1
Ekert, K; Hinterleitner, C; Horger, M1
Li, C; Liu, W; Shi, L; Tao, K; Wan, W; Wang, G; Yang, W; Yin, Y; Zeng, X; Zhang, P1
Ikeda, H; Inaguma, S; Kato, H; Kobayashi, M; Kuwabara, Y; Lasota, J; Miettinen, M; Mitsui, A; Raffeld, M; Suzuki, S; Takahashi, S; Wakasugi, T1
Arora, A; Jamwal, KD; Kulkarni, AV; Sharma, MK1
Banerjee, S; Burgoyne, AM; de la Torre, J; Fanta, PT; Parry, L; Ramamoorthy, S; Scherzer, N; Sicklick, JK; Stuart, E; Wang, Y1
Flamourakis, M; Georgiou, G; Karmiris, K; Kazamias, G; Velegraki, M1
Abu Sammour, D; Erich, K; Findeisen, P; Geisel, A; Hohenberger, P; Hopf, C; Marsching, C; Marx, A; Rabe, JH; Ramallo Guevara, C; Schulz, S1
Alessandrino, F; Jagannathan, JP; Ramaiya, NH; Tirumani, SH1
Chang, HH; Chen, LT; Fletcher, JA; Hsueh, YS; Li, CF; Shan, YS; Sun, HS1
Almaazmi, H; Atallah, C; Efron, JE; Fang, SH; Lo, BD; Safar, B; Stem, M; Taylor, JP1
Gao, J; Li, J; Shen, L; Sun, N; Tian, Y; Yuan, J1
Hashikura, Y; Hirota, S; Isozaki, K; Kajimoto, N; Liu, NN; Matsuda, I; Nishida, T; Ohkouchi, M; Takahashi, T; Toh, Y1
Berner, JM; Bruland, ØS; Holm, R; Joensuu, H; Kristian, A; Malinen, E; Revheim, ME; Seierstad, T1
Patel, S2
Ba-Ssalamah, A; Bareck, E; Brodowicz, T; Eisterer, W; Häfner, M; Högenauer, C; Kastner, U; Kühr, T; Längle, F; Liegl-Atzwanger, B; Ploner, F; Schoppmann, SF; Widmann, G; Wrba, F; Zacherl, J1
Nishida, T; Tori, M; Yoshidome, K1
Pan, ZZ; Wu, XJ1
Dang, YZ; Gao, J; Li, J; Shen, L1
Chen, ZF; Chi, P; Guan, GX; Jiang, WZ; Liu, X; Lu, HS1
Bu, ZD; Ji, JF; Ji, X; Li, SX; Li, ZY; Shan, F; Wu, AW; Wu, XJ; Zhang, LH; Zong, XL1
Cao, H; Xu, J1
Ji, JF; Ji, X1
Beckett, R; Kumari, S; Sherriff, JM; Spooner, D1
Chen, MF; Chiang, KC; Fu, CJ; Jan, YY; Yeh, CN; Yen, TC1
DeMatteo, RP; Demetri, G1
Bryon, J; Needham, SJ; Nicolle, A; Panter, S; Speight, RA; Verrill, MW1
Jia, J; Lu, HS; Pan, YL; Tao, DY; Zheng, S1
Messingham, KN; Srikantha, R; Swick, BL1
Corless, CL; Hohenberger, P; Joensuu, H1
Antonescu, CR; Ballman, K; DeMatteo, R; Engel, LS; McCall, L; O'Brien, KM; Orlow, I1
Belgaumkar, AP; Cananzi, FC; Lorenzi, B; Mudan, S1
Al-Barrak, J; Cheung, WY1
Lopez, NE; Sicklick, JK1
Aiba, S; Kagimoto, Y; Kikuchi, K; Mizuashi, M1
Gelderblom, H; Gray, E; Majer, IM; van den Hout, WB; Verheggen, BG1
Fujisawa, T; Matsumoto, Y; Nishizawa, A; Takata, M1
Chen, LT; Chen, TS; Chiang, NJ; Hsueh, YS; Ko, CH; Li, CF; Lin, CL; Shan, YS; Shih, NY; Wang, LM; Yen, CC1
Dimitrova, V; Taneva, I1
Antonescu, CR; Ballman, KV; Brennan, MF; Corless, C; DeMatteo, RP; Demetri, GD; Kolesnikova, V; Maki, RG; McCarter, MD; Norton, J; Owzar, K; Pisters, PW; von Mehren, M1
De Giorgi, U1
Claxton, Z; Malik, V; Mongan, AM; Muldoon, C; O'Toole, D; Ravi, N; Reynolds, JV; Rowley, S1
Akça, Z; Büyükçelik, A; Kaya, N; Mutlu, H1
Blay, JY; Joensuu, H; Reichardt, P1
Beck, MY; Kang, YK; Ryoo, BY; Ryu, MH; Yoo, C; Yoon, S1
Lyseng-Williamson, KA1
Akasbi, Y; Arifi, S; Brahmi, SA; El Mesbahi, O; El Mrabet, FZ; Mellas, N; Mernisi, FZ1
Jacene, H; Jagannathan, JP; Krajewski, KM; Ramaiya, NH; Shinagare, AB; Tirumani, SH1
Binot, E; Büttner, R; Hartmann, W; Hohenberger, P; Huss, S; Kleine, MA; Künstlinger, H; Loeser, H; Merkelbach-Bruse, S; Mittler, J; Reichardt, P; Schildhaus, HU; Wardelmann, E1
Benson, C; Cananzi, FC; Judson, I; Lorenzi, B; Mudan, S1
Blay, JY; Joensuu, H; Le Cesne, A; Reichardt, P1
Adenis, A; Amela, EY; Blay, JY; Bui-Nguyen, B; Cassier, PA; Chauzit, E; Clisant, S; Fournier, C; Italiano, A; Molimard, M; Penel, N; Ray-Coquard, I; Tresch-Bruneel, E1
Bamboat, ZM; DeMatteo, RP2
Fang, Y; Gao, X; Hou, Y; Ling, J; Qin, J; Qin, X; Shen, K; Shi, Y; Sun, Y; Wang, C; Wang, H1
Wang, W; Xu, Z; Zhi, X; Zhou, X1
Jagannathan, JP; Krajewski, KM; Ramaiya, NH; Raut, CP; Shinagare, AB; Tirumani, SH1
Dobbs, B; Fischer, J; Frizelle, F; Ing, A; Lim, M; Siu, J; Wakeman, C1
Cambrosio, A; Keating, P1
Hwang, SR; Kim, HU; Lee, NR; Park, J; Song, KH; Yun, SK1
Butrynski, JE; D'Adamo, D; Demetri, GD; Fisher, GA; Ganjoo, KN; George, S; Kamaya, A; McMillan, A; Morgan, JA; Villalobos, VM; Wagner, AJ1
Ahlen, J; Akcakaya, P; Aluthgedara, W; Berglund, E; Bergquist, J; Bränström, R; Fröbom, R; Karlsson, F; Larsson, C; Lui, WO; Nilsson, IL; Ubhayasekera, SJ; Zedenius, J1
Allgayer, H; Hohenberger, P; Leupold, J; Nowak, K; Rotert, JV1
Belgaumkar, A; Benson, C; Cananzi, FC; Judson, I; Lorenzi, B; Mudan, S1
Girotti, P; Königsrainer, A; Kopp, HG; Ladurner, R; Rolinger, J1
Ahrens, M; Bauer, S; Bock, E; Grabellus, F; Grunewald, S; Hilger, RA; Hoiczyk, M; Mühlenberg, T; Nagarajah, J; Pink, D; Pustowka, A; Reichardt, A; Reichardt, P; Scheulen, ME; Schuler, M1
Bauer, S; Casali, PG; Cats, A; Fiore, M; Fumagalli, E; Gronchi, A; Hohenberger, P; Hoiczyk, M; Kerst, M; Miceli, R; Nguyen, BP; Nyckowski, P; Rutkowski, P; Siedlecki, JA; Treckmann, J; van Coevorden, F1
Cerullo, C; Fonte, C; Iori, A; Lunghi, A; Molinara, E; Neri, B; Pellegrini, E; Rediti, M1
Cao, H; Gu, J; Ma, H; Ma, MZ; Qin, W; Yang, S; Yang, XM; You, H; Zhang, WM; Zhang, ZG; Zhang, ZZ; Zhuang, C1
Friedenberg, FK; Iorio, N; Sawaya, RA1
Devarajan, K; Godwin, AK; Hensley, H; Johnson, JR; Piwnica-Worms, D; Rink, L; von Mehren, M1
Liang, H1
Liang, X; Shi, Y2
Dai, Y; Gong, H; Jiang, L; Lin, H; Ning, L; Yan, W; Zhang, D; Zhang, M; Zhou, Y1
Cai, M; Cui, Q; Deng, J; Liang, H; Liu, N; Pan, Y; Wang, B; Wang, X; Zhang, L; Zhang, R1
Cao, H; Du, CY; He, YL; Jie, ZG; Liang, XB; Shi, YQ; Song, C; Wang, YP; Yan, ZS; Zhou, Y1
Jones, RL1
Adisa, AO; Alatishe, OI; Anomneze, EE; Ayansanwo, AO; Badmos, K; Bolarinwa, RA; Durosinmi, MA; Lawal, OO; Ojo, OS; Oyekunle, AA; Salawu, L1
DeCaprio, JA; Duensing, A1
Conley, AP; Gauthier, G; Guerin, A; Keir, CH; Sasane, M; Schwiep, F; Wu, EQ1
Bartsch, DK; Fendrich, V1
Cao, H; Tu, L; Wang, CJ; Wang, M; Xu, J; Zhang, ZG; Zhang, ZZ; Zhao, WY1
Ko, AH; Simko, JP; Walker, EJ1
Chung, KM; Lai, EC; Lau, SH; Lau, WY1
Gao, Y; Liu, X; Ma, Y; Shen, Q; Shi, X; Yang, W; Yu, J; Zhang, Q; Zhao, Z; Zhu, K1
Hayakumo, T; Ikura, Y; Iwai, Y; Kadota, C; Shigaki, Y1
Aihara, R; Ando, H; Fukuchi, M; Haga, N; Kimura, A; Kogure, N; Kuwano, H; Mochiki, E; Ogata, K; Ohno, T; Ojima, H; Suzuki, M; Toyomasu, Y; Uchida, N; Yokobori, T1
Chen, JS; Chen, TW; Chen, YY; Cheng, CT; Chiang, KC; Hsu, CC; Jan, YY; Liu, YY; Tsai, CY; Tseng, JH; Wu, CE; Yeh, CN; Yeh, TS1
Balachandran, VP; DeMatteo, RP1
Åhlen, J; Akçakaya, P; Berglund, E; Bränström, R; Caramuta, S; Ghaderi, M; Larsson, C; Lui, WO; Östman, A1
Liu, K; Wen, Y; Wu, L; Xiong, L; Yao, H; Zhang, Z1
Cao, H; Liu, Q; Qiu, WQ; Shen, YY; Tu, L; Wang, CJ; Wang, M; Xu, J; Zhang, Y1
Beck, MY; Kang, YK; Kim, EY; Koo, DH; Lee, SS; Na, YS; Ryoo, BY; Ryu, MH; Shin, JG1
Belgaumkar, A; Cananzi, FC; Lorenzi, B; Mudan, S1
Abou Al-Shaar, H; Abu-Zaid, A; Amin, T; Azzam, A; Solimanie, S1
Chen, H; Chen, J; Chen, Z; Shen, C; Yin, Y; Zhang, B1
Amadori, D; Bongiovanni, A; Calpona, S; Cavaliere, D; De Vita, A; Foca, F; Gunelli, E; Ibrahim, T; La Manna, F; Liverani, C; Mercatali, L; Oboldi, D; Pieri, F; Ricci, M; Riva, N1
Hirano, H; Kawakami, T; Kimura, Y; Kurata, Y; Miyagi, Y; Nagata, K; Nagata, T; Sakuma, Y; Suzuki, Y1
Boglione, A; Comandone, A1
Demetri, GD; Doi, T; Kanda, T; Komatsu, Y; Kuss, I; Nishida, T; Sawaki, A; Yamada, Y1
Blay, JY; Casali, PG; Dei Tos, AP; Le Cesne, A; Reichardt, P1
Chacón, M; Eleta, M; Espindola, AR; Méndez, G; Pupareli, C; Roca, E; Rojo, S1
Bencsikova, B; Bortlicek, Z; Brabec, P; Jureckova, A; Kocak, I; Kocakova, I; Krejci, E; Spelda, S; Strenkova, J; Vyzula, R1
Albegova, ZhK; Kanaev, PM; Kazani, Z; Kharitonov, SV; Myrksin, SA; Plotnikova, NA; Sabirov, AKh; Singkh, RB1
Kang, YK; Kim, BS; Koh, YW; Park, HJ; Park, YS; Ryoo, BY; Ryu, MH; Yoo, C; Yook, JH1
Casali, PG; Cioffi, A; Gibbs, E; Goldstein, D; Joensuu, H; Kanjanapan, Y; Lee, CK; Lord, SJ; Maki, RG; Mcarthur, G; Rutkowski, P; Verweij, J; Yip, D; Zalcberg, J1
Andoh, A; Bamba, S; Ban, H; Hirota, S; Imaeda, H; Inatomi, O; Murata, S; Nishida, A; Nishimura, T; Sasaki, M; Shioya, M1
Antonescu, CR; Beckman, MJ; Besmer, P; Cohen, NA; Crawley, MH; DeMatteo, RP; Green, BL; Greer, JB; Kim, TS; Rossi, F; Santamaria-Barria, JA; Seifert, AM; Sorenson, EC; Zeng, S1
Pilotte, AP1
He, Y; Zhang, X1
Boccardi, V; Marano, L; Marrelli, D; Roviello, F1
Aloia, TA; Brudvik, KW; Conrad, C; Cormier, JN; Feig, BW; Hunt, KK; Patel, SH; Roland, CL; Torres, KE; Vauthey, JN1
Irie, M; Kagawa, Y; Miyoshi, T; Nagata, N; Ohtake, Y; Suzuki, H; Takeuchi, Y; Yamagami, T1
Abdel-Rahman, O; Fouad, M1
Choi, H; Jang, BH; Ji, JS; Kim, BG; Kim, BW; Kim, JS; Lim, KJ; Park, SM1
Chen, H; Chen, J; Chen, Z; Han, L; Shen, C; Tang, S; Yin, Y; Zhang, B1
Angelini, S; Astolfi, A; Biasco, G; Hrelia, P; Nannini, M; Pantaleo, MA; Ravegnini, G; Sammarini, G1
Bauer, S; Joensuu, H1
Blay, JY; Hirota, S; Kang, YK; Kitagawa, Y; Nishida, T1
Kato, S1
Hirota, S; Ishikawa, T; Kanda, T; Kosugi, SI; Naito, T; Ueki, K; Wakai, T1
Ahmad, A; Katz, SC; Libbey, NP; Somasundar, P1
Blay, JY; Levard, A1
Hoang, U; Khan, U; Mehta, VR; Rachshtut, M1
Al-Batran, SE; Alvegård, T; Bauer, S; Bono, P; Eriksson, M; Hartmann, JT; Hohenberger, P; Joensuu, H; Junnila, J; Kallio, R; Nilsson, B; Pink, D; Ramadori, G; Reichardt, A; Reichardt, P; Schlemmer, M; Sihto, H; Sundby Hall, K; Wardelmann, E1
Deutsch, JM; Milhem, M1
Adenis, A; Blay, JY; Broto, JM; Casali, PG; Dei Tos, AP; Duffaud, F; Fumagalli, E; Gelderblom, H; Goldstein, D; Gronchi, A; Hartmann, JT; Hohenberger, P; Italiano, A; Judson, IR; Kotasek, D; Le Cesne, A; Litière, S; Marréaud, S; Poveda Velasco, A; Rutkowski, P; van der Graaf, WT; Zalcberg, JR1
Cao, X; Hu, J; Lai, S; Luo, X; Wang, G; Wang, J; Xia, X1
Fujita, J; Hirota, S; Imamura, H; Kishi, K; Nishida, T; Sato, S; Takagi, M; Takahashi, T; Tsujinaka, T; Yamamoto, K1
Huang, JS; Pi, ZM; Yu, MY; Zhang, LY1
Ivan, ME; Komotar, RJ; Shah, AH; Theodotou, CB1
Benjamin, RS; Casali, PG1
Adenis, A; Bertucci, F; Blay, JY; Bui-Nguyen, B; Chabaud, S; Chevreau, C; Coindre, JM; Cupissol, D; Domont, J; Duffaud, F; Emile, JF; Le Cesne, A; Patrikidou, A; Pérol, D; Ray-Coquard, I; Rios, M1
Demetri, GD; Kang, YK; Nam, BH; Ryoo, BY; Ryu, MH; Yoo, C1
Altimari, A; Biasco, G; Ceccarelli, C; Di Nunno, V; Di Scioscio, V; Fanti, S; Fiorentino, M; Gatto, L; Gruppioni, E; Nannini, M; Pantaleo, MA; Santini, D; Saponara, M; Tabacchi, E; Zompatori, M1
Doki, Y; Hamakawa, T; Hirota, S; Kurokawa, Y; Makino, T; Miyazaki, Y; Mori, M; Naka, T; Nakajima, K; Takahashi, T; Takiguchi, S; Wada, N; Yamasaki, M1
Fairweather, M; Keung, EZ; Raut, CP1
Dong, B; Gao, J; Gong, J; Li, J; Li, Y; Li, Z; Liu, N; Qi, C; Shen, L; Wu, J1
Abouelfath, A; Adenis, A; Blay, JY; Bompas, E; Bouché, O; Bouchet, S; Bui, B; Chevreau, C; Collard, O; Cupissol, D; Duffaud, F; Italiano, A; Lassalle, R; Le Cesne, A; Molimard, M; Moore, N; Poulette, S; Ray-Coquard, I; Rios, M; Titier, K1
Chen, Z; Li, J; Su, K; Zhang, H1
Fang, Y; Gao, X; Hou, Y; Ling, J; Qin, J; Qin, X; Shen, K; Shu, P; Sun, Y; Xue, A2
Nannini, M; Pantaleo, MA1
Gao, X; Hou, Y; Hu, Q; Jiang, D; Li, X; Lin, J; Liu, Y; Lu, S; Shen, K; Shi, Y; Tan, Y; Xu, C; Xu, J; Xue, A1
Azuma, M; Kanamaru, H; Koda, K; Kyo, K; Maema, A; Nakamura, T; Nishiyama, M; Okamoto, K; Shimamura, T; Shinmura, K; Shirakawa, M; Yokoyama, H1
Asif, S; Gupta, G; Gupta, N; Mehta, A; Singh, S1
Delgado, S; Fernandez-Esparrach, G; Hessheimer, A; Jimenez, M; Lacy, AM; Momblan, D; Navarrete, A1
Alvegård, T; Bauer, S; Cameron, S; Eriksson, M; Hohenberger, P; Joensuu, H; Leinonen, M; Reichardt, A; Reichardt, P; Rejmyr Davis, M; Schütte, J; Sundby Hall, K1
de Jong, KP; de Wilt, JH; Nagtegaal, ID; Seesing, MF; Tielen, R; van Coevorden, F; van Hillegersberg, R; Verhoef, C1
Ando, T; Hosokawa, A; Kajiura, S; Nakada, N; Nanjyo, S; Sugiyama, T1
Hanazaki, K; Kitagawa, H; Kobayashi, M; Maeda, M; Munekage, E; Munekage, M; Namikawa, T; Obatake, M; Sakamoto, K; Yatabe, T1
Boscato, E; Cacciatore, M; Carraro, V; Dei Tos, AP; Dell'Orto, MC; Gallina, G; Gasparotto, D; Maestro, R; Mancini, C; Mandolesi, A; Mazzoleni, G; Niero, M; Pilozzi, E; Romeo, S; Rossi, S; Sbaraglia, M; Sessa, F; Sonzogni, A; Toffolatti, L1
Cheville, JC; Gleeson, FC; Henry, MR; Kerr, SE; Kipp, BR; Lazaridis, KN; Levy, MJ; Minot, DM; Tu, ZJ; Vasmatzis, G; Voss, JS1
Angelini, S; Hrelia, P; Ravegnini, G; Sammarini, G1
Chen, P; Li, Q; Ma, L; Røe, OD; Sun, L; Tao, R; Zhang, J; Zhi, X; Zhou, J1
Bauer, S; Corless, C; Falkenhorst, J; Fletcher, JA; Grunewald, S; Heinrich, M; Marino-Enriquez, A; Mühlenberg, T; Podleska, LE; Reis, AC; Schuler, M; Treckmann, J1
Fujita, J; Hirota, S; Masuzawa, T; Nishida, T; Sato, S; Takagi, M; Takahashi, T; Tsujinaka, T; Yamamoto, K; Yamashita, Y1
Patel, S; Schvartsman, G; Somaiah, N; Trinh, VA; Wagner, MJ; Zobniw, CM1
Luo, JR; Xiang, XJ; Xiong, JP1
Almenara, R; Lacy, A; Momblán, D; Navarrete, A1
Ambrifi, M; Bottoni, U; Calvieri, S; Clerico, R; Corsetti, P; Didona, D; Paolino, G1
Bins, S; de Bruijn, P; de Man, FM; Eechoute, K; Kloth, JS; Mathijssen, RH; Oosten, AW; Sleijfer, S1
Maki, RG; Martínez-Marín, V1
Hompes, D; Rutkowski, P1
Bai, J; Cai, KL; Chang, WL; Deng, R; Gao, JB; Liu, K; Shuai, XM; Tao, KX; Wang, GB; Zhang, P1
Kondo, T1
Angenendt, P; Diehl, F; Fredebohm, J; Holtrup, F; Löber, AK; Mehnert, DH; van Rahden, V1
Ha, HK; Kim, AY; Kim, HJ; Kim, JS; Lee, JS; Park, SH1
Albuquerque, C; Claro, I; Dias Pereira, A; Francisco, I; Lemos, MM; Limbert, M; Pereira da Silva, J; Santos, F; Vale Rodrigues, R1
Bardsley, MR; Burgoyne, AM; Chan, JC; Chmielecki, J; Gao, F; Harismendy, O; Kendrick, ML; Lee, TE; Leonard, SY; Mao, J; Morosini, D; Ordog, T; Ross, JS; Shi, E; Sicklick, JK; Siena, M; Syed, SA; Tang, CM; Wang, K1
Cheng, J; Den, J; Hong, N; Pan, F; Wang, H; Wang, Y; Wu, W; Zhang, C1
Chen, T; Chen, Z; Du, C; Feng, X; Huang, C; Li, G; Li, J; Li, R; Li, Y; Liu, X; Pan, F; Qiu, H; Sun, X; Tao, K; Yin, X; Yu, J; Zhang, B; Zhang, P; Zhao, Y; Zheng, G; Zhou, Y; Zhou, Z1
Ali, AA; Boichuk, S; Brown, MF; Duensing, A; Kuan, SF; Lee, DM; Liu, L; Liu, Y; Makielski, KR; Patil, SS; Rausch, JL; Taguchi, T1
Elzawahry, A; Furukawa, E; Hirota, S; Kato, M; Mimaki, S; Naka, T; Nakamura, H; Nakatsuka, R; Nishida, T; Nishigaki, T; Serada, S; Shibata, T; Takahashi, T; Tsuchihara, K1
Campan, M; Chopra, S; Martin, SE; Naritoku, W; Pettersson, J; Ward, PM; Wei, CH1
Fu, Y; Guo, L; Hao, H; Yang, G; Zhang, X1
Chandrashekar, L; Colombo, EA; Fontana, L; Gervasini, C; Gupta, D; Kate, V; Larizza, L; Rajappa, M; Rajendiran, KS; Sreenath, GS; Thappa, DM1
Baker, LH; Benjamin, RS; Blackstein, ME; Blanke, CD; Borden, EC; Corless, CL; Crowley, JJ; Demetri, GD; Fletcher, JA; Heinrich, MC; Maki, RG; Owzar, K; Priebat, DA; Rankin, C; Ryan, CW; Tap, WD; von Mehren, M1
Abongwa, HK; Ansaloni, L; Catena, F; Coccolini, F; DE Simone, B; DI Saverio, S; Nannini, M; Napoli, JA; Pantaleo, MA; Saponara, M; Sartelli, M1
Casali, PG; Fiore, M; Fumagalli, E; Gronchi, A; Palassini, E; Pennacchioli, E; Pilotti, S; Stacchiotti, S; Tamborini, E1
Ahrar, K; Ensor, J; Gupta, S; Hicks, ME; Kobayashi, K; Madoff, DC; Murthy, R; Szklaruk, J; Trent, JC; Wallace, MJ1
Araujo, DM; Benjamin, RS; Fan, D; Khakoo, AY; Lenihan, DJ; Patel, SR; Patel, SS; Plana, JC; Trent, JC; Zhang, J1
Eriksson, B; Eriksson, C; Granberg, D; Gustavsson, B; Janson, ET; Kindmark, H; Kozlowacki, G; Larsson, G; Oberg, K; Skogseid, B; Welin, S1
Heinrich, MC1
Adenis, A; Bertucci, F; Blay, JY; Bui, BN; Chabaud, S; Chevreau, C; Cioffi, A; Cupissol, D; Duffaud, F; Emile, JF; Le Cesne, A; Pérol, D; Ray-Coquard, I; Rios, M1
Coyne, J; Janku, F; Kidney, D1
Berger, F; Bruns, C; Reichardt, P; Schinwald, N; Schlemmer, M1
Liang, ZY1
Al-Amri, AM; Al-Johi, KS; El-Hassan, AY; Shawarbi, MA1
Raut, CP; Winer, JH1
Kamiya, K; Kikuchi, H; Konno, H; Miyazaki, S; Ohta, M; Sakaguchi, T; Setoguchi, T; Yamamoto, M1
Hanazaki, K; Ikezoe, T; Nishioka, C; Taguchi, T; Takezaki, Y; Yang, J; Yokoyama, A1
Blanke, CD; Picus, J; Pisters, PWT; Sirulnik, A; Stealey, E; Trent, JC; von Mehren, M1
Dupart, J; Trent, JC; Zhang, W1
de Bruijn, P; Eechoute, K; Loos, WJ; Mathijssen, RH; Schiavon, G; Sleijfer, S; van der Bol, JM; Verweij, J1
Cervera, P; Fléjou, JF1
Guan, GX; Huang, HG; Jiang, WZ; Kang, DY; Lu, HS; Yang, YH1
Debiec-Rychter, M; Faa, G; Floris, G; Normant, E; Schöffski, P; Sciot, R; Van Looy, T; Wellens, J; Wozniak, A1
Cunningham, D; Yim, KL1
Reichardt, A; Reichardt, P1
Fu, H; Shi, YQ; Wang, CM; Wang, J; Zhao, GF1
Barnes, T; Reinke, D1
Patil, DT; Rubin, BP1
Barutca, S; Guney, E; Meydan, N; Sargin, G; Tanriverdi, O; Taskin, F; Unubol, M1
Akcakaya, MO; Aras, Y; Bilgic, B; Unal, OF; Unal, SN1
Akkus, M; Baykara, M; Benekli, M; Buyukberber, S; Coskun, U; Dane, F; Dursun, A; Gonul, II; Sevinc, A; Yildiz, R1
Adenis, A; Antonescu, CR; Blay, JY; Bompas, E; Bui, B; Casali, P; Cioffi, A; Coco, P; Coindre, JM; Debiec-Rychter, M; Duffaud, F; Isambert, N; Italiano, A; Keohan, ML; Le Cesne, A; Maki, RG; Rutkowski, P; Schöffski, P; Toulmonde, M1
Caram, MV; Schuetze, SM1
Colombo, C; Pisters, PW1
Kim, EJ; Zalupski, MM1
Akiyama, T; Hao, H; Hashikura, Y; Hirai, T; Hirota, S; Isozaki, K; Kajimoto, N; Nakai, M; Ohkouchi, M; Shiba, K; Tsukamoto, Y; Yamamura, M1
Barnett, CM; Corless, CL; Heinrich, MC1
Liang, J; Liu, ZM; Yu, Z1
Egorin, MJ; Mulder, KE; Sawyer, MB1
Andtbacka, RH; Benjamin, RS; Cano, P; Chan, BK; Chen, LC; Chen, LL; Chen, X; Choi, H; Frazier, ML; Gouw, L; Hill, HR; Jensen, P; Jimenez, A; Jones, KA; Lazar, AJ; Lin, P; Martins, T; Morton, K; Oyedeji, CO; Patel, S; Randall, RL; Rodesch, CK; Sang, H; Scaife, CL; Schumacher, J; Trent, JC; Ward, JH; Willmore, C; Zhang, H1
Maeda, Y; Nagashima, Y; Nakamura, M; Nishimura, T; Okada, T; Sakata, K; Setoguchi, M1
Chen, P; Shi, L; Zhao, W; Zong, L1
Janeway, KA; Weldon, CB1
Anania, MC; Bordoni, A; Conca, E; Frattini, M; Greco, A; Mazzucchelli, L; Miranda, C; Molinari, F; Nucifora, M; Pierotti, MA; Pilotti, S; Saletti, P; Tamborini, E1
Aggarwal, B; Ashraf, M; Biswas, J; Chakraborty, J; Choudhry, A; Jha, J; Majumder, S; Nayak, S1
Arya, S; Bal, M; Goel, M; Marda, SS; Mohandas, KM; Shetty, GS; Shrikhande, SV; Shukla, PJ; Suradkar, K1
Blay, JY; Le Cesne, A; Pérol, D1
Blay, JY; Bui-Nguyen, B; Demetri, GD; Galetic, I; Gelderblom, H; Hsu, Y; McArthur, GA; Reichardt, P; Rutkowski, P; Schlemmer, M; Yazji, S1
Blevins, M; de Vries, DJ; Eisenberg, B; Gatsonis, C; Godwin, AK; Huang, M; Melenevsky, Y; Rink, L; Sicks, J; Siegel, BA; Szot-Barnes, A; Van den Abbeele, AD; Yap, JT1
Mourad, F; Saad Aldin, E; Tfayli, A1
Call, J; Eickhoff, JC; Scherzer, N; Walentas, CD1
Brzeskwiniewicz, M; Bylina, E; Falkowski, S; Grzesiakowska, U; Klimczak, A; Kroc, J; Limon, J; Lugowska, I; Melerowicz, W; Mierzejewska, E; Nowecki, ZI; Osuch, C; Rutkowski, P; Siedlecki, JA; Switaj, T; Wasielewski, K; Woźniak, A1
Gürlich, R; Koldová, L; Kostka, R1
Al-Batran, SE; Alvegård, T; Bauer, S; Bono, P; Duyster, J; Eriksson, M; Hartmann, JT; Hohenberger, P; Joensuu, H; Kallio, R; Leinonen, M; Monge, OR; Nilsson, B; Pink, D; Ramadori, G; Reichardt, P; Sarlomo-Rikala, M; Schlemmer, M; Schütte, J; Sihto, H; Sundby Hall, K; Vehtari, A; Wardelmann, E1
Blanke, CD1
Braggio, D; Cruz, F; Cubero, D; Ferreira, CG; Gonçalves, R; Guimarães, DP; Linhares, E; Martinho, O; Oliveira, AT; Pimenta-Inada, HK; Reis, RM; Romano, S; Santos, AF; Small, I; Valadão, M; Vilhena, B1
Ajioka, Y; Hatakeyama, K; Hirota, S; Ishikawa, T; Kanda, T; Kosugi, S; Mashima, Y; Ohashi, M; Suzuki, S; Yajima, K1
Koshenkov, VP; Rodgers, SE1
Gronchi, A; Morosi, C; Reichardt, P; Wardelmann, E1
Bantel, H; Fenner, M; Ganser, A; Grünwald, V; Länger, F; Seidel, C1
Pericay Pijaume, C; Saigi Grau, E1
Lai, EC; Lau, SH; Lau, WY1
Cohen, MH; Johnson, JR; Justice, R; Pazdur, R1
Gao, J; Hong, J; Li, J; Shen, L1
Cao, XY; He, L; Jiang, J; Jin, MS; Suo, J; Wang, YP1
Blay, JY; Casali, PG; Cohen, DP; Demetri, GD; Garrett, CR; Goldstein, D; Harmon, CS; Huang, X; Hurwitz, HI; Le Cesne, A; Leyvraz, S; McArthur, GA; Paz-Ares, L; Pousa, AL; Schöffski, P; Shah, MH; Tassell, V; Verweij, J; Xu, QC1
Bauer, S; Debiec-Rychter, M; Fletcher, JA; Grabellus, F; Henze, J; Mühlenberg, T; Rubin, B; Schuler, M; Simon, S; Taeger, G; Taguchi, T; Treckmann, J1
Cubedo, R; Quintero, CB1
de Juan Ferré, A; Fernández, F; Garicano, F; Gutiérrez, L; Malaxetxebarria, S1
Ballesteros, J; Pulido, EG; Riquelme, A; Vaz, MÁ1
del Muro, XG; López, RL1
Bonastre, MT; Izquierdo, ME1
Casali, PG; Fumagalli, E; Gronchi, A1
Agulnik, M; Giel, JL1
Agayeva, A; Andican, A; Gökçal, F; Gülşen, F; Özben, V; Özden, F1
Huang, KE; Jia, J; Lu, HS; Pan, YL; Tao, DY; Wang, XJ; Zheng, S1
Dasanu, CA1
Chu, YC; Gong, NJ; Gu, J; Wong, CS1
Donohue, JH; Nagorney, DM; Okuno, SH; Que, FG; Zaydfudim, V1
Blay, JY; Boukovinas, I; Brodowicz, T; Broto, JM; Casali, PG; Decatris, M; Eriksson, M; Gelderblom, H; Joensuu, H; Kosmidis, P; Le Cesne, A; Pousa, AL; Reichardt, P; Schlemmer, M; Verweij, J1
Kochar, R; Pandey, R1
Carrió-Gasset, I; Fuertes-Cabero, S; García-Garzón, JR; Lomeña-Caballero, F; Moragas-Solanes, M; Ponce-López, A; Riera-Gil, E; Soler-Peter, M; Valls-Ferrusola, E1
Cohen, DP; Demetri, GD; George, S; Lechner, T; Li, S; Reichardt, P1
Buclin, T; Csajka, C; Decosterd, LA; Eap, CB; Guidi, M; Haouala, A; Leyvraz, S; Montemurro, M; Widmer, N1
Bang, YJ; Heo, DS; Im, SA; Kim, DW; Kim, JH; Kim, SH; Kim, TY; Kim, WH; Koh, Y; Lee, HE; Lee, SH; Oh, DY1
DeLuca, C; Haskes, C; Shenouda-Awad, N; Wrzesinski, S1
Wardelmann, E1
Joensuu, H3
Nishida, T; Ueshima, S; Wakasugi, M1
Bednarski, BK; Hunt, KK; Pisters, PW1
Aberger, F; Antonescu, CR; Beissbarth, T; Binder, C; Bleckmann, A; Dittmann, K; Dressel, R; Gruber, W; Guijarro, MV; Hahn, H; Heijmans, J; Hernando, E; Hogendoorn, PC; Nitzki, F; Pelczar, P; Rubin, BP; Schulz-Schaeffer, W; Taguchi, T; Uhmann, A; van den Brink, GR; van Dop, WA; Wienands, J; Wojnowski, L; Zibat, A1
Chang, HM; Im, SA; Jung, KH; Kang, BW; Kang, WK; Kang, YK; Kim, TW; Lee, JL; Oh, DY; Park, SR; Ryu, MH1
Bonenkamp, JJ; de Wilt, JH; Gelderblom, H; Hartgrink, HH; Sleijfer, S; Tielen, R; van Coevorden, F; van der Graaf, WT; Verhoef, C1
Chen, G; Liu, SL; Wu, WM; Zhang, TP; Zhao, YP1
Angelini, S; Biasco, G; Cantelli-Forti, G; Casali, PG; Cavrini, G; Di Battista, M; Fumagalli, E; Hrelia, P; Nannini, M; Palassini, E; Pantaleo, MA; Ravegnini, G; Saponara, M; Zenesini, C1
Bekers, DJ; Eechoute, K; Krestin, GP; Mathijssen, RH; Ruggiero, A; Schiavon, G; Schöffski, P; Sleijfer, S; van der Holt, B; Vandecaveye, V; Verweij, J1
Bauer, S; Bitz, U; Blay, JY; Duffaud, F; Gelderblom, H; Joensuu, H; Montemurro, M; Pink, D; Rutkowski, P; Schütte, J; Trent, J1
Cunningham, D; Waddell, T1
Badalamenti, G; Bauer, S; Blackstein, M; Blay, JY; Casali, PG; Chung, J; Demetri, GD; Gelderblom, H; Hohenberger, P; Joensuu, H; Kang, YK; Kappeler, C; Kuss, I; Laurent, D; Le Cesne, A; Leahy, M; Maki, RG; Nguyen, BB; Nishida, T; Reichardt, P; Rutkowski, P; Schöffski, P; von Mehren, M; Xu, J1
Chen, G; Ding, PR; Fang, YJ; Kong, LH; Li, LR; Lu, ZH; Pan, ZZ; Wan, DS; Wu, XJ; Zhang, RX1
Bhalgami, R; Manish, K; Mehta, S; Mohandas, KM; Patil, P1
Debiec-Rychter, M; Deroose, CM; Fletcher, JA; Floris, G; Friedman, L; Li, H; Schöffski, P; Sciot, R; Van Looy, T; Vermaelen, P; Wellens, J; Wozniak, A1
Ando, T; Hosokawa, A; Kajiura, S; Nakata, K; Saito, S; Sugiyama, T1
Baker, DE1
Blay, JY; Ray-Coquard, I1
Campbell, SC; Hantel, A; Kash, J; Paner, GP; Sakamoto, K; Voelzke, BB; Waters, WB1
Fujimoto, H; Hirota, S; Kitamura, Y; Ko, S; Miyagawa, S1
Schwartz, R1
Blanke, CD; Capdeville, R; Corless, C; Demetri, GD; Dimitrijevic, S; Druker, BJ; Eisenberg, B; Fletcher, CD; Fletcher, JA; Heinrich, MC; Janicek, M; Joensuu, H; Kiese, B; Peng, B; Roberts, PJ; Silberman, SL; Silverman, SG; Singer, S; Tuveson, DA; Van den Abbeele, AD; von Mehren, M1
Demetri, GD5
Baker, L; Muler, JH; Zalupski, MM1
Cormier, JN; Patel, SR; Pisters, PW1
Fletcher, CD; Fletcher, JA1
Chen, G; Cohen, M; Dagher, R; Gobburu, J; Griebel, D; Pazdur, R; Rahman, A; Robbie, G; Rothmann, M; Staten, A; Williams, G1
Pindolia, VK; Zarowitz, BJ1
Desai, J; George, S1
Bauer, S; Bojko, P; Hagen, V; Pielken, HJ; Schütte, J; Seeber, S1
Judson, I1
Cohen, MH; Dagher, R; Griebel, DJ; Ibrahim, A; Martin, A; Pazdur, R; Scher, NS; Sokol, GH; Williams, GA1
De Mestier, P; Des Guetz, G; Pierga, JY1
DeMatteo, RP2
Demetri, G; Dimitrijevic, S; Fletcher, C; Joensuu, H; Roberts, P; Silberman, S1
Hasuike, Y; Kawahara, K; Kurata, A; Mishima, H; Mukaide, H; Nishisyou, I; Shin, E; Takeda, Y; Tujinaka, T1
Buchdunger, E; O'Reilly, T; Wood, J1
Badawi, RD; Van den Abbeele, AD1
Joensuu, H; Silberman, S1
Dimitrijevic, S; Donato di Paola, E; Dumez, H; Judson, IR; Nielsen, OS; Sciot, R; Stroobants, S; Van Glabbeke, M; van Oosterom, AT; Verweij, J1
Antonescu, C; Brennan, MF; Dematteo, RP; Maki, RG1
Croom, KF; Perry, CM1
Hirota, S1
Baty, V; Blay, JY; Boukovinas, I; Le Cesne, A; Michallet, V; Ranchere, D; Ray-Coquard, I; Thiesse, P1
Hinterleitner, TA; Höfler, G; Högenauer, C; Krejs, GJ; Langner, C; Lipp, RW1
Maturo, A; Peparini, N1
Chander, S; Lay Ergun, E; Shields, AF1
Antoch, G; Bauer, S; Corless, CL; Dirsch, O; Heinrich, MC; Kanja, J; Schütte, J; Seeber, S1
Chen, H; Hirota, S; Isozaki, K; Kinoshita, K; Kitamura, Y; Matsuzawa, Y; Ohashi, A; Shinomura, Y1
Clark, SH; Duvic, M; Prieto, VG; Prietol, VG1
Greenson, JK1
de Silva, CM; Reid, R1
Colecchia, M; Diment, J1
Dei Tos, AP1
Patel, SR2
von Mehren, M3
Eisenberg, BL; von Mehren, M1
Chmelik, P; Felix, R; Gaffke, G; Hohenberger, P; Jost, D; Pink, D; Reichardt, P; Schlecht, I; Schneider, U; Stroszczynski, C1
Hirota, S; Kitamura, Y; Nishida, T1
Hatakeyama, K; Kanda, T; Kaneko, K; Makino, S; Matsuki, A; Nakagawa, S; Ohashi, M1
Kondo, H; Motohara, T; Ohira, N; Oku, T; Shikishima, H; Sumiyoshi, T; Takayama, T; Waga, E; Yoshizaki, N1
Ahlman, H; Andersson, J; Bümming, P; Engström, K; Jansson, S; Kindblom, LG; Klingenstierna, H; Meis-Kindblom, JM; Nilsson, B; Stierner, U; Wängberg, B1
Rosai, J1
Lilien, DL; Reddy, MP; Reddy, P1
Nishida, T; Yasumasa, K1
Arnoletti, JP; Chahwan, S; Eisenberg, B; Favorova, O; Fletcher, J; Frolov, A; Godwin, AK; Ochs, M; Pan, ZZ; von Mehren, M1
Hirota, S; Isozaki, K; Kinoshita, K; Kitamura, Y; Nishida, T; Ohashi, A; Shinomura, Y2
Blay, JY; Brown, M; di Paola, ED; Hogendoorn, PC; Judson, I; Le Cesne, A; Nielsen, OS; Radford, J; Rodenhuis, S; van der Graaf, W; van Oosterom, A; Verweij, J1
Cole, P; Dimitrijevic, S; Dumez, H; Dupont, P; Goeminne, J; Martens, M; Mortelmans, L; Nuyts, J; Sciot, R; Seegers, M; Silberman, S; Stroobants, S; van den Borne, B; van Oosterom, A1
Fahn, W; Milani, V; Schlemmer, M; Tschoep, K; Wendtner, CM1
Connolly, EM; Gaffney, E; Reynolds, JV1
Larsen, JB1
Berthelsen, AK; Eigtved, AI; Kinnander, C; Krarup-Hansen, A1
Catania, C; Curigliano, G; Danesi, R; De Braud, F; De Pas, T1
Hirohashi, K; Kanazawa, A; Kinoshita, H; Kubo, S; Shuto, T; Takemura, S; Tanaka, H; Yamamoto, S; Yamamoto, T1
Hart, J; Langerman, A; Posner, MC; Ryan, CW; Swiger, S; Wu, PC1
Gelderblom, H; Verweij, J1
Kuenen, BC; Pinedo, HM1
Gelderblom, H; Hogendoorn, PC; van der Graaf, WT; Verweij, J1
Nakajima, M; Toga, W1
Blanke, CD; Chen, CJ; Corless, CL; Demetri, GD; Dimitrijevic, S; Druker, BJ; Eisenberg, B; Fletcher, CD; Fletcher, JA; Heinrich, MC; Joensuu, H; Kiese, B; McGreevey, LS; Roberts, PJ; Silberman, S; Singer, S; Van den Abbeele, AD; von Mehren, M1
Babu, KG; Bapsy, PP; Girish, MH; Prabhash, K1
Blay, JY; Duffaud, F1
Benjamin, RS; Burgess, MA; Chen, LL; Cormier, JN; Feig, BW; Hunt, KK; Patel, SR; Pisters, PW; Pollock, RE; Raymond, AK; Scaife, CL; Trent, J1
Eisenberg, BL1
Besznyák, I; Bodoky, G; Eckhardt, S; Esik, O; Gödény, M; Horti, J; Jakab, K; Nagy, T; Orosz, Z; Pápai, Z; Sápi, Z; Tamás, K; Trón, L1
de Jong, FA; Verweij, J1
Dudek, K; Grzesiakowska, U; Krawczyk, M; Nasierowska-Guttmejer, A; Nowecki, ZI; Nyckowski, P; Pienkowski, A; Ruka, W; Rutkowski, P1
Cunningham, SC; Shibata, D; Volpe, C1
Dawkins, F; Dinh, K; Hasan, S; Hassan, M; Jack, M; Lombardo, F; Oke, L; Onojobi, G1
Gayed, I; Iyer, R; Johnson, M; Macapinlac, H; Podoloff, D; Swanston, N; Vu, T1
Egerer, G; Hensel, M; Lehnert, T; Libicher, M; Mechtersheimer, G; Penzel, R; Rieker, RJ1
Hohenberger, P; Pink, D; Reichardt, P; Schneider, U; Stroszczynski, C1
A'Hern, R; Burton, P; Hayes, AJ; Koban, MU; Mostyn-Jones, A; Thomas, JM1
Amalesh, T1
Cho, H; Imada, T; Kobayashi, O; Miyagi, Y; Motohashi, H; Sairenji, M; Sugiyama, Y; Tsuburaya, A; Yoshida, T1
de Vos tot Nederveen Cappel, RJ; Peterse, JL; Rodenhuis, S; van Coevorden, F; van Hillegersberg, R1
Ajmi, S; Arfaoui, D; Elloumi, H; Frikha, F; Mokni, M; Yacoubi, MT1
Antoch, G; Bauer, S; Bockisch, A; Debatin, JF; Freudenberg, LS; Kanja, J; Kuehl, H; Renzing-Koehler, K; Schuette, J1
Brown, M; Debiec-Rychter, M; Dimitrijevic, S; Dumez, H; Hagemeijer, A; Judson, I; Sciot, R; Scurr, M; Stul, M; van Glabbeke, M; van Oosterom, AT; Verweij, J; Vranck, H; Wasag, B1
Chen, L; El-Naggar, A; Hunt, K; Koh, JS; Pollock, R; Trent, J; Zhang, W1
Chang, KM; Huang, MJ; Lin, SC; Liu, CL; Tzen, CY1
Matsuda, H; Nishida, T; Ohmori, T1
Imai, K; Yoshida, Y1
Duensing, A; Fletcher, CD; Fletcher, JA; Heinrich, MC1
Blanke, CD; Bono, P; Demetri, GD; Dimitrijevic, S; Heinrich, MC; Joensuu, H; Krause, A; von Mehren, M1
Hohenberger, P; Lindner, T; Mrozek, A; Pink, D; Reichardt, P1
Gietema, JA; Jager, PL; van der Graaf, WT1
Bucher, P; Buhler, LH; Egger, JF; Morel, P; Villiger, P1
Eisenberg, BL; Judson, I1
Hochhaus, A2
Hatakeyama, K; Hirota, S; Kanda, T; Ohashi, A; Shirai, Y; Wakai, T1
Hara, K; Ito, S; Kawai, H; Mochiduki, Y; Nakamura, T; Ohno, R; Okubo, K; Sawaki, A; Suzuki, T; Yamamura, Y; Yamao, K1
Blay, JY; Boillot, O; Bompas, E; Bringuier, PP; Dumortier, J1
Joensuu, H; Kindblom, LG1
Fernberg, JO; Hall, KS1
Alberton, Y; Catane, R; Cherny, NI; Jurim, O; Katz, D; Reissman, P; Segal, A1
Verweij, J1
Corless, CL; Heinrich, MC1
Abad, M; Astudillo, A; Balbín, M; Blay, P; Braña, A; Buesa, JM; Campo, E; Freije, JM; García-García, J; Lacave, A; Losa, R; Marco, V; Miquel, R; Sierra, M1
Corless, CL; Duensing, A; Fletcher, CD; Fletcher, JA; Heinrich, MC; Hornick, JL; Medeiros, F; Oliveira, AM1
Brandes, AA; Nicolardi, L; Tosoni, A1
Debiec-Rychter, M; Nasierowska-Guttmejer, A; Nowecki, Z; Ruka, W; Rutkowski, P1
Mizunuma, N1
Angevin, E; Bernard, J; Blay, JY; Borg, C; Chung-Scott, V; Crépineau, F; Emile, JF; Flament, C; Fletcher, JA; Heinrich, MC; Lazar, V; Le Cesne, A; Lemoine, F; Maruyama, K; Mécheri, S; Ménard, C; Robert, C; Spatz, A; Taïeb, J; Tchou, I; Terme, M; Thielemans, K; Turhan, A; Tursz, T; Wakasugi, H; Zitvogel, L1
Sawaki, A; Yamao, K1
Büchner-Steudel, P; Fleig, WE1
Gebauer, B; Hohenberger, P; Reichardt, P; Wardelmann, E1
Druker, BJ1
Benjamin, RS; Burgess, MA; Chen, LL; Choi, H; Feig, BW; Frazier, ML; Fuller, GN; Hayes, KJ; Hittelman, W; Hunt, KK; Macapinlac, HA; Oyedeji, CO; Patel, S; Pollock, RE; Prieto, VG; Ramdas, L; Raymond, AK; Trent, JC; Velasco, MA; Wu, EF; Zhang, W1
Corless, CL; Fletcher, JA; Heinrich, MC1
Gastl, G; Hiddemann, W1
Blackstein, ME; Dubé, P; Fletcher, JA; Keller, OR; Knowling, M; Létourneau, R; Morris, D; Riddell, R; Rorke, S; Swallow, CJ1
Bainbridge, T; Corless, CL; Fletcher, JA; Harrell, P; Heinrich, MC; McGreevey, L; Schroeder, A; Town, A1
Baba, M; Hiramatsu, Y; Kamiya, K; Kanda, T; Kikuchi, H; Kondo, K; Konn, H; Nakamura, S; Ohashi, M; Ohta, M; Sugimura, H; Tanaka, T; Yamamoto, M1
Chang, TM; Chen, TW; Hsieh, CB; Liu, HD; Shih, ML; Shyu, RY; Yu, JC1
Balwierz, W; Klekawka, T; Niezgoda, A; Pawińska, K; Skoczeń, S; Strojny, W1
Bertulli, R; Casali, PG; Coco, P; Fumagalli, E; Grosso, F; Stacchiotti, S1
Barghouth, G; Dizendorf, E; Goerres, GW; Hany, TF; Leyvraz, S; Luthi, F; Pestalozzi, B; Schnyder, P; Stupp, R; von Schulthess, GK1
Candelaria, M; de la Garza, J; Duenas-Gonzalez, A1
De Giorgi, U; Verweij, J1
Bonginelli, P; Carillio, G; Gasparini, G; Longo, R; Morabito, A; Vitale, S1
Beauchet, A; Callard, P; Devocelle, A; Emile, JF; Faivre-Bonhomme, L; Farinotti, R; Gil, S; Julié, C; Lavergne-Slove, A; Le Cesne, A; Lemoine, A; Théou, N1
Błasiak, J; Majsterek, I; Pytel, D1
Dziewirski, W; Grzesiakowska, U; Krawczyk, M; Nasierowska-Guttmejer, A; Nowecki, Z; Nyckowski, P; Ruka, W; Rutkowski, P1
Araki, K; Jin, T; Kobayashi, M; Nakano, T; Nakatani, H; Okabayashi, T; Sugimoto, T; Taguchi, T1
Benjamin, RS; Trent, JC1
Bertucci, F; Dubreuil, P; Goncalves, A; Guiramand, J; Madroszyk, A; Monges, G; Moutardier, V; Noguchi, T; Sobol, H1
Dematteo, RP; Gold, JS1
Baker, SD; Bates, SE; Burger, H; de Bruijn, EA; de Jong, FA; Figg, WD; Gardner, ER; Guetens, G; Nooter, K; Prenen, H; Sparreboom, A; van Oosterom, AT; van Schaik, RH; Verweij, J1
Chang, HM; Kang, HJ; Kang, YK; Kim, TW; Lee, JL; Lee, JS; Ryu, MH; Sohn, HJ1
Andtbacka, RH; Benjamin, RS; Burgess, MA; Chen, LL; Cormier, JN; Feig, BW; Hunt, KK; Ng, CS; Patel, SR; Pisters, PW; Pollock, RE; Raymond, K; Scaife, CL; Trent, J1
Antonescu, CR; Brennan, MF; De Matteo, RP; Gold, JS; Gönen, M; Maki, RG; Singer, S; van der Zwan, SM1
Baloglu, O; Gerin, F; Kesari, S; Morgan, JA1
Aiello, C; Barbieri, F; Beninati, S; Budillon, A; Caraglia, M; Di Vizio, D; Florio, T; Insabato, L; Montella, L; Palmieri, G; Schulz, S1
Chen, G; Ding, PR; Li, LR; Lu, ZH; Pan, ZZ; Wan, DS; Wu, XJ; Zhou, ZW1
Fitzpatrick, JE; Ravdel, L; Robinson, WA; Swick, BL1
Fletcher, CD; Hornick, JL1
Hansen, MB; Ponsaing, LG1
Ali, S1
Akmansu, M; Atik, ET; Boruban, C; Ozbek, S; Sencan, O1
Blanke, C1
Bono, P; Bosselli, S; Casali, PG; Coco, P; De Braud, F; De Pas, T; Jalava, T; Joensuu, H; Laurent, D; Putzu, C; Spreafico, C1
Gao, Y; Yang, WL; Yang, XJ; Yu, JR; Zhang, Q1
Shen, L1
Date, RS; Mughal, MM1
Stephenson, J1
Berman, J; O'Leary, TJ1
Blay, JY; Cesne, AL; Ray-Coquard, I1
Demetri, GD; Fletcher, CD; Fletcher, JA; Griffin, JD; Jacks, T; Singer, S; Tuveson, DA; Willis, NA1
Sawyers, CL1
Birgens, H; Dufva, IH1
Judson, I; van Oosterom, A; Verweij, J1
Jeanteur, P1
Dimitrijevic, S; Joensuu, H1
Dimitrijevic, S; Donato di Paola, E; Judson, I; Martens, M; Nielsen, OS; Sciot, R; Silberman, S; Stroobants, S; Van Glabbeke, M; van Oosterom, AT; Verweij, J; Webb, A1
Bani, JC; Brooks, BJ; Demeteri, GD; Fletcher, CD1
Heinzl, S1
Antman, KH; Savage, DG1
Schwetz, BA1
Blanke, CD; Eisenberg, BL; Heinrich, MC1
Berman, JJ; Corless, C; Fletcher, CD; Gorstein, F; Lasota, J; Longley, BJ; Miettinen, M; O'Leary, TJ; Remotti, H; Rubin, BP; Shmookler, B; Sobin, LH; Weiss, SW2
Dematteo, RP; Demetri, G; El-Rifai, WM; Heinrich, MC1
El-Rifai, W; H L Sobin, L; Lasota, J; Miettinen, M1

Reviews

180 review(s) available for imatinib mesylate and Cancer of Gastrointestinal Tract

ArticleYear
[Surgical and interdisciplinary treatment of gastrointestinal stromal tumors].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2022, Volume: 93, Issue:1

    Topics: Antineoplastic Agents; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Prognosis; Proto-Oncogene Proteins c-kit

2022
Current update on molecular cytogenetics, diagnosis and management of gastrointestinal stromal tumors.
    World journal of gastroenterology, 2021, Nov-07, Volume: 27, Issue:41

    Topics: Antineoplastic Agents; Cytogenetic Analysis; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Prognosis; Proto-Oncogene Proteins c-kit; Tomography, X-Ray Computed

2021
KIT Exon 9-Mutated Gastrointestinal Stromal Tumours: Biology and Treatment.
    Chemotherapy, 2022, Volume: 67, Issue:2

    Topics: Antineoplastic Agents; Biology; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit

2022
New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.
    Current oncology reports, 2022, Volume: 24, Issue:2

    Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit

2022
The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours.
    Targeted oncology, 2022, Volume: 17, Issue:2

    Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Sunitinib

2022
Gastrointestinal Stromal Tumors: What Is the Best Sequence of TKIs?
    Current treatment options in oncology, 2022, Volume: 23, Issue:5

    Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Protein Kinase Inhibitors; Sunitinib

2022
Avances en tumores del estroma gastrointestinal: ¿hacia dónde vamos?
    Cirugia y cirujanos, 2022, Volume: 90, Issue:2

    Topics: Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Sunitinib

2022
The GIST of Advances in Treatment of Advanced Gastrointestinal Stromal Tumor.
    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2022, Volume: 42

    Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit

2022
Next questions for the medical treatment of gastrointestinal stromal tumor.
    Current opinion in oncology, 2022, 07-01, Volume: 34, Issue:4

    Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Tumor Microenvironment

2022
Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval.
    Future oncology (London, England), 2022, Volume: 18, Issue:26

    Topics: Antineoplastic Agents; Drug Approval; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Naphthyridines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Urea

2022
Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges.
    Current treatment options in oncology, 2022, Volume: 23, Issue:9

    Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib

2022
TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors.
    Drugs, 2023, Volume: 83, Issue:1

    Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Sunitinib

2023
Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2023, Volume: 26, Issue:3

    Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Stomach Neoplasms

2023
Efficacy of post-first-line agents for advanced gastrointestinal stromal tumors following imatinib failure: A network meta-analysis.
    Cancer medicine, 2023, Volume: 12, Issue:11

    Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Network Meta-Analysis; Protein Kinase Inhibitors; Pyrroles; Sunitinib

2023
The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib.
    Pharmacology & therapeutics, 2023, Volume: 248

    Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Sunitinib

2023
Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib: a plain language summary of the phase 3 INTRIGUE trial.
    Future oncology (London, England), 2023, Volume: 19, Issue:36

    Topics: Adult; Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Quality of Life; Sunitinib

2023
Liver resection for metastatic GIST tumor improves survival in the era of tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Langenbeck's archives of surgery, 2023, Sep-23, Volume: 408, Issue:1

    Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver; Peritoneal Neoplasms; Retrospective Studies; Tyrosine Kinase Inhibitors

2023
Gastrointestinal Stromal Tumours (GIST): A Review of Cases from Nigeria.
    Journal of gastrointestinal cancer, 2020, Volume: 51, Issue:3

    Topics: DNA Mutational Analysis; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestines; Nigeria; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Stomach; Survival Analysis; Treatment Outcome; Tumor Burden

2020
Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors.
    Future oncology (London, England), 2020, Volume: 16, Issue:22

    Topics: Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Pyrazoles; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Standard of Care; Triazines

2020
Ripretinib: First Approval.
    Drugs, 2020, Volume: 80, Issue:11

    Topics: Antineoplastic Agents; Drug Approval; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Proto-Oncogene Mas; Receptor, Platelet-Derived Growth Factor alpha

2020
The Landmark Series: Systemic Therapy for Resectable Gastrointestinal Stromal Tumors.
    Annals of surgical oncology, 2020, Volume: 27, Issue:10

    Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local

2020
Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.
    Expert opinion on investigational drugs, 2021, Volume: 30, Issue:2

    Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Mutation; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Signal Transduction; Sunitinib; Treatment Outcome

2021
The management of metastatic GIST: current standard and investigational therapeutics.
    Journal of hematology & oncology, 2021, 01-05, Volume: 14, Issue:1

    Topics: Animals; Antineoplastic Agents; Disease Management; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sunitinib

2021
Gastrointestinal stromal tumor: a review of current and emerging therapies.
    Cancer metastasis reviews, 2021, Volume: 40, Issue:2

    Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immune Checkpoint Inhibitors; Mutation; Neoadjuvant Therapy; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Randomized Controlled Trials as Topic; Receptor, Platelet-Derived Growth Factor alpha

2021
Disease-free Interval Is Associated with Oncologic Outcomes in Patients with Recurrent Gastrointestinal Stromal Tumor.
    Annals of surgical oncology, 2021, Volume: 28, Issue:12

    Topics: Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Metastasectomy; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies

2021
GEIS guidelines for gastrointestinal sarcomas (GIST).
    Cancer treatment reviews, 2017, Volume: 55

    Topics: Antineoplastic Agents; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Pyrroles; Sunitinib

2017
Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.
    Targeted oncology, 2017, Volume: 12, Issue:3

    Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit

2017
Long-Term Imatinib Treatment for Patients with Unresectable or Recurrent Gastrointestinal Stromal Tumors.
    Digestion, 2018, Volume: 97, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Female; Follow-Up Studies; Gastrectomy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Japan; Long-Term Care; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome

2018
CD117 is not always positive in infantile gastrointestinal stromal tumor.
    World journal of pediatrics : WJP, 2018, Volume: 14, Issue:1

    Topics: Anastomosis, Surgical; Biomarkers, Tumor; Biopsy, Needle; Colectomy; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Infant; Laparotomy; Multimodal Imaging; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins c-kit; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography, Doppler, Color

2018
The Story of Imatinib in GIST - a Journey through the Development of a Targeted Therapy.
    Oncology research and treatment, 2018, Volume: 41, Issue:7-8

    Topics: Clinical Trials as Topic; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Protein Kinase Inhibitors

2018
Hepatitis B virus reactivation following imatinib therapy: A comparative review of 9 cases.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2019, Volume: 25, Issue:6

    Topics: Aged, 80 and over; Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatitis B; Hepatitis B virus; Humans; Imatinib Mesylate; Male; Risk Factors; Virus Activation

2019
The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature.
    Digestion, 2019, Volume: 99, Issue:2

    Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Drug Substitution; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Sunitinib; Treatment Outcome

2019
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2018, 10-02, Volume: 138, Issue:15

    Topics: Antineoplastic Agents; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Tomography, X-Ray Computed

2018
Dedifferentiated gastrointestinal stromal tumor: Recent advances.
    Annals of diagnostic pathology, 2019, Volume: 39

    Topics: Biomarkers, Tumor; Cell Dedifferentiation; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry

2019
Gastrointestinal stromal tumor - A review of clinical studies.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2019, Volume: 25, Issue:6

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sunitinib

2019
Imaging surveillance of gastrointestinal stromal tumour: current recommendation by National Comprehensive Cancer Network and European Society of Medical Oncology-European Reference Network for rare adult solid cancers.
    Clinical radiology, 2019, Volume: 74, Issue:10

    Topics: Chemotherapy, Adjuvant; Continuity of Patient Care; Contrast Media; Diagnostic Imaging; Drug Resistance, Neoplasm; Early Diagnosis; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Practice Guidelines as Topic; Protein Kinase Inhibitors; Risk Assessment

2019
Long-term efficacy of imatinib for treatment of metastatic GIST.
    Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:2

    Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; DNA Mutational Analysis; Dose-Response Relationship, Drug; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Patient Compliance; Piperazines; Pyrimidines; Survival Analysis; Treatment Outcome

2013
[Molecular mechanism and therapeutic strategy for resistance to tyrosine kinase inhibitors in targeted treatment of gastrointestinal stromal tumors].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2013, Volume: 16, Issue:3

    Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib

2013
[Treatment progress of gastrointestinal stromal tumor].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2013, Volume: 16, Issue:3

    Topics: Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines

2013
Gastrointestinal stromal tumour.
    Lancet (London, England), 2013, Sep-14, Volume: 382, Issue:9896

    Topics: Antineoplastic Agents; Benzamides; Chondroma; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leiomyosarcoma; Lung Neoplasms; Mutation; Neurofibromatosis 1; Paraganglioma, Extra-Adrenal; Piperazines; Preoperative Care; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Stomach Neoplasms

2013
Adherence to imatinib therapy in gastrointestinal stromal tumors and chronic myeloid leukemia.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013, Volume: 21, Issue:8

    Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medication Adherence; Piperazines; Pyrimidines

2013
Optimizing surgical and imatinib therapy for the treatment of gastrointestinal stromal tumors.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2013, Volume: 17, Issue:11

    Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperazines; Pyrimidines

2013
Gastrointestinal stromal tumors.
    Khirurgiia, 2011, Issue:1

    Topics: Animals; Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines

2011
New fronts in the adjuvant treatment of GIST.
    Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:4

    Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Prognosis; Pyrimidines; Risk Factors; Survival Rate; Time Factors

2013
Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib.
    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2013, Volume: 27, Issue:5

    Topics: Animals; Benzamides; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sunitinib

2013
Intolerance to imatinib in gastrointestinal stromal tumors: a case report and a review of literature.
    Journal of gastrointestinal cancer, 2014, Volume: 45 Suppl 1

    Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Pyrimidines

2014
Imatinib and beyond in gastrointestinal stromal tumors: A radiologist's perspective.
    AJR. American journal of roentgenology, 2013, Volume: 201, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multimodal Imaging; Piperazines; Positron-Emission Tomography; Pyrimidines; Tomography, X-Ray Computed

2013
Multidisciplinary care of gastrointestinal stromal tumour: a review and a proposal for a pre-treatment classification.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2013, Volume: 39, Issue:11

    Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Interdisciplinary Communication; Molecular Targeted Therapy; Neoadjuvant Therapy; Patient Care Team; Patient Selection; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Research Design; Terminology as Topic

2013
Optimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppression.
    The oncologist, 2013, Volume: 18, Issue:11

    Topics: Benzamides; Disease Progression; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome

2013
Metastasectomy for gastrointestinal stromal tumors.
    Journal of surgical oncology, 2014, Volume: 109, Issue:1

    Topics: Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Metastasectomy; Mutation; Patient Selection; Piperazines; Pyrimidines

2014
Practical role of mutation analysis for imatinib treatment in patients with advanced gastrointestinal stromal tumors: a meta-analysis.
    PloS one, 2013, Volume: 8, Issue:11

    Topics: Benzamides; Disease-Free Survival; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Odds Ratio; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome

2013
Review article: the biology, diagnosis and management of gastrointestinal stromal tumours.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:12

    Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines

2014
Practical aspects of risk assessment in gastrointestinal stromal tumors.
    Journal of gastrointestinal cancer, 2014, Volume: 45, Issue:3

    Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Consensus Development Conferences, NIH as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mitotic Index; Molecular Targeted Therapy; Multicenter Studies as Topic; Mutation; Nomograms; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome; Tumor Burden; United States

2014
The DREAM complex in antitumor activity of imatinib mesylate in gastrointestinal stromal tumors.
    Current opinion in oncology, 2014, Volume: 26, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; E2F4 Transcription Factor; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retinoblastoma-Like Protein p130

2014
[Gastrointestinal stromal tumors: diagnostics and therapy].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2014, Volume: 85, Issue:6

    Topics: Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Guideline Adherence; Humans; Imatinib Mesylate; Lymph Node Excision; Neoplasm Seeding; Neoplasm Staging; Piperazines; Pyrimidines; Risk Assessment

2014
Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:14

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Metastasis; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib

2014
Gastrointestinal stromal tumors: who should get imatinib and for how long?
    Advances in surgery, 2014, Volume: 48

    Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Drug Resistance; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha

2014
Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
    Drug design, development and therapy, 2014, Volume: 8

    Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Treatment Outcome

2014
Management of Gastrointestinal Stromal Tumour: Current Practices and Visions for the Future.
    Oncology, 2015, Volume: 89, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Congresses as Topic; Consensus; Drug Administration Schedule; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Medical Oncology; Molecular Targeted Therapy; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome

2015
Current management of patients with gastrointestinal stromal tumor receiving the multitargeted tyrosine kinase inhibitor sunitinib.
    Current medical research and opinion, 2015, Volume: 31, Issue:7

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Protein Kinase Inhibitors; Pyrroles; Sunitinib

2015
Duodenal gastrointestinal stromal tumor: From clinicopathological features to surgical outcomes.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2015, Volume: 41, Issue:7

    Topics: Age Distribution; Antineoplastic Agents; Benzamides; Biopsy, Fine-Needle; Endoscopy, Gastrointestinal; Endosonography; Europe; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Indoles; Mutation; Pancreaticoduodenectomy; Phenylurea Compounds; Piperazines; Prevalence; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Sex Distribution; Sunitinib; United States

2015
Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review.
    Future oncology (London, England), 2015, Volume: 11, Issue:12

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Treatment Outcome

2015
Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA Analysis.
    International journal of molecular sciences, 2015, Jul-09, Volume: 16, Issue:7

    Topics: DNA, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Precision Medicine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha

2015
Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions.
    Drugs, 2015, Volume: 75, Issue:12

    Topics: Animals; Antineoplastic Agents; Drug Discovery; Drug Resistance, Neoplasm; Drugs, Investigational; Forecasting; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Signal Transduction; Treatment Outcome

2015
The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2016, Volume: 19, Issue:1

    Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Recurrence, Local; Phenylurea Compounds; Practice Guidelines as Topic; Proto-Oncogene Proteins c-kit; Pyridines

2016
[Molecular targeted drugs for soft tissue sarcoma and neuroendocrine tumor].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:8

    Topics: Antibodies, Monoclonal, Humanized; Benzamides; Denosumab; Drug Discovery; Everolimus; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Indazoles; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sarcoma; Sirolimus; Sorafenib; Sulfonamides; Sunitinib

2015
Imatinib Dosing in Gastrointestinal Stromal Tumors (GISTs): When, How Much, and How Long?
    Current clinical pharmacology, 2015, Volume: 10, Issue:4

    Topics: Antineoplastic Agents; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Protein Kinase Inhibitors; Survival Analysis; Time Factors

2015
The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors.
    Current treatment options in oncology, 2016, Volume: 17, Issue:2

    Topics: Antineoplastic Agents; Cytoreduction Surgical Procedures; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Protein Kinase Inhibitors

2016
Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia.
    Expert opinion on drug metabolism & toxicology, 2016, Volume: 12, Issue:7

    Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pharmacogenetics; Polymorphism, Genetic; Protein Kinase Inhibitors

2016
An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients.
    Current oncology reports, 2016, Volume: 18, Issue:8

    Topics: Aged; Fatal Outcome; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Retinal Vein Occlusion

2016
Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy.
    Gastroenterology clinics of North America, 2016, Volume: 45, Issue:3

    Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Digestive System Surgical Procedures; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoadjuvant Therapy; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib

2016
Combined Therapy of Gastrointestinal Stromal Tumors.
    Surgical oncology clinics of North America, 2016, Volume: 25, Issue:4

    Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease Management; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Treatment Outcome

2016
What is changing in the surgical treatment of gastrointestinal stromal tumors after multidisciplinary approach? A comprehensive literature's review.
    Minerva chirurgica, 2017, Volume: 72, Issue:3

    Topics: Antineoplastic Agents; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Interdisciplinary Communication; Laparoscopy; Neoadjuvant Therapy; Neoplasm Staging; Preoperative Care; Prognosis; Robotic Surgical Procedures; Treatment Outcome

2017
[Internal medical therapy of gastrointestinal stroma tumors].
    Der Radiologe, 2009, Volume: 49, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drugs, Investigational; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Indoles; Neoadjuvant Therapy; Piperazines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib

2009
Gastrointestinal stromal tumours (GISTs): case report and review of the literature.
    The Gulf journal of oncology, 2011, Issue:9

    Topics: Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines

2011
Management of recurrent gastrointestinal stromal tumors.
    Journal of surgical oncology, 2011, Volume: 104, Issue:8

    Topics: Benzamides; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Pyrroles; Sunitinib

2011
Gastrointestinal stromal tumor and its targeted therapeutics.
    Chinese journal of cancer, 2011, Volume: 30, Issue:5

    Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Drug Delivery Systems; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha

2011
Changing pathology with changing drugs: tumors of the gastrointestinal tract.
    Pathobiology : journal of immunopathology, molecular and cellular biology, 2011, Volume: 78, Issue:2

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Liver Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Pancreatic Neoplasms; Pathology, Molecular; Piperazines; Precision Medicine; Pyrimidines; Signal Transduction; Trastuzumab

2011
Targeted drug therapies and cancer.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2011, Volume: 185

    Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Drug Delivery Systems; Erlotinib Hydrochloride; Gastrointestinal Neoplasms; Gefitinib; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2011
[Gastrointestinal stromal tumour (GIST): current standards in multimodal management].
    Zentralblatt fur Chirurgie, 2011, Volume: 136, Issue:4

    Topics: Alleles; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; DNA Mutational Analysis; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Maintenance Chemotherapy; Neoplasm Invasiveness; Neoplasm Staging; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib

2011
Practical management of imatinib in gastrointestinal stromal tumors.
    Clinical journal of oncology nursing, 2011, Volume: 15, Issue:5

    Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Nursing Methodology Research; Oncology Nursing; Piperazines; Practice Guidelines as Topic; Pyrimidines; Treatment Outcome

2011
Gastrointestinal stromal tumor: advances in diagnosis and management.
    Archives of pathology & laboratory medicine, 2011, Volume: 135, Issue:10

    Topics: Benzamides; Diagnosis, Differential; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Platelet-Derived Growth Factor; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib

2011
Imatinib-associated bilateral gynecomastia and unilateral testicular hydrocele in male patient with metastatic gastrointestinal stromal tumor: a literature review.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2012, Volume: 18, Issue:2

    Topics: Aged; Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gynecomastia; Humans; Imatinib Mesylate; Male; Piperazines; Pyrimidines; Testicular Hydrocele

2012
Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance.
    Cancer treatment reviews, 2012, Volume: 38, Issue:5

    Topics: Benzamides; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Patient Compliance; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib

2012
Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options.
    Journal of surgical oncology, 2011, Volume: 104, Issue:8

    Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib

2011
Adjuvant imatinib therapy for gastrointestinal stromal tumors.
    Journal of surgical oncology, 2011, Volume: 104, Issue:8

    Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha

2011
Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.
    Journal of surgical oncology, 2011, Volume: 104, Issue:8

    Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Piperidines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib; Thiazoles

2011
Gastrointestinal stromal tumours: origin and molecular oncology.
    Nature reviews. Cancer, 2011, Nov-17, Volume: 11, Issue:12

    Topics: Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Succinate Dehydrogenase

2011
Efficacy evaluation of imatinib in the treatment of patients with gastrointestinal stromal tumors.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2011, Volume: 22, Issue:5

    Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; Dose-Response Relationship, Drug; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Treatment Outcome

2011
Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:7

    Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome

2012
Gastric antral vascular ectasia in a patient with GIST after treatment with imatinib: case report and literature review.
    Japanese journal of clinical oncology, 2012, Volume: 42, Issue:5

    Topics: Aged; Antineoplastic Agents; Benzamides; Endoscopy, Digestive System; Female; Gastric Antral Vascular Ectasia; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines

2012
Adjuvant therapy of gastrointestinal stromal tumors.
    Current opinion in oncology, 2012, Volume: 24, Issue:4

    Topics: Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib

2012
Gastrointestinal stromal tumors: evolving role of the multidisciplinary team approach in management.
    Expert review of anticancer therapy, 2012, Volume: 12, Issue:8

    Topics: Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Molecular Diagnostic Techniques; Neoplasm Staging; Patient Care Team; Piperazines; Preoperative Period; Pyrimidines; Risk Assessment; Treatment Outcome

2012
Current management of gastrointestinal stromal tumors--a comprehensive review.
    International journal of surgery (London, England), 2012, Volume: 10, Issue:7

    Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Sunitinib

2012
Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.
    Anti-cancer drugs, 2012, Volume: 23 Suppl

    Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mitotic Index; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Risk; Rupture, Spontaneous

2012
Adjuvant therapy of gastrointestinal stromal tumors (GIST).
    Current treatment options in oncology, 2012, Volume: 13, Issue:3

    Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome

2012
Understanding rechallenge and resistance in the tyrosine kinase inhibitor era: imatinib in gastrointestinal stromal tumor.
    American journal of clinical oncology, 2014, Volume: 37, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Patient Compliance; Piperazines; Protein Kinase Inhibitors; Pyrimidines

2014
Adjuvant therapy in primary GIST: state-of-the-art.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:11

    Topics: Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome

2012
Management of gastrointestinal stromal tumors: looking beyond the knife. An update on the role of adjuvant and neoadjuvant imatinib therapy.
    Journal of gastrointestinal cancer, 2012, Volume: 43, Issue:4

    Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines

2012
[Translational research and diagnosis in GIST].
    Der Pathologe, 2012, Volume: 33 Suppl 2

    Topics: Adult; Antineoplastic Agents; Benzamides; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Silencing; Germ-Line Mutation; Humans; Imatinib Mesylate; Lymphatic Metastasis; Male; Mitotic Index; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Succinate Dehydrogenase; Transcriptional Activation; Translational Research, Biomedical; Tumor Burden; Young Adult

2012
The role of surgery in the multidisciplinary management of patients with localized gastrointestinal stromal tumors.
    Expert review of anticancer therapy, 2012, Volume: 12, Issue:8

    Topics: Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Neoadjuvant Therapy; Patient Care Team; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines

2012
Optimized dose of imatinib for treatment of gastrointestinal stromal tumors: a meta-analysis.
    Journal of digestive diseases, 2013, Volume: 14, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Confidence Intervals; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Odds Ratio; Piperazines; Pyrimidines; Survival Rate

2013
Imatinib mesylate.
    Reviews in gastroenterological disorders, 2002, Volume: 2, Issue:2

    Topics: Animals; Antineoplastic Agents; Benzamides; Drug Interactions; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines

2002
Gastrointestinal stromal tumor: involvement in urologic patients and recent therapeutic advances.
    Urology, 2002, Volume: 60, Issue:2

    Topics: Antigens, Neoplasm; Antineoplastic Agents; Benzamides; Carcinoma, Renal Cell; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Piperazines; Prostatic Neoplasms; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma

2002
Gastrointestinal stromal tumors: chemotherapy and imatinib.
    Current oncology reports, 2002, Volume: 4, Issue:6

    Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma; Stomach Neoplasms; Stromal Cells; Tomography, Emission-Computed; Tomography, X-Ray Computed

2002
Gastrointestinal stromal tumors: rationale for surgical adjuvant trials with imatinib.
    Current oncology reports, 2002, Volume: 4, Issue:6

    Topics: Animals; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Stomach Neoplasms; Stromal Cells

2002
Imatinib mesylate, the first molecularly targeted gene suppressor.
    Pharmacotherapy, 2002, Volume: 22, Issue:10

    Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Neoplasm; Food-Drug Interactions; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Patient Education as Topic; Piperazines; Pyrimidines; Sarcoma; Stromal Cells

2002
Management of gastrointestinal stromal tumors in the era of tyrosine kinase inhibitors.
    Current treatment options in oncology, 2002, Volume: 3, Issue:6

    Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Sarcoma

2002
Gastrointestinal stromal tumours (GIST): biology and treatment.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13 Suppl 4

    Topics: Benzamides; Biopsy, Needle; Clinical Trials as Topic; Combined Modality Therapy; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Neoplasm Staging; Neoplasms, Connective Tissue; Piperazines; Prognosis; Pyrimidines; Risk Assessment; Stomach Neoplasms; Stromal Cells; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome

2002
[At last, an effective therapy for non-differentiated GI sarcomas (gastro intestinal stromal tumor)].
    Journal de chirurgie, 2002, Volume: 139, Issue:5

    Topics: Adult; Antineoplastic Agents; Benzamides; Diagnosis, Differential; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Immunohistochemistry; Leiomyosarcoma; Middle Aged; Mutation; Piperazines; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Stomach; Stomach Neoplasms; Time Factors

2002
The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571).
    Annals of surgical oncology, 2002, Volume: 9, Issue:9

    Topics: Antineoplastic Agents; Benzamides; Embolization, Therapeutic; Enzyme Inhibitors; Gastrointestinal Neoplasms; Hepatic Artery; Humans; Imatinib Mesylate; Immunohistochemistry; Liver Neoplasms; Mutation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines

2002
Management of malignant gastrointestinal stromal tumours.
    The Lancet. Oncology, 2002, Volume: 3, Issue:11

    Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Combined Modality Therapy; Diagnosis, Differential; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Immunohistochemistry; Mesoderm; Oncogene Proteins; Piperazines; Prognosis; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiotherapy, Adjuvant; Sarcoma

2002
Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development.
    Hematology/oncology clinics of North America, 2002, Volume: 16, Issue:5

    Topics: Antineoplastic Agents; Benzamides; Drug Design; Enzyme Inhibitors; Female; Forecasting; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Middle Aged; Multicenter Studies as Topic; Neoplasm Proteins; Oncogene Proteins, Fusion; Phosphorylation; Piperazines; Protein Processing, Post-Translational; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Sequence Deletion; Signal Transduction

2002
[Tyrosine kinase inhibitor as a targeted therapy for GIST tumors].
    Duodecim; laaketieteellinen aikakauskirja, 2002, Volume: 118, Issue:22

    Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leiomyosarcoma; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma; Treatment Outcome

2002
Pharmacology of imatinib (STI571).
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38 Suppl 5

    Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Connective Tissue; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Stromal Cells

2002
Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38 Suppl 5

    Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasms, Connective Tissue; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor Protein-Tyrosine Kinases; Stromal Cells; Tomography, Emission-Computed

2002
Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs).
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38 Suppl 5

    Topics: Antineoplastic Agents; Benzamides; Drug Monitoring; Enzyme Inhibitors; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Neoplasms, Connective Tissue; Piperazines; Pyrimidines; Radiopharmaceuticals; Stromal Cells; Tomography, Emission-Computed; Treatment Outcome

2002
Overview of issues related to imatinib therapy of advanced gastrointestinal stromal tumors: a discussion among the experts.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38 Suppl 5

    Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Neoplasms, Connective Tissue; Piperazines; Pyrimidines; Stromal Cells

2002
Targeted molecular therapy for cancer: the application of STI571 to gastrointestinal stromal tumor.
    Current problems in surgery, 2003, Volume: 40, Issue:3

    Topics: Benzamides; Biopsy, Needle; Chemotherapy, Cancer, Regional Perfusion; Enzyme Inhibitors; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Immunohistochemistry; Liver Neoplasms; Male; Neoplasm Staging; Peritoneal Neoplasms; Piperazines; Prognosis; Pyrimidines; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Stromal Cells; Survival Analysis; Treatment Outcome

2003
Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Drugs, 2003, Volume: 63, Issue:5

    Topics: Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Multicenter Studies as Topic; Piperazines; Proto-Oncogene Mas; Pyrimidines; Randomized Controlled Trials as Topic; Stromal Cells; Treatment Outcome

2003
[Gain-of-function mutation of c-kit gene and molecular target therapy in GISTs].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2003, Volume: 100, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines

2003
[Gastro-intestinal stromal tumors: news and comments].
    Bulletin du cancer, 2003, Volume: 90, Issue:1

    Topics: Age Factors; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Mutation; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Soft Tissue Neoplasms

2003
Gastrointestinal stromal tumors and other mesenchymal lesions of the gut.
    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2003, Volume: 16, Issue:4

    Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Diagnosis, Differential; Gastrointestinal Neoplasms; Imatinib Mesylate; Immunohistochemistry; Mesoderm; Molecular Biology; Piperazines; Prognosis; Pyrimidines

2003
Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib.
    Pathology oncology research : POR, 2003, Volume: 9, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Diagnosis, Differential; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Incidence; Mutation; Piperazines; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Stromal Cells

2003
The reappraisal of gastrointestinal stromal tumors: from Stout to the KIT revolution.
    Virchows Archiv : an international journal of pathology, 2003, Volume: 442, Issue:5

    Topics: Antineoplastic Agents; Benzamides; Consensus Development Conferences, NIH as Topic; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Mitosis; Mutation; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; United States

2003
Recent advances in the management of gastrointestinal stromal tumors.
    Current oncology reports, 2003, Volume: 5, Issue:4

    Topics: Benzamides; Female; Gastrointestinal Neoplasms; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Male; Mutation; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome

2003
Pharmacotherapy of gastrointestinal stromal tumours.
    Expert opinion on pharmacotherapy, 2003, Volume: 4, Issue:6

    Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Pyrimidines; Stromal Cells

2003
Gastrointestinal stromal tumors (GIST): a model for molecule-based diagnosis and treatment of solid tumors.
    Cancer science, 2003, Volume: 94, Issue:4

    Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Models, Biological; Mutation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines

2003
GIST: an update.
    International journal of surgical pathology, 2003, Volume: 11, Issue:3

    Topics: Antineoplastic Agents; Benzamides; Cell Differentiation; Cell Lineage; Diagnosis, Differential; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Piperazines; Prognosis; Pyrimidines

2003
[Target-based therapy against gastrointestinal stromal tumors--from molecular diagnosis to molecular target therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:8

    Topics: Antineoplastic Agents; Benzamides; Drug Tolerance; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Piperazines; Pyrimidines

2003
[Gastrointestinal stromal tumors].
    Deutsche medizinische Wochenschrift (1946), 2003, Sep-26, Volume: 128, Issue:39

    Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Gastrointestinal Neoplasms; Genetic Therapy; Humans; Imatinib Mesylate; Mutation; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Risk Factors; Stromal Cells

2003
Gastrointestinal stromal tumours.
    The British journal of surgery, 2003, Volume: 90, Issue:10

    Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Mutation; Neoplasms, Connective Tissue; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor Protein-Tyrosine Kinases; Stromal Cells

2003
[Imatinib--a breakthrough in the treatment of gastrointestinal stromal tumors (GIST)].
    Ugeskrift for laeger, 2003, Sep-08, Volume: 165, Issue:37

    Topics: Adult; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor Protein-Tyrosine Kinases; Stromal Cells; Tomography, X-Ray Computed

2003
Gastrointestinal stromal tumors: a paradigm for molecularly targeted therapy.
    Cancer investigation, 2003, Volume: 21, Issue:4

    Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Genetic Therapy; Humans; Imatinib Mesylate; Incidence; Piperazines; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Stromal Cells

2003
[Imatinib, a specific tyrosine-kinase inhibitor, for the treatment of patients with a gastrointestinal stroma cell tumor].
    Nederlands tijdschrift voor geneeskunde, 2003, Oct-18, Volume: 147, Issue:42

    Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Diagnosis, Differential; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Stromal Cells; Treatment Outcome

2003
Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor.
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2003, Volume: 122, Issue:6

    Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines

2003
Gastrointestinal stromal tumour--a paradigm shift in management of solid tumours.
    The Journal of the Association of Physicians of India, 2003, Volume: 51

    Topics: Antineoplastic Agents; Benzamides; Embolization, Therapeutic; Enzyme Inhibitors; Gastrointestinal Neoplasms; Genetic Markers; Humans; Imatinib Mesylate; Immunohistochemistry; Neoplasm Metastasis; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiotherapy, Adjuvant

2003
Gastrointestinal stromal tumors: biology and treatment.
    Oncology, 2003, Volume: 65, Issue:3

    Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Stromal Cells; Survival Rate

2003
Imatinib mesylate: a molecularly targeted therapy for gastrointestinal stromal tumors.
    Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:11

    Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Drug Delivery Systems; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Pyrimidines

2003
Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors.
    Expert review of anticancer therapy, 2003, Volume: 3, Issue:6

    Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Sarcoma; Stromal Cells

2003
Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib.
    Virchows Archiv : an international journal of pathology, 2004, Volume: 444, Issue:2

    Topics: Animals; Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Stromal Cells

2004
[Gastrointestinal stromal tumors. Current data].
    La Tunisie medicale, 2003, Volume: 81, Issue:12

    Topics: Antineoplastic Agents; Benzamides; Carcinoma; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Stromal Cells

2003
Gastrointestinal stromal tumors: overview of pathologic features, molecular biology, and therapy with imatinib mesylate.
    Histology and histopathology, 2004, Volume: 19, Issue:2

    Topics: Antineoplastic Agents; Benzamides; Binding Sites; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Immunohistochemistry; Mutation; Piperazines; Prognosis; Protein Structure, Tertiary; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Stromal Cells

2004
[Tailored therapy in gastrointestinal and hepatic cancer--toward ideal medicine through genomic science].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2004, Volume: 101, Issue:3

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Drug Design; Drug Resistance, Neoplasm; Enzymes; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Targeting; Genetic Therapy; Genomics; Humans; Imatinib Mesylate; Liver Neoplasms; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines; Vascular Endothelial Growth Factor A

2004
Biology of gastrointestinal stromal tumors: KIT mutations and beyond.
    Cancer investigation, 2004, Volume: 22, Issue:1

    Topics: Benzamides; Cell Transformation, Neoplastic; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Stromal Cells

2004
[Gastrointestinal stromal tumors (GIST)].
    Zeitschrift fur Gastroenterologie, 2004, Volume: 42, Issue:4

    Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Patient Care Management; Piperazines; Practice Patterns, Physicians'; Proto-Oncogene Proteins c-kit; Pyrimidines; Stromal Cells

2004
Management of gastrointestinal stromal tumors: from diagnosis to treatment.
    Swiss medical weekly, 2004, Mar-20, Volume: 134, Issue:11-12

    Topics: Algorithms; Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Immunohistochemistry; Lymphatic Metastasis; Neoplasm Invasiveness; Piperazines; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Stromal Cells; Treatment Outcome

2004
Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy.
    Annals of surgical oncology, 2004, Volume: 11, Issue:5

    Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Neoplasm Metastasis; Patient Selection; Piperazines; Prognosis; Pyrimidines; Risk Assessment; Stromal Cells; Survival Analysis

2004
Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
    Annals of hematology, 2004, Volume: 83 Suppl 1

    Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Clinical Trials as Topic; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Stromal Cells

2004
Gastrointestinal stromal tumors--a review.
    Acta orthopaedica Scandinavica. Supplementum, 2004, Volume: 75, Issue:311

    Topics: Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Germ-Line Mutation; Humans; Imatinib Mesylate; Immunohistochemistry; Neoplasm Recurrence, Local; Piperazines; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Risk Assessment; Stromal Cells

2004
Chemotherapy in soft tissue sarcoma. The Scandinavian Sarcoma Group experience.
    Acta orthopaedica Scandinavica. Supplementum, 2004, Volume: 75, Issue:311

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Disease-Free Survival; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Meta-Analysis as Topic; Piperazines; Prospective Studies; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Registries; Remission Induction; Sarcoma; Scandinavian and Nordic Countries; Soft Tissue Neoplasms

2004
KIT and PDGF as targets.
    Cancer treatment and research, 2004, Volume: 120

    Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Piperazines; Platelet-Derived Growth Factor; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Sarcoma; Soft Tissue Neoplasms

2004
Targeting mutant kinases in gastrointestinal stromal tumors: a paradigm for molecular therapy of other sarcomas.
    Cancer treatment and research, 2004, Volume: 120

    Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Mutation; Piperazines; Platelet-Derived Growth Factor; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Sarcoma; Soft Tissue Neoplasms

2004
Current clinical management of gastrointestinal stromal tumors.
    Expert review of anticancer therapy, 2004, Volume: 4, Issue:4

    Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease Progression; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Isoenzymes; Piperazines; Protein Kinase C; Protein Kinase C-theta; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Stromal Cells; Zinc Fingers

2004
[The effect of imatinib for gastrointestinal tumor].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62, Issue:7

    Topics: Antineoplastic Agents; Benzamides; Drug Delivery Systems; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Piperazines; Pyrimidines

2004
Imatinib mesylate acts in metastatic or unresectable gastrointestinal stromal tumor by targeting KIT receptors--a review.
    Cancer chemotherapy and pharmacology, 2004, Volume: 54 Suppl 1

    Topics: Benzamides; Drug Delivery Systems; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Neoplasm Metastasis; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines

2004
[Diagnosis and conservative treatment of gastrointestinal stromal tumors (GIST)].
    Deutsche medizinische Wochenschrift (1946), 2004, Aug-20, Volume: 129, Issue:34-35

    Topics: Antineoplastic Agents; Benzamides; Diagnosis, Differential; Endoscopy, Gastrointestinal; Endosonography; Enzyme Inhibitors; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leiomyoma, Epithelioid; Leiomyosarcoma; Male; Mesenchymoma; Neurilemmoma; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Sex Factors; Tomography, X-Ray Computed

2004
[Gastrointestinal stromal tumors (GIST)--current concepts of surgical management].
    Deutsche medizinische Wochenschrift (1946), 2004, Aug-20, Volume: 129, Issue:34-35

    Topics: Benzamides; Chemotherapy, Adjuvant; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leiomyoma; Leiomyoma, Epithelioid; Leiomyosarcoma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neurilemmoma; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors

2004
Imatinib as a paradigm of targeted therapies.
    Advances in cancer research, 2004, Volume: 91

    Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Design; Drug Evaluation, Preclinical; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Models, Molecular; Neoplasm Proteins; Neoplasms; Oncogenes; Patient Selection; Piperazines; Protein Conformation; Protein-Tyrosine Kinases; Pyrimidines

2004
Biology of gastrointestinal stromal tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Sep-15, Volume: 22, Issue:18

    Topics: Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Mutation; Oncogenes; Phenotype; Phosphotransferases; Piperazines; Prognosis; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Stromal Cells

2004
Gastrointestinal stromal tumours: etiology, pathology and clinical management.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2004, Volume: 18 Suppl B

    Topics: Antineoplastic Agents; Benzamides; Cell Death; Cell Differentiation; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Piperazines; Pyrimidines; Signal Transduction

2004
[Perspectives in the use of imatinib in the treatment of childhood cancers].
    Przeglad lekarski, 2004, Volume: 61 Suppl 2

    Topics: Antineoplastic Agents; Benzamides; Brain Neoplasms; Child; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Male; Neuroblastoma; Piperazines; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines

2004
Some lessons learned from imatinib mesylate clinical development in gastrointestinal stromal tumors.
    Journal of chemotherapy (Florence, Italy), 2004, Volume: 16 Suppl 4

    Topics: Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Neoplasm Staging; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Risk Assessment; Survival Analysis; Treatment Outcome

2004
A clinical and biological overview of gastrointestinal stromal tumors.
    Medical oncology (Northwood, London, England), 2005, Volume: 22, Issue:1

    Topics: Benzamides; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Mutation; Phosphatidylinositol 3-Kinases; Piperazines; Positron-Emission Tomography; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Stromal Cells

2005
Imatinib and gastrointestinal stromal tumors: Where do we go from here?
    Molecular cancer therapeutics, 2005, Volume: 4, Issue:3

    Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Oncogene Proteins; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Time Factors

2005
[Tyrosine kinases. New target of anticancer therapy].
    Postepy biochemii, 2005, Volume: 51, Issue:3

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Breast Neoplasms; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphatic Metastasis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptor, ErbB-2; Trastuzumab

2005
New developments in gastrointestinal stromal tumor.
    Current opinion in oncology, 2006, Volume: 18, Issue:4

    Topics: Antineoplastic Agents; Benzamides; Dimerization; Disease Progression; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Medical Oncology; Piperazines; Prognosis; Pyrimidines

2006
Combined surgical and molecular therapy: the gastrointestinal stromal tumor model.
    Annals of surgery, 2006, Volume: 244, Issue:2

    Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines

2006
The role of KIT in the management of patients with gastrointestinal stromal tumors.
    Human pathology, 2007, Volume: 38, Issue:5

    Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib

2007
Therapeutic procedures for submucosal tumors in the gastrointestinal tract.
    World journal of gastroenterology, 2007, Jun-28, Volume: 13, Issue:24

    Topics: Benzamides; Endoscopy, Gastrointestinal; Female; Gastric Mucosa; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Mucosa; Middle Aged; Piperazines; Pyrimidines

2007
Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST).
    Gene, 2007, Oct-15, Volume: 401, Issue:1-2

    Topics: Benzamides; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Ligands; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Stem Cell Factor; Stromal Cells; Treatment Outcome

2007
[STI571 and gastro intestinal stromal tumors].
    Bulletin du cancer, 2001, Volume: 88, Issue:7

    Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Sarcoma

2001
STI571: a magic bullet?
    European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:15

    Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mesenchymoma; Piperazines; Protein-Tyrosine Kinases; Pyrimidines

2001
Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Seminars in oncology, 2001, Volume: 28, Issue:5 Suppl 17

    Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Mesoderm; Mutation; Neoplasm Metastasis; Piperazines; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines

2001
Imatinib mesylate--a new oral targeted therapy.
    The New England journal of medicine, 2002, Feb-28, Volume: 346, Issue:9

    Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Resistance; Gastrointestinal Neoplasms; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Sarcoma

2002
[Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease].
    Deutsche medizinische Wochenschrift (1946), 2002, Mar-01, Volume: 127, Issue:9

    Topics: Adult; Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytogenetics; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Chronic; Lung Neoplasms; Male; Mastocytosis; Multicenter Studies as Topic; Mutation; Neoplasms; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Time Factors

2002
Gastrointestinal stromal tumors.
    Current treatment options in oncology, 2001, Volume: 2, Issue:6

    Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Chemotherapy, Adjuvant; Combined Modality Therapy; Digestive System Surgical Procedures; Enzyme Inhibitors; Epidemiologic Methods; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Immunotherapy; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasms, Connective Tissue; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome

2001
Diagnosis of gastrointestinal stromal tumors: a consensus approach.
    International journal of surgical pathology, 2002, Volume: 10, Issue:2

    Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Mutation; Oncogene Proteins; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Stromal Cells

2002
Diagnosis of gastrointestinal stromal tumors: A consensus approach.
    Human pathology, 2002, Volume: 33, Issue:5

    Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma; Stromal Cells

2002
Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review.
    Human pathology, 2002, Volume: 33, Issue:5

    Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Genetic Markers; Humans; Imatinib Mesylate; Immunohistochemistry; Loss of Heterozygosity; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma; Stromal Cells

2002

Trials

73 trial(s) available for imatinib mesylate and Cancer of Gastrointestinal Tract

ArticleYear
Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 04-14, Volume: 28, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate

2022
Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors.
    Expert review of gastroenterology & hepatology, 2023, Volume: 17, Issue:2

    Topics: Adult; Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Protein Kinase Inhibitors

2023
Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data.
    Targeted oncology, 2023, Volume: 18, Issue:3

    Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Prospective Studies; Retrospective Studies; Routinely Collected Health Data

2023
Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 12-15, Volume: 25, Issue:24

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Patient Safety; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Salvage Therapy; Sunitinib; Treatment Outcome

2019
Quality of surgery and surgical reporting for patients with primary gastrointestinal stromal tumours participating in the EORTC STBSG 62024 adjuvant imatinib study.
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 120

    Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Digestive System Surgical Procedures; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Postoperative Complications; Prognosis; Quality of Health Care; Quality of Life; Survival Rate

2019
Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial.
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 121

    Topics: Administration, Oral; Aged; Benzamides; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Japan; Male; Middle Aged; Neoplasm Metastasis; Phenylurea Compounds; Pyrazoles; Pyridines; Sunitinib; Treatment Outcome

2019
Safety of Imatinib Mesylate in a Multicenter Expanded Access Program in Adult Patients with Gastrointestinal Stromal Tumors in the Adjuvant Setting.
    Oncology research and treatment, 2019, Volume: 42, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Protein Kinase Inhibitors; Survival Analysis; Treatment Outcome; Young Adult

2019
Impact of L-carnitine on imatinib-related muscle cramps in patients with gastrointestinal stromal tumor.
    Investigational new drugs, 2020, Volume: 38, Issue:2

    Topics: Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carnitine; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Muscle Cramp; Protein Kinase Inhibitors; Quality of Life; Treatment Outcome; Young Adult

2020
Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib.
    Future oncology (London, England), 2020, Volume: 16, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Naphthyridines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Research Design; Sunitinib; Survival Rate; Urea; Young Adult

2020
Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study.
    British journal of cancer, 2020, Volume: 122, Issue:8

    Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mental Disorders; Middle Aged; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Sunitinib

2020
Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib.
    JAMA surgery, 2020, 06-01, Volume: 155, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Digestive System Surgical Procedures; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; International Cooperation; Male; Middle Aged; Quality of Health Care; Treatment Outcome; Young Adult

2020
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.
    JAMA oncology, 2020, 08-01, Volume: 6, Issue:8

    Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Protein Kinase Inhibitors; Risk; Survival Analysis

2020
Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II tri
    European journal of cancer (Oxford, England : 1990), 2020, Volume: 134

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Pyridines; Salvage Therapy; Sunitinib; Survival Rate

2020
Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sar
    Annals of oncology : official journal of the European Society for Medical Oncology, 2021, Volume: 32, Issue:4

    Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Italy; Neoplasm Recurrence, Local; Sarcoma

2021
Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Tr
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, May-20, Volume: 35, Issue:15

    Topics: Adult; Aged; Antineoplastic Agents; Cross-Over Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prognosis

2017
Does a glass of Coke boost the exposure to imatinib in gastrointestinal stromal tumour patients after gastrectomy?
    British journal of clinical pharmacology, 2017, Volume: 83, Issue:10

    Topics: Antineoplastic Agents; Carbonated Beverages; Cross-Over Studies; Food-Drug Interactions; Gastrectomy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate

2017
Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib.
    British journal of cancer, 2017, Oct-24, Volume: 117, Issue:9

    Topics: Adult; Aged; Benzimidazoles; Biomarkers, Tumor; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinolones; Salvage Therapy

2017
Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment.
    PloS one, 2018, Volume: 13, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis Regulatory Proteins; Cell Cycle Proteins; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Risk Factors; Tumor Suppressor Protein p53; Young Adult

2018
Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.
    JAMA oncology, 2018, 06-01, Volume: 4, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Dasatinib; Drug Resistance, Neoplasm; Drug Substitution; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Proteins; Progression-Free Survival; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; src-Family Kinases; Succinate Dehydrogenase; Young Adult

2018
A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor.
    Investigational new drugs, 2019, Volume: 37, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Receptors, Fibroblast Growth Factor; Tissue Distribution

2019
Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
    JAMA oncology, 2018, 12-01, Volume: 4, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Staging; Risk Factors; Treatment Outcome

2018
Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 08-01, Volume: 25, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Deletion; Humans; Imatinib Mesylate; Male; Middle Aged; Patient Safety; Piperazines; Pyridines; Sunitinib; Survival Rate; Treatment Outcome

2019
Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.
    The oncologist, 2019, Volume: 24, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Non-Randomized Controlled Trials as Topic; Phenylurea Compounds; Prognosis; Pyridines; Salvage Therapy; Sunitinib; Survival Rate

2019
Specific analysis of KIT and PDGFR-alpha expression and mutational status in Merkel cell carcinoma.
    Journal of cutaneous pathology, 2013, Volume: 40, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Carcinoma, Merkel Cell; Codon; Exons; Female; Gastrointestinal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Mutation, Missense; Piperazines; Polymerase Chain Reaction; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Skin Neoplasms

2013
Gastrointestinal stromal tumors, somatic mutations and candidate genetic risk variants.
    PloS one, 2013, Volume: 8, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Benzamides; Cytochrome P-450 CYP1B1; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Risk Factors

2013
Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
    Journal of medical economics, 2013, Volume: 16, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Drug Administration Schedule; Drug Costs; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Health Care Costs; Humans; Imatinib Mesylate; Male; Markov Chains; Middle Aged; Neoplasm Recurrence, Local; Netherlands; Piperazines; Pyrimidines; Quality-Adjusted Life Years; Risk Assessment; Survival Analysis

2013
Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
    Annals of surgery, 2013, Volume: 258, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Risk; Survival Analysis; Treatment Outcome; Young Adult

2013
A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours.
    British journal of cancer, 2013, Nov-12, Volume: 109, Issue:10

    Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chordoma; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Feasibility Studies; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Molecular Targeted Therapy; Neoplasms; Piperazines; Pyrimidines; Skin Neoplasms

2013
A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:1

    Topics: Adult; Aged; Angiogenesis Inhibitors; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indazoles; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Piperazines; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Failure; Tumor Burden; Young Adult

2014
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors.
    British journal of cancer, 2014, Mar-04, Volume: 110, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Panobinostat; Piperazines; Pyrimidines

2014
Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:10

    Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; China; Disease Progression; Disease-Free Survival; Early Termination of Clinical Trials; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Metastasectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Patient Selection; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Sample Size; Time Factors; Treatment Outcome

2014
Imatinib (Glivec) and gastrointestinal stromal tumours in Nigerians.
    African journal of medicine and medical sciences, 2013, Volume: 42, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Histocytochemistry; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Nigeria; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines

2013
Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial.
    International journal of clinical oncology, 2015, Volume: 20, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Double-Blind Method; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Middle Aged; Phenylurea Compounds; Pyridines; Pyrroles; Sunitinib; Survival Analysis; Young Adult

2015
Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib.
    European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Nomograms; Piperazines; Prognosis; Pyrimidines; Survival Analysis; Young Adult

2015
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, Jan-20, Volume: 34, Issue:3

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged

2016
Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Tr
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Dec-20, Volume: 33, Issue:36

    Topics: Adult; Aged; Aged, 80 and over; Australasia; Chemotherapy, Adjuvant; Disease-Free Survival; European Union; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; International Cooperation; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Odds Ratio; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Salvage Therapy; Treatment Failure

2015
Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 52

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; DNA Mutational Analysis; Exons; Female; France; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Mutation; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Risk Factors; Time Factors; Treatment Outcome

2016
Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT).
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 52

    Topics: Aged; Analysis of Variance; Antineoplastic Agents; Disease-Free Survival; Double-Blind Method; Drug Resistance, Neoplasm; Drug Substitution; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Republic of Korea; Surveys and Questionnaires; Time Factors; Treatment Outcome

2016
Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence?
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 59

    Topics: Abdominal Wall; Antineoplastic Agents; Biopsy, Needle; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Neoplasm Seeding; Protein Kinase Inhibitors; Risk Factors; Tomography, X-Ray Computed

2016
Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2009, Volume: 35, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Preoperative Care; Prospective Studies; Pyrimidines; Survival Analysis; Treatment Outcome

2009
Five patients with malignant endocrine tumors treated with imatinib mesylate (Glivec).
    Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Carcinoid Tumor; Endocrine Gland Neoplasms; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Pancreatic Neoplasms; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor

2010
Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; France; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm, Residual; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Risk Assessment; Risk Factors; Time Factors; Tomography, X-Ray Computed; Treatment Outcome

2010
A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:11

    Topics: Academic Medical Centers; Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hospitals, Community; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Practice Patterns, Physicians'; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Registries; Sunitinib; United States; Young Adult

2011
Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months.
    Journal of surgical oncology, 2011, Volume: 104, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Survival Analysis

2011
Exploiting antitumor immunity to overcome relapse and improve remission duration.
    Cancer immunology, immunotherapy : CII, 2012, Volume: 61, Issue:7

    Topics: Aged; Aged, 80 and over; Benzamides; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunotherapy; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Lymphocytes; Middle Aged; Piperazines; Polyethylene Glycols; Pyrimidines; Recombinant Proteins; Recurrence; T-Lymphocytes, Cytotoxic

2012
Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome; Young Adult

2012
ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2012, Volume: 53, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Benzamides; Biological Transport; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Genotype; Glucose Transporter Type 4; Humans; Image Processing, Computer-Assisted; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines; Time Factors; Treatment Outcome; Young Adult

2012
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
    JAMA, 2012, Mar-28, Volume: 307, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Survival Analysis; Treatment Outcome; Young Adult

2012
Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumors.
    The oncologist, 2012, Volume: 17, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Young Adult

2012
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jun-01, Volume: 18, Issue:11

    Topics: Adult; Aged; Benzamides; Biomarkers, Tumor; Cross-Over Studies; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neovascularization, Pathologic; Piperazines; Placebos; Pyrimidines; Pyrroles; Retreatment; Sunitinib; Survival Analysis; Young Adult

2012
Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Blood Pressure; Carcinoma, Renal Cell; Child; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hypertension; Imatinib Mesylate; Indoles; Kidney Neoplasms; Male; Middle Aged; Piperazines; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors; Young Adult

2012
Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours.
    British journal of clinical pharmacology, 2013, Volume: 75, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Models, Biological; Orosomucoid; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Serum Albumin

2013
Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease-Free Survival; Exons; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Piperazines; Prospective Studies; Proto-Oncogene Proteins c-kit; Pyrimidines; Republic of Korea; Treatment Outcome

2013
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Lancet (London, England), 2013, Jan-26, Volume: 381, Issue:9863

    Topics: Aged; Antineoplastic Agents; Benzamides; Double-Blind Method; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sunitinib; Survival Rate; Treatment Failure

2013
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
    The New England journal of medicine, 2002, Aug-15, Volume: 347, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Signal Transduction; Stromal Cells; Survival Analysis

2002
Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Benzamides; Drug Approval; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Stromal Cells; Tissue Distribution; Treatment Outcome; United States; United States Food and Drug Administration

2002
Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38 Suppl 5

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms, Connective Tissue; Piperazines; Pyrimidines; Sarcoma; Stromal Cells; Treatment Outcome

2002
Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Drugs, 2003, Volume: 63, Issue:5

    Topics: Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Multicenter Studies as Topic; Piperazines; Proto-Oncogene Mas; Pyrimidines; Randomized Controlled Trials as Topic; Stromal Cells; Treatment Outcome

2003
Early results from randomized phase III trial of imatinib mesylate for gastrointestinal stromal tumors.
    Current oncology reports, 2003, Volume: 5, Issue:4

    Topics: Benzamides; Cross-Over Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Piperazines; Prognosis; Pyrimidines; Stromal Cells; Survival Rate; Treatment Outcome

2003
[Morphology of gastrointestinal stromal tumors in advanced stages of the disease: baseline findings before chemotherapy with imatinib].
    RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 2003, Volume: 175, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Benzamides; Chemotherapy, Adjuvant; Contrast Media; Digestive System; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Image Enhancement; Imatinib Mesylate; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Mesothelial; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Tomography, X-Ray Computed

2003
Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients.
    British journal of cancer, 2003, Aug-04, Volume: 89, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Palliative Care; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Risk Factors; Stromal Cells; Treatment Outcome

2003
Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma
    European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:14

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma; Survival Analysis; Treatment Outcome

2003
18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).
    European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:14

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prospective Studies; Pyrimidines; Radiopharmaceuticals; Sarcoma; Survival Analysis; Tomography, Emission-Computed; Treatment Failure

2003
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Dec-01, Volume: 21, Issue:23

    Topics: Animals; Antineoplastic Agents; Benzamides; CHO Cells; Cricetinae; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; Exons; Gastrointestinal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Mutagenesis, Site-Directed; Mutation; Phosphorylation; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Stromal Cells; Survival Rate; Transfection

2003
[Effect of imatinib treatment of gastrointestinal stromal tumors].
    Orvosi hetilap, 2003, Nov-09, Volume: 144, Issue:45

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Stromal Cells; Survival Analysis; Tomography, Emission-Computed; Tomography, X-Ray Computed; Treatment Outcome

2003
The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2004, Volume: 45, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Benzamides; False Positive Reactions; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Pyrimidines; Radiography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic; Stromal Cells; Tomography, Emission-Computed; Treatment Outcome

2004
Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2004, Volume: 45, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Stromal Cells; Subtraction Technique; Tomography, Emission-Computed; Tomography, X-Ray Computed; Treatment Outcome

2004
Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group.
    European journal of cancer (Oxford, England : 1990), 2004, Volume: 40, Issue:5

    Topics: Adult; Aged; Amino Acid Sequence; Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Female; Gastrointestinal Neoplasms; Genotype; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Survival Analysis; Treatment Outcome

2004
Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib.
    Blood, 2004, Apr-15, Volume: 103, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Oncogene Proteins; Piperazines; Prospective Studies; Proto-Oncogene Proteins c-kit; Pyrimidines; Stem Cell Factor; Vascular Endothelial Growth Factor A

2004
Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET.
    Nuclear medicine communications, 2004, Volume: 25, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Positron-Emission Tomography; Prognosis; Pyrimidines; Radiopharmaceuticals; Reproducibility of Results; Sarcoma; Sensitivity and Specificity; Treatment Outcome

2004
The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.
    European journal of nuclear medicine and molecular imaging, 2005, Volume: 32, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Longitudinal Studies; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Prognosis; Pyrimidines; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Survival Analysis; Switzerland; Tomography, X-Ray Computed; Treatment Outcome

2005
Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Proteins; Phthalazines; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Salvage Therapy

2008
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.
    Lancet (London, England), 2001, Oct-27, Volume: 358, Issue:9291

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Radionuclide Imaging; Treatment Outcome

2001

Other Studies

389 other study(ies) available for imatinib mesylate and Cancer of Gastrointestinal Tract

ArticleYear
Comparison of outcomes between neoadjuvant imatinib and upfront surgery in patients with localized rectal GIST: An inverse probability of treatment weighting analysis.
    Journal of surgical oncology, 2021, Volume: 124, Issue:8

    Topics: Aged; Antineoplastic Agents; Case-Control Studies; Combined Modality Therapy; Digestive System Surgical Procedures; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoadjuvant Therapy; Prognosis; Retrospective Studies; Survival Rate

2021
Gastrointestinal Stromal Tumours.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2021, Volume: 31, Issue:9

    Topics: Adult; Aged; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Prognosis; Proto-Oncogene Proteins c-kit; Retrospective Studies

2021
E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor.
    Oncogene, 2021, Volume: 40, Issue:48

    Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Therapy, Combination; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Mice; Muscle Proteins; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrimidines; SKP Cullin F-Box Protein Ligases; Sulfides; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2021
Imatinib Regulates
    International journal of molecular sciences, 2021, Sep-30, Volume: 22, Issue:19

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Down-Regulation; Electron Transport Complex II; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; MicroRNAs; Mitochondria; Oxidative Phosphorylation; RNA, Messenger; Signal Transduction; Transfection

2021
Rectal gastrointestinal stromal tumor: an unusual presentation of an uncommon pathology (a case report).
    The Pan African medical journal, 2021, Volume: 39

    Topics: Adult; Antigens, CD34; Antineoplastic Agents; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Obstruction; Male; Proto-Oncogene Proteins c-kit; Rectal Neoplasms; Urinary Retention

2021
BRD9 inhibition promotes PUMA-dependent apoptosis and augments the effect of imatinib in gastrointestinal stromal tumors.
    Cell death & disease, 2021, 10-19, Volume: 12, Issue:11

    Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; DNA Damage; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Male; Mice, Nude; Middle Aged; Proto-Oncogene Proteins; RNA, Small Interfering; Transcription Factors; Xenograft Model Antitumor Assays

2021
Glucose transporter‑1 inhibition overcomes imatinib resistance in gastrointestinal stromal tumor cells.
    Oncology reports, 2022, Volume: 47, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Glucose Transporter Type 1; Humans; Hydroxybenzoates; Imatinib Mesylate

2022
Clinicopathological characteristics and prognosis of gastrointestinal stromal tumors containing air-fluid levels.
    PloS one, 2021, Volume: 16, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Digestive System Fistula; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Humans; Imatinib Mesylate; Intestinal Mucosa; Magnetic Resonance Imaging; Male; Middle Aged; Prognosis; Retrospective Studies; Tomography, X-Ray Computed

2021
Hope as a Lifeline: Imatinib Discontinuation in Patients With Oligometastatic Gastrointestinal Stromal Tumours.
    Anticancer research, 2022, Volume: 42, Issue:2

    Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hope; Humans; Imatinib Mesylate; Interviews as Topic; Protein Kinase Inhibitors; Qualitative Research; Remission Induction; Withholding Treatment

2022
Surgical and histopathologic outcomes of gastrointestinal stromal tumors.
    Annali italiani di chirurgia, 2021, Volume: 92

    Topics: Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lymph Nodes; Male; Middle Aged; Omentum; Retrospective Studies

2021
The nerve-tumour regulatory axis GDNF-GFRA1 promotes tumour dormancy, imatinib resistance and local recurrence of gastrointestinal stromal tumours by achieving autophagic flux.
    Cancer letters, 2022, 06-01, Volume: 535

    Topics: Antineoplastic Agents; Autophagy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Glial Cell Line-Derived Neurotrophic Factor; Glial Cell Line-Derived Neurotrophic Factor Receptors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Prospective Studies

2022
Do you get the GIST? Successful resection of a giant 3.5 kg gastrointestinal stromal tumour.
    ANZ journal of surgery, 2022, Volume: 92, Issue:12

    Topics: Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Pyrimidines

2022
Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability.
    Scientific reports, 2022, 05-18, Volume: 12, Issue:1

    Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Homoharringtonine; Humans; Imatinib Mesylate; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit

2022
Long-term adjuvant therapy for high-risk gastrointestinal stromal tumors in the real world.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2022, Volume: 25, Issue:5

    Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Stomach Neoplasms

2022
GASTROINTESTINAL STROMAL TUMOR: OUTCOMES OF THE PAST DECADE IN A REFERENCE INSTITUTION IN SOUTHERN BRAZIL.
    Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery, 2022, Volume: 35

    Topics: Antineoplastic Agents; Benzamides; Brazil; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Retrospective Studies

2022
[Advanced GIST: Which treatments in 2022?]
    Bulletin du cancer, 2022, Volume: 109, Issue:10

    Topics: Antineoplastic Agents; Electron Transport Complex II; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Metabolism, Inborn Errors; Mitochondrial Diseases; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Succinate Dehydrogenase; Sunitinib

2022
Surgical treatment of the metastatic gastrointestinal stromal tumor after resistance to available tyrosine kinase inhibitors: A case report.
    Asian journal of surgery, 2023, Volume: 46, Issue:2

    Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Tyrosine Kinase Inhibitors

2023
SPK1/S1P axis confers gastrointestinal stromal tumors (GISTs) resistance of imatinib.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2023, Volume: 26, Issue:1

    Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Proto-Oncogene Proteins c-kit; Signal Transduction; Stomach Neoplasms

2023
[Gastrointestinal stromal tumors (GIST)].
    Wiener medizinische Wochenschrift (1946), 2023, Volume: 173, Issue:9-10

    Topics: Aged; Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha

2023
Imatinib use for gastrointestinal stromal tumors among older patients in Japan and Taiwan.
    Scientific reports, 2022, 12-28, Volume: 12, Issue:1

    Topics: Adjuvants, Immunologic; Aged; Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Japan; Protein Kinase Inhibitors; Retrospective Studies; Taiwan

2022
Identification of M4205─A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors.
    Journal of medicinal chemistry, 2023, 02-23, Volume: 66, Issue:4

    Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-kit

2023
Transvaginal Resection of a Gastrointestinal Stromal Tumor (GIST) of the Rectum.
    The American surgeon, 2023, Volume: 89, Issue:7

    Topics: Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Rectal Neoplasms; Rectum

2023
Mesenchymal stromal cells promote the drug resistance of gastrointestinal stromal tumors by activating the PI3K-AKT pathway via TGF-β2.
    Journal of translational medicine, 2023, 03-25, Volume: 21, Issue:1

    Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mesenchymal Stem Cells; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Transforming Growth Factor beta2; Tumor Microenvironment

2023
Development of Highly Sensitive Digital Droplet PCR for Detection of cKIT Mutations in Circulating Free DNA That Mediate Resistance to TKI Treatment for Gastrointestinal Stromal Tumor (GIST).
    International journal of molecular sciences, 2023, Mar-12, Volume: 24, Issue:6

    Topics: Cell-Free Nucleic Acids; Circulating Tumor DNA; DNA; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Proto-Oncogene Proteins c-kit; Receptor Protein-Tyrosine Kinases

2023
Gastrointestinal Stromal Tumor Patients with Molecular Testing Exhibit Superior Survival Compared to Patients without Testing: Results from the Life Raft Group (LRG) Registry.
    Cancer investigation, 2023, Volume: 41, Issue:5

    Topics: Antineoplastic Agents; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Molecular Diagnostic Techniques; Registries; Retrospective Studies

2023
SPRY4 inhibits and sensitizes the primary KIT mutants in gastrointestinal stromal tumors (GISTs) to imatinib.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2023, Volume: 26, Issue:5

    Topics: Animals; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Stomach Neoplasms

2023
Cytoreductive surgery offers prognostic benefits in metastatic gastrointestinal stromal tumors with generalized progression following imatinib therapy: a single institute retrospective study.
    BMC surgery, 2023, Jul-04, Volume: 23, Issue:1

    Topics: Antineoplastic Agents; Cytoreduction Surgical Procedures; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Prognosis; Retrospective Studies

2023
Targeting BCL6 in Gastrointestinal Stromal Tumor Promotes p53-Mediated Apoptosis to Enhance the Antitumor Activity of Imatinib.
    Cancer research, 2023, 11-01, Volume: 83, Issue:21

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Proto-Oncogene Proteins c-bcl-6; Proto-Oncogene Proteins c-kit; Pyrimidines; Tumor Suppressor Protein p53

2023
MicroRNA-409-5p Inhibits GIST Tumorigenesis and Improves Imatinib Resistance by Targeting KDM4D Expression.
    Current medical science, 2023, Volume: 43, Issue:5

    Topics: Carcinogenesis; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Jumonji Domain-Containing Histone Demethylases; MicroRNAs; Vascular Endothelial Growth Factor A

2023
Multidrug resistant gastrointestinal stromal tumor with multiple metastases to the skin and subcutaneous soft tissue: A case report and review of literature.
    Journal of cutaneous pathology, 2020, Volume: 47, Issue:4

    Topics: Adult; Aged; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Skin Neoplasms; Sunitinib

2020
Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
    Pathology oncology research : POR, 2020, Volume: 26, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha

2020
Two step treatment for giant malignant gastrointestinal stromal tumor: A case report.
    Asian journal of surgery, 2020, Volume: 43, Issue:1

    Topics: Combined Modality Therapy; Digestive System Surgical Procedures; Embolization, Therapeutic; Enzyme Inhibitors; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Male; Middle Aged; Molecular Targeted Therapy; Protein-Tyrosine Kinases; Tomography, X-Ray Computed

2020
Coordinated targeting of CK2 and KIT in gastrointestinal stromal tumours.
    British journal of cancer, 2020, Volume: 122, Issue:3

    Topics: Apoptosis; Casein Kinase II; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Survival; Chaperonins; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Knockdown Techniques; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Naphthyridines; Phenazines; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Signal Transduction; TOR Serine-Threonine Kinases

2020
TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours.
    British journal of cancer, 2020, Volume: 122, Issue:5

    Topics: Animals; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Golgi Apparatus; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Proto-Oncogene Proteins c-kit; Pyrazoles; Signal Transduction; Xenograft Model Antitumor Assays

2020
Long-Term Survival After Multidisciplinary Treatment Including Surgery for Metachronous Metastases of Small Intestinal Gastrointestinal Stromal Tumors after Curative Resection: A Case Report.
    The American journal of case reports, 2019, Dec-26, Volume: 20

    Topics: Bone Neoplasms; Combined Modality Therapy; Fatal Outcome; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leiomyosarcoma; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Sunitinib

2019
Inhibition of FGFR2-Signaling Attenuates a Homology-Mediated DNA Repair in GIST and Sensitizes Them to DNA-Topoisomerase II Inhibitors.
    International journal of molecular sciences, 2020, Jan-05, Volume: 21, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; DNA Breaks, Double-Stranded; Doxorubicin; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Knockdown Techniques; Gene Silencing; Histones; Humans; Imatinib Mesylate; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Pyrimidines; Rad51 Recombinase; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Recombinational DNA Repair; RNA, Small Interfering; Signal Transduction; Topoisomerase II Inhibitors

2020
Adherence to Adjuvant Imatinib Therapy in Patients with Gastrointestinal Stromal Tumor in Clinical Practice: A Cross-Sectional Study.
    Chemotherapy, 2019, Volume: 64, Issue:4

    Topics: Chemotherapy, Adjuvant; Cross-Sectional Studies; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Health Status; Humans; Imatinib Mesylate; Logistic Models; Male; Medication Adherence; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Sex Factors; Social Support

2019
Bromodomain and extraterminal domain inhibitor enhances the antitumor effect of imatinib in gastrointestinal stromal tumours.
    Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:4

    Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Male; Mice; Mice, Nude; Middle Aged; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors

2020
Hyperpigmentation due to imatinib: A rare case of cutaneous involvement.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:6

    Topics: Aged; Antineoplastic Agents; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hyperpigmentation; Imatinib Mesylate; Protein Kinase Inhibitors

2020
Preoperative imatinib treatment in patients with locally advanced and metastatic/recurrent gastrointestinal stromal tumors: A single-center analysis.
    Medicine, 2020, Volume: 99, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; China; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Medical Records; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Retrospective Studies; Survival Analysis; Treatment Outcome

2020
[A Case of Gastrointestinal Stromal Tumor Re-Resected Ten Years after the Resection of Its Recurrence].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:13

    Topics: Aged; Angiomyolipoma; Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Neoplasm Recurrence, Local

2019
Treatment options for giant gastrointestinal stromal tumours and related prognosis: a single-centre retrospective study.
    ANZ journal of surgery, 2020, Volume: 90, Issue:5

    Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Prognosis; Retrospective Studies

2020
Generalized lentigines associated with familial gastrointestinal stromal tumors dramatically improved by imatinib treatment.
    The Journal of dermatology, 2020, Volume: 47, Issue:6

    Topics: Chemotherapy, Adjuvant; Dermoscopy; DNA Mutational Analysis; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Female; Gastrectomy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gastroscopy; Humans; Imatinib Mesylate; Lentigo; Middle Aged; Neoplastic Syndromes, Hereditary; Point Mutation; Proto-Oncogene Proteins c-kit; Skin; Stomach; Treatment Outcome

2020
MicroRNA-30a targets BECLIN-1 to inactivate autophagy and sensitizes gastrointestinal stromal tumor cells to imatinib.
    Cell death & disease, 2020, 03-23, Volume: 11, Issue:3

    Topics: Animals; Antineoplastic Agents; Autophagy; Beclin-1; Cell Line, Tumor; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mice; Mice, Nude; MicroRNAs; Transfection; Xenograft Model Antitumor Assays

2020
Preoperative adjuvant therapy for locally advanced and recurrent/metastatic gastrointestinal stromal tumors: a retrospective study.
    World journal of surgical oncology, 2020, Apr-07, Volume: 18, Issue:1

    Topics: Adult; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies

2020
Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience.
    Oncology, 2020, Volume: 98, Issue:7

    Topics: Aged; Coronary Artery Disease; Dasatinib; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Pulse Wave Analysis; Pyridazines; Pyrimidines; Retrospective Studies; Treatment Outcome

2020
[Case of Intestinal GIST with Long-Term Survival after Multidisciplinary Treatment, Including Surgical Resection for Liver Metastasis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:1

    Topics: Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged

2020
[A Case of Multidisciplinary Treatment for a Recurrent Gastrointestinal Stromal Tumor of the Stomach].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:2

    Topics: Aged; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Stomach

2020
Therapeutic drug monitoring-based dose optimization for imatinib-associated serious cutaneous reactions in a patient with gastrointestinal stromal tumours: A case report.
    Journal of clinical pharmacy and therapeutics, 2020, Volume: 45, Issue:4

    Topics: Aged; Drug Eruptions; Drug Monitoring; Eczema; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Skin Diseases

2020
An Unexpected Response to Imatinib in a "Wild-Type" Gastrointestinal Stromal Tumor.
    Oncology research and treatment, 2020, Volume: 43, Issue:9

    Topics: Antineoplastic Agents; DNA Mutational Analysis; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Middle Aged; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Treatment Outcome

2020
Gastrointestinal stromal tumors and second primary malignancies: a retrospective monocentric analysis.
    Neoplasma, 2020, Volume: 67, Issue:6

    Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasms, Second Primary; Prognosis; Retrospective Studies

2020
Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours - Results from daily clinical practice.
    European journal of cancer (Oxford, England : 1990), 2020, Volume: 136

    Topics: Aged; Cohort Studies; Dose-Response Relationship, Drug; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Netherlands; Practice Patterns, Physicians'; Progression-Free Survival; Retrospective Studies

2020
Locally Advanced Gastrointestinal Stromal Tumor in a 33-Year-Old Woman Seeking to Conceive.
    Oncology (Williston Park, N.Y.), 2020, Aug-12, Volume: 34, Issue:8

    Topics: Adult; Combined Modality Therapy; Female; Fertility Preservation; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Staging; Protein Kinase Inhibitors; Treatment Outcome

2020
Pemphigus foliaceus in a patient with gastrointestinal stromal tumor treated with adjuvant imatinib mesylate.
    Dermatology online journal, 2020, Jun-15, Volume: 26, Issue:6

    Topics: Aged, 80 and over; Antineoplastic Agents; Biopsy; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunologic Factors; Male; Pemphigus; Rituximab; Skin

2020
[Significance of surgical treatment for recurrent and metastatic gastrointestinal stromal tumors].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2020, Sep-25, Volume: 23, Issue:9

    Topics: Antineoplastic Agents; Cytoreduction Surgical Procedures; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Patient Care Team; Sunitinib; Treatment Outcome; Tumor Burden

2020
[Research advance of liquid biopsy in gastrointestinal stromal tumors].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2020, Sep-25, Volume: 23, Issue:9

    Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Early Detection of Cancer; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liquid Biopsy; Neoplasm Recurrence, Local

2020
Gastric Gastrointestinal Stromal Tumor with Repeated Recurrence at the Anastomosis Site in a Very Elderly Patient.
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2020, 10-25, Volume: 76, Issue:4

    Topics: Abdomen; Aged, 80 and over; Endoscopy, Gastrointestinal; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Tomography, X-Ray Computed

2020
Prognostic Factors After Neoadjuvant Imatinib for Newly Diagnosed Primary Gastrointestinal Stromal Tumor.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2021, Volume: 25, Issue:7

    Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Prognosis; Prospective Studies; Retrospective Studies

2021
Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan.
    JAMA network open, 2020, 11-02, Volume: 3, Issue:11

    Topics: Antineoplastic Agents; Budgets; Cost-Benefit Analysis; Formularies as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indazoles; Managed Care Programs; Medicaid; Medicare; Molecular Diagnostic Techniques; Phenylurea Compounds; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sulfonamides; Sunitinib; Treatment Failure; Triazines; United States

2020
Imatinib-induced pancreatic hypertrophy in patients with gastrointestinal stromal tumor: Association with overall survival.
    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2021, Volume: 21, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Atrophy; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hypertrophy; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Pancreas; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis

2021
Impaired Wound Healing with Imatinib Mesylate Therapy.
    Advances in skin & wound care, 2021, Feb-01, Volume: 34, Issue:2

    Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Skin Ulcer; Wound Healing

2021
Clinical significance of surgical intervention for imatinib-resistant gastrointestinal stromal tumors in the era of multiple tyrosine kinase inhibitors.
    Surgery today, 2021, Volume: 51, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Retrospective Studies; Survival Rate; Treatment Outcome

2021
Imatinib-resistant gastrointestinal stromal tumors in the era of second- and third-line tyrosine kinase inhibitors: Does surgical resection have a role?
    Surgery, 2021, Volume: 170, Issue:5

    Topics: Adult; Aged; Decision Making; Digestive System Surgical Procedures; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Protein Kinase Inhibitors; Registries; Retrospective Studies; Time Factors

2021
Oncogene mutational analysis in imatinib naive population of gastrointestinal stromal tumor patients.
    Cellular and molecular biology (Noisy-le-Grand, France), 2020, Dec-31, Volume: 66, Issue:8

    Topics: Adult; Aged; Anoctamin-1; Antigens, CD34; Antineoplastic Agents; DNA Mutational Analysis; Drug Resistance, Neoplasm; Exons; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha

2020
Clinicopathological Features and Outcomes of Gastrointestinal Stromal Tumours in Oman: A multi-centre study.
    Sultan Qaboos University medical journal, 2021, Volume: 21, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Oman; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Retrospective Studies; Survival Rate; United States

2021
Inhibition of PI3K and MAPK pathways along with KIT inhibitors as a strategy to overcome drug resistance in gastrointestinal stromal tumors.
    PloS one, 2021, Volume: 16, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; MAP Kinase Signaling System; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Xenograft Model Antitumor Assays

2021
New response evaluation criteria using early morphological change in imatinib treatment for patients with gastrointestinal stromal tumor.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2022, Volume: 25, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Retrospective Studies; Stomach Neoplasms; Treatment Outcome

2022
Skeletal muscle metastasis from a gastrointestinal stromal tumor: A case report.
    Medicine, 2021, Aug-27, Volume: 100, Issue:34

    Topics: Drug Resistance, Neoplasm; Exome Sequencing; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Muscle Neoplasms; Muscle, Skeletal; Sunitinib; Thigh

2021
Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany.
    Clinical drug investigation, 2017, Volume: 37, Issue:6

    Topics: Aged; Antineoplastic Agents; Cost-Benefit Analysis; Drug Costs; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Phenylurea Compounds; Pyridines; Quality-Adjusted Life Years

2017
An Epithelioid Gastrointestinal Stromal Tumor of the Stomach With Strong Expression of Keratin: Clinicopathologic Correlation and Follow-up Post-Imatinib Therapy.
    Applied immunohistochemistry & molecular morphology : AIMM, 2019, Volume: 27, Issue:9

    Topics: Aged; Anoctamin-1; Antigens, CD34; Antineoplastic Agents; Biomarkers, Tumor; Diagnosis, Differential; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Keratins; Male; Mutation; Neoplasm Proteins; Proto-Oncogene Proteins c-kit; Stomach

2019
Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients.
    Pharmacogenetics and genomics, 2017, Volume: 27, Issue:6

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Cytochrome P-450 CYP2C8; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Prospective Studies

2017
Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST).
    World journal of surgical oncology, 2017, Apr-11, Volume: 15, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Preoperative Care; Prognosis; Retrospective Studies; Survival Rate

2017
Conventional transanal excision for a very low gastrointestinal stromal tumour.
    BMJ case reports, 2017, Apr-21, Volume: 2017

    Topics: Adult; Anal Canal; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Treatment Outcome

2017
Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors: A 2-institutional Analysis.
    Annals of surgery, 2018, Volume: 268, Issue:2

    Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Metastasectomy; Neoplasm Metastasis; Prognosis; Retrospective Studies; Sunitinib; Survival Analysis

2018
Simultaneous quantification of imatinib and its main metabolite N-demethyl-imatinib in human plasma by liquid chromatography-tandem mass spectrometry and its application to therapeutic drug monitoring in patients with gastrointestinal stromal tumor.
    Biomedical chromatography : BMC, 2017, Volume: 31, Issue:12

    Topics: Adult; Antineoplastic Agents; Chromatography, Liquid; Drug Monitoring; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Limit of Detection; Linear Models; Male; Middle Aged; Reproducibility of Results; Tandem Mass Spectrometry

2017
Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.
    Cancer research, 2017, 09-15, Volume: 77, Issue:18

    Topics: Animals; Antigens, CD; Apoptosis; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Mice; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Insulin; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2017
New Mechanisms of mTOR Pathway Activation in KIT-mutant Malignant GISTs.
    Applied immunohistochemistry & molecular morphology : AIMM, 2019, Volume: 27, Issue:1

    Topics: 3T3 Cells; Adult; Aged; Aged, 80 and over; Animals; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Female; Fibroblasts; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Male; Mice; Middle Aged; Mutation; Patient Selection; Proto-Oncogene Proteins c-kit; PTEN Phosphohydrolase; Signal Transduction; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 2 Protein

2019
Early Evaluation of Response Using
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018, Volume: 59, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult

2018
[Gastrointestinal stromal tumors. Analysis of 40 cases].
    Medicina, 2017, Volume: 77, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Prognosis; Retrospective Studies

2017
Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 86

    Topics: Angiogenic Proteins; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Exons; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genetic Association Studies; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Mutation; Pharmacogenetics; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Retrospective Studies; Risk Factors; Solute Carrier Organic Anion Transporter Family Member 1B3; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2017
Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome.
    Annals of surgical oncology, 2017, Volume: 24, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Medical Oncology; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organ Preservation; Prognosis; Prospective Studies; Rectal Neoplasms; Retrospective Studies; Survival Rate

2017
Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series.
    BMC cancer, 2017, Nov-06, Volume: 17, Issue:1

    Topics: Adolescent; Antineoplastic Agents; Child; Europe; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Proto-Oncogene Proteins c-kit; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome; United States; Young Adult

2017
Gastrointestinal stromal tumor (GIST) with liver metastases: An 18-year experience from the GIST cooperation group in North China.
    Medicine, 2017, Volume: 96, Issue:46

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; China; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Retrospective Studies; Young Adult

2017
Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 02-15, Volume: 24, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hydrazones; Imatinib Mesylate; Metabolic Networks and Pathways; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Mitochondria; Protein Kinase Inhibitors; Treatment Outcome; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays

2018
[Treatment of Regorafenib in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Phenylurea Compounds; Pyridines; Pyrroles; Sunitinib

2018
[Gastrointestinal stromal tumors (GIST): The particularities aspects in African countries].
    Bulletin du cancer, 2018, Volume: 105, Issue:2

    Topics: Adolescent; Adult; Africa; Aged; Antineoplastic Agents; Developing Countries; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mali; Middle Aged; Retrospective Studies; Survival Analysis; Young Adult

2018
[Gatrointestinal stromal tumor: a case report].
    Ginecologia y obstetricia de Mexico, 2016, Volume: 84, Issue:9

    Topics: Abdominal Pain; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparotomy; Middle Aged; Tomography, X-Ray Computed

2016
Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene.
    International journal of molecular sciences, 2018, Mar-04, Volume: 19, Issue:3

    Topics: Adult; Aged; Benzimidazoles; Drug Resistance, Neoplasm; Electron Transport Complex II; F-Box-WD Repeat-Containing Protein 7; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation, Missense; Piperidines; Protein Binding; Protein Kinase Inhibitors; Protein Stability; Receptor, Platelet-Derived Growth Factor alpha; Transcriptome; Tumor Suppressor Protein p53

2018
Prediction of morbidity following cytoreductive surgery for metastatic gastrointestinal stromal tumour in patients on tyrosine kinase inhibitor therapy.
    The British journal of surgery, 2018, Volume: 105, Issue:6

    Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Cytoreduction Surgical Procedures; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Metastasectomy; Middle Aged; Protein-Tyrosine Kinases; Risk Factors

2018
Treatment outcomes in older patients with advanced gastrointestinal stromal tumor (GIST).
    Journal of geriatric oncology, 2018, Volume: 9, Issue:5

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Progression-Free Survival; Prospective Studies; Protein Kinase Inhibitors; Sunitinib; Young Adult

2018
Inhibition of fibroblast growth factor receptor-signaling sensitizes imatinib-resistant gastrointestinal stromal tumors to low doses of topoisomerase II inhibitors.
    Anti-cancer drugs, 2018, Volume: 29, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; DNA Damage; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Phenylurea Compounds; Pyrimidines; Rad51 Recombinase; Receptors, Fibroblast Growth Factor; Signal Transduction; Topoisomerase II Inhibitors

2018
A naphthalene diimide G-quadruplex ligand inhibits cell growth and down-regulates BCL-2 expression in an imatinib-resistant gastrointestinal cancer cell line.
    Bioorganic & medicinal chemistry, 2018, 07-15, Volume: 26, Issue:11

    Topics: Down-Regulation; Drug Resistance, Neoplasm; G-Quadruplexes; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Imides; Ligands; MCF-7 Cells; Molecular Structure; Naphthalenes; Proto-Oncogene Proteins c-bcl-2

2018
Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.
    Molecular oncology, 2018, Volume: 12, Issue:8

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Imatinib Mesylate; Mice, Nude; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha

2018
Imatinib-Related Conjunctival Pigmentation.
    Ophthalmology, 2018, Volume: 125, Issue:7

    Topics: Aged; Antineoplastic Agents; Conjunctival Diseases; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Pigmentation Disorders

2018
Inhibition of stromal-interacting molecule 1-mediated store-operated Ca
    Cancer science, 2018, Volume: 109, Issue:9

    Topics: Adult; Aged; Animals; Antineoplastic Agents; Calcium; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; MAP Kinase Signaling System; Mice; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Neoplasm Proteins; Stromal Interaction Molecule 1

2018
Surgical resection as an adjuvant to tyrosine kinase inhibitors in metastatic GIST: Association or causation?/Are we any closer to an answer?
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2018, Volume: 44, Issue:9

    Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Protein-Tyrosine Kinases

2018
Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor.
    Future oncology (London, England), 2018, Volume: 14, Issue:17

    Topics: Antineoplastic Agents; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Postoperative Period; Prognosis; Survival Rate

2018
Pemphigus foliaceus associated with imatinib therapy in a patient with gastrointestinal stromal tumor.
    International journal of dermatology, 2018, Volume: 57, Issue:10

    Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Drug Eruptions; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Pemphigus

2018
Genome-scale CRISPR-Cas9 knockout screening in gastrointestinal stromal tumor with Imatinib resistance.
    Molecular cancer, 2018, 08-13, Volume: 17, Issue:1

    Topics: Cell Line, Tumor; CRISPR-Cas Systems; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Imatinib Mesylate; Signal Transduction

2018
Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.
    The oncologist, 2019, Volume: 24, Issue:5

    Topics: Adult; Antineoplastic Agents; Case-Control Studies; Disease Progression; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Prognosis; Progression-Free Survival; Sarcoma; Time Factors

2019
miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors.
    Experimental cell research, 2018, 10-01, Volume: 371, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Focal Adhesion Kinase 1; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; MicroRNAs; Oligoribonucleotides; Phosphorylation; Prognosis; Protein Kinase Inhibitors; Protein Tyrosine Phosphatases, Non-Receptor; RNA, Messenger; RNA, Small Interfering; Signal Transduction; STAT3 Transcription Factor; Survival Analysis

2018
Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo.
    Molecules (Basel, Switzerland), 2018, Oct-15, Volume: 23, Issue:10

    Topics: Animals; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Random Allocation; Signal Transduction; Xenograft Model Antitumor Assays

2018
Radiofrequency ablation versus resection for resectable liver metastases of gastrointestinal stromal tumours: Results from three national centres in China.
    Clinics and research in hepatology and gastroenterology, 2019, Volume: 43, Issue:3

    Topics: Adult; Aged; China; Combined Modality Therapy; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Length of Stay; Liver Neoplasms; Male; Middle Aged; Postoperative Complications; Prognosis; Protein Kinase Inhibitors; Radiofrequency Ablation; Retrospective Studies; Sunitinib

2019
Relationship between R1 resection, tumour rupture and recurrence in resected gastrointestinal stromal tumour.
    The British journal of surgery, 2019, Volume: 106, Issue:4

    Topics: Adult; Aged; Databases, Factual; Digestive System Surgical Procedures; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hospitals, University; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Margins of Excision; Middle Aged; Neoplasm Recurrence, Local; Norway; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Rupture; Survival Analysis; Treatment Outcome

2019
Serum miR-518e-5p is a potential biomarker for secondary imatinib-resistant gastrointestinal stromal tumor.
    Journal of biosciences, 2018, Volume: 43, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Case-Control Studies; Drug Resistance, Neoplasm; Early Diagnosis; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression; Humans; Imatinib Mesylate; Male; MicroRNAs; Middle Aged; Neoplasms, Second Primary; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; ROC Curve

2018
Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition.
    Cancer research, 2019, 03-01, Volume: 79, Issue:5

    Topics: Animals; Apoptosis; Azepines; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression; HEK293 Cells; Humans; Imatinib Mesylate; Mice; Mice, Nude; Protein Domains; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-kit; Triazoles; Xenograft Model Antitumor Assays

2019
Diagnosis and Treatment Monitoring of a Patient with Gastrointestinal Stromal Tumor by Next-Generation Sequencing and Droplet Digital Polymerase Chain Reaction Assay of a PDGFRA Mutation in Plasma-Derived Cell-Free Tumor DNA.
    The oncologist, 2019, Volume: 24, Issue:6

    Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Circulating Tumor DNA; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Liquid Biopsy; Mutation; Polymerase Chain Reaction; Prognosis; Receptor, Platelet-Derived Growth Factor alpha

2019
Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience.
    Cancer medicine, 2019, Volume: 8, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cancer Survivors; Cohort Studies; Combined Modality Therapy; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Survival Rate; Treatment Outcome; Young Adult

2019
Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors.
    The pharmacogenomics journal, 2019, Volume: 19, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cytochrome P-450 CYP1A2; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Single Nucleotide; Retrospective Studies; Young Adult

2019
PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
    Cell proliferation, 2019, Volume: 52, Issue:3

    Topics: Apoptosis; B7-H1 Antigen; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Interferon-gamma; Lymphocytes, Tumor-Infiltrating; Phosphatidylinositol 3-Kinases; Prognosis; Programmed Cell Death 1 Receptor; Proto-Oncogene Proteins c-akt; RNA, Messenger; RNA, Neoplasm; Signal Transduction; TOR Serine-Threonine Kinases

2019
Molecular modelling evaluation of exon 18 His845_Asn848delinsPro PDGFRα mutation in a metastatic GIST patient responding to imatinib.
    Scientific reports, 2019, 02-18, Volume: 9, Issue:1

    Topics: Aged; Antineoplastic Agents; Binding Sites; Computer Simulation; Exons; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; INDEL Mutation; Models, Molecular; Molecular Docking Simulation; Mutant Proteins; Protein Conformation; Receptor, Platelet-Derived Growth Factor alpha

2019
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.
    British journal of cancer, 2019, Volume: 120, Issue:6

    Topics: Animals; CHO Cells; Clinical Trials, Phase II as Topic; Cricetulus; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Mice, Nude; Mutation; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Sunitinib; Xenograft Model Antitumor Assays

2019
Small intestinal perforation due to a huge gastrointestinal stromal tumor in a kidney transplant recipient: a case report and literature review.
    BMC nephrology, 2019, 04-03, Volume: 20, Issue:1

    Topics: Antineoplastic Agents; Digestive System Surgical Procedures; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunocompromised Host; Intestinal Perforation; Intestine, Small; Kidney Transplantation; Male; Middle Aged; Mutation; Proto-Oncogene Proteins c-kit; Treatment Outcome; Tumor Burden

2019
Ethyl-2-amino-pyrrole-3-carboxylates are active against imatinib-resistant gastrointestinal stromal tumors in vitro and in vivo.
    Anti-cancer drugs, 2019, Volume: 30, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carboxylic Acids; Cell Proliferation; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; In Vitro Techniques; Mice; Mice, Nude; Pyrroles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2019
Management of complicated tumor response to tyrosine-kinase inhibitors in gastrointestinal stromal tumors.
    Journal of surgical oncology, 2019, Volume: 120, Issue:2

    Topics: Antineoplastic Agents; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Incidence; Male; Middle Aged; Postoperative Complications; Protein Kinase Inhibitors; Retrospective Studies; Sunitinib

2019
Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness study.
    British journal of clinical pharmacology, 2019, Volume: 85, Issue:9

    Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Computer Simulation; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Costs; Drug Monitoring; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Markov Chains; Models, Economic; Progression-Free Survival; Quality-Adjusted Life Years

2019
Prognosis assessment in metastatic gastrointestinal stromal tumors treated with tyrosine kinase inhibitors based on CT-texture analysis.
    European journal of radiology, 2019, Volume: 116

    Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Humans; Imatinib Mesylate; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Tomography, X-Ray Computed; Treatment Outcome

2019
Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2020, Volume: 23, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Male; Middle Aged; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrimidinones

2020
Epithelioid variant of gastrointestinal stromal tumor harboring PDGFRA mutation and MLH1 gene alteration: A case report.
    Pathology international, 2019, Volume: 69, Issue:9

    Topics: Amino Acid Substitution; Anoctamin-1; Antineoplastic Agents; Epithelioid Cells; Exons; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Humans; Imatinib Mesylate; Middle Aged; Mutation; MutL Protein Homolog 1; Neoplasm Proteins; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha

2019
An unusual cause of gastrointestinal bleed in patients with liver cirrhosis.
    BMJ case reports, 2019, Jul-10, Volume: 12, Issue:7

    Topics: Aged; Antineoplastic Agents; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Humans; Imatinib Mesylate; Liver Cirrhosis; Male; Middle Aged; Tomography, X-Ray Computed

2019
Frequent rectal gastrointestinal stromal tumor recurrences in the imatinib era: Retrospective analysis of an International Patient Registry.
    Journal of surgical oncology, 2019, Volume: 120, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; International Agencies; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Rectal Neoplasms; Registries; Retrospective Studies; Survival Rate

2019
Replacement Resistant Iron Deficiency Anemia in a Patient With Ulcerative Colitis in Remission: Investigating Beyond the Obvious.
    Inflammatory bowel diseases, 2019, 09-18, Volume: 25, Issue:10

    Topics: Anemia, Iron-Deficiency; Colitis, Ulcerative; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Iron; Iron Deficiencies; Middle Aged; Prognosis; Remission Induction

2019
Quantitative Mass Spectrometry Imaging Reveals Mutation Status-independent Lack of Imatinib in Liver Metastases of Gastrointestinal Stromal Tumors.
    Scientific reports, 2019, 07-23, Volume: 9, Issue:1

    Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver; Liver Neoplasms; Mutation; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

2019
Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors.
    Oncogene, 2019, Volume: 38, Issue:38

    Topics: Animals; Cell Nucleus; Chlorocebus aethiops; COS Cells; Drug Resistance, Neoplasm; Feedback, Physiological; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Homeostasis; Humans; I-kappa B Proteins; Imatinib Mesylate; Male; Mice; Mice, Inbred NOD; Mice, SCID; Proto-Oncogene Proteins c-kit; Signal Transduction; Transcription Factor RelA; Up-Regulation

2019
The Impact of Imatinib on Survival and Treatment Trends for Small Bowel and Colorectal Gastrointestinal Stromal Tumors.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2020, Volume: 24, Issue:1

    Topics: Aged; Antineoplastic Agents; Colorectal Neoplasms; Databases, Factual; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestine, Small; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; United States

2020
Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.
    Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:2

    Topics: Adult; Aged; Amino Acid Sequence; Antineoplastic Agents; Asian People; Benzamides; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Sequence Data; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Treatment Outcome; Young Adult

2013
Extracellular domain c-kit mutation with duplication of Ser501Ala502 found in gastrointestinal stromal tumors is more imatinib- and nilotinib-sensitive than that with duplication of Ala502Tyr503.
    Laboratory investigation; a journal of technical methods and pathology, 2013, Volume: 93, Issue:5

    Topics: Aged; Amino Acid Sequence; Animals; Antineoplastic Agents; Base Sequence; Benzamides; CHO Cells; Cricetinae; Cricetulus; Drug Resistance, Neoplasm; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Duplication; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Molecular Sequence Data; Mutation; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Transfection

2013
Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H.
    Acta oncologica (Stockholm, Sweden), 2013, Volume: 52, Issue:4

    Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Aspartic Acid; Benzamides; Drug Administration Schedule; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Histidine; Humans; Imatinib Mesylate; Mice; Mice, Nude; Mutation, Missense; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Xenograft Model Antitumor Assays

2013
Gastrointestinal stromal tumors: diagnosis, therapy and follow-up care in Austria.
    Wiener medizinische Wochenschrift (1946), 2013, Volume: 163, Issue:5-6

    Topics: Adult; Aftercare; Austria; Benzamides; Biopsy; Child; Combined Modality Therapy; Cooperative Behavior; Diagnosis, Differential; Diagnostic Imaging; Disease Progression; Endoscopy, Gastrointestinal; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Humans; Imatinib Mesylate; Indoles; Interdisciplinary Communication; Mitotic Index; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Nomograms; Palliative Care; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Sunitinib

2013
[Gastrointestinal stromal tumor (GIST)--tyrosine kinase inhibitors].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 8

    Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib

2012
[New prospective on adjuvant treatment for gastrointestinal stromal tumors].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2013, Volume: 16, Issue:3

    Topics: Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines

2013
[Efficacy observation on imatinib adjuvant therapy with longer duration in patients with gastrointestinal stromal at intermediate or high risk of recurrence].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2013, Volume: 16, Issue:3

    Topics: Adult; Aged; Benzamides; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Retrospective Studies; Treatment Outcome

2013
[Efficacy and safety of sunitinib on patients with imatinib-resistant gastrointestinal stromal tumor].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2013, Volume: 16, Issue:3

    Topics: Adult; Aged; Benzamides; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome

2013
[Application of perioperative imatinib mesylate therapy in initial resectable primary local advanced gastrointestinal stromal tumor at intermediate or high risk].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2013, Volume: 16, Issue:3

    Topics: Adult; Aged; Benzamides; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Perioperative Care; Piperazines; Prognosis; Pyrimidines; Retrospective Studies

2013
Peripheral neuropathy induced by red yeast rice in a patient with a known small bowel gastrointestinal tumour.
    BMJ case reports, 2013, Apr-05, Volume: 2013

    Topics: Antineoplastic Agents; Benzamides; Biological Products; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Intestine, Small; Male; Middle Aged; Peripheral Nervous System Diseases; Piperazines; Pyrimidines

2013
Osteonecrosis of the tibia associated with imatinib in metastatic GI stromal tumor.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jun-01, Volume: 31, Issue:16

    Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Incidental Findings; Liver Neoplasms; Middle Aged; Osteonecrosis; Pain; Peritoneal Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Range of Motion, Articular; Tibia

2013
NCCN Task Force report: gastrointestinal stromal tumor (GIST).
    Journal of the National Comprehensive Cancer Network : JNCCN, 2004, Volume: 2 Suppl 3

    Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperazines; Pyrimidines

2004
Rare, germline mutation of KIT with imatinib-resistant multiple GI stromal tumors and mastocytosis.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jun-01, Volume: 31, Issue:16

    Topics: Adult; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Drug Resistance, Neoplasm; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Germ-Line Mutation; Humans; Imatinib Mesylate; Immunohistochemistry; Intestine, Small; Male; Mastocytosis; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Tomography, X-Ray Computed

2013
[Molecular and histologic characteristics of secondary imatinib-resistant gastrointestinal stromal tumors].
    Zhonghua bing li xue za zhi = Chinese journal of pathology, 2013, Volume: 42, Issue:1

    Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Exons; Gastrectomy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines

2013
Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour.
    ANZ journal of surgery, 2014, Volume: 84, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines; Retrospective Studies; Survival Analysis; Treatment Outcome

2014
Lichenoid drug eruption with hyperpigmentation caused by imatinib mesylate.
    International journal of dermatology, 2014, Volume: 53, Issue:3

    Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hyperpigmentation; Imatinib Mesylate; Lichenoid Eruptions; Middle Aged; Piperazines; Pyrimidines

2014
[A case of liver and bone metastases after complete resection of gastric GIST effectively treated with radiotherapy and imatinib mesylate].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2013, Volume: 110, Issue:7

    Topics: Aged; Antineoplastic Agents; Benzamides; Bone Neoplasms; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Piperazines; Pyrimidines

2013
Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.
    PloS one, 2013, Volume: 8, Issue:6

    Topics: Amino Acid Motifs; Animals; Antineoplastic Agents; Benzamides; Chlorocebus aethiops; COS Cells; Dasatinib; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hydrogen Bonding; Imatinib Mesylate; Indoles; Molecular Docking Simulation; Mutation, Missense; Piperazines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Thiazoles

2013
Value of pharmacokinetic studies for patients with gastrointestinal stromal tumors.
    Future oncology (London, England), 2013, Volume: 9, Issue:11

    Topics: Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Piperazines; Pyrimidines; Pyrroles; Sunitinib

2013
Presentation and management of gastrointestinal stromal tumours.
    Irish medical journal, 2013, Volume: 106, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Child; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopes; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Retrospective Studies; Survival Rate; Young Adult

2013
Sunitinib-induced reversible purpuric rash in a patient with gastrointestinal stromal tumor.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2014, Volume: 20, Issue:4

    Topics: Aged; Antineoplastic Agents; Exanthema; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Protein Kinase Inhibitors; Pyrroles; Sunitinib

2014
Imatinib plasma monitoring-guided dose modification for managing imatinib-related toxicities in gastrointestinal stromal tumor patients.
    Journal of Korean medical science, 2013, Volume: 28, Issue:8

    Topics: Aged; Antineoplastic Agents; Benzamides; Drug Monitoring; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Mutation; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines; Tomography, X-Ray Computed

2013
Gastrointestinal stromal tumors with KIT exon 9 mutations: Update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testing.
    The American journal of surgical pathology, 2013, Volume: 37, Issue:11

    Topics: Aged; Antineoplastic Agents; Benzamides; Chi-Square Distribution; DNA Mutational Analysis; Exons; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Nucleic Acid Denaturation; Phenotype; Piperazines; Predictive Value of Tests; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Registries; Reproducibility of Results; Treatment Outcome

2013
MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors.
    Acta biochimica et biophysica Sinica, 2014, Volume: 46, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Down-Regulation; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; MicroRNAs; Piperazines; Pyrimidines

2014
Radiologic assessment of earliest, best, and plateau response of gastrointestinal stromal tumors to neoadjuvant imatinib prior to successful surgical resection.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2014, Volume: 40, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Digestive System Surgical Procedures; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Outcome

2014
Ten-year review of gastrointestinal stromal tumours at a tertiary referral hospital in New Zealand.
    ANZ journal of surgery, 2016, Volume: 86, Issue:3

    Topics: Aged; Clinical Decision-Making; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; New Zealand; Prognosis; Survival Analysis; Tertiary Care Centers; Treatment Outcome

2016
21st-century oncology: a tangled web.
    Lancet (London, England), 2013, Dec-14, Volume: 382, Issue:9909

    Topics: Antineoplastic Agents; Benzamides; Biomedical Research; Drug Industry; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines

2013
Hair graying and loss induced by imatinib mesylate.
    The Journal of dermatology, 2014, Volume: 41, Issue:1

    Topics: Adult; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hair; Hair Color; Hair Diseases; Humans; Imatinib Mesylate; Piperazines; Pyrimidines

2014
Intracellular concentration of the tyrosine kinase inhibitor imatinib in gastrointestinal stromal tumor cells.
    Anti-cancer drugs, 2014, Volume: 25, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Reproducibility of Results

2014
Src activity is increased in gastrointestinal stromal tumors--analysis of associations with clinical and other molecular tumor characteristics.
    Journal of surgical oncology, 2014, Volume: 109, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; src-Family Kinases; Vascular Endothelial Growth Factor A

2014
Prognostic factors for primary gastrointestinal stromal tumours: are they the same in the multidisciplinary treatment era?
    Langenbeck's archives of surgery, 2014, Volume: 399, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Colectomy; Combined Modality Therapy; Disease-Free Survival; Female; Gastrectomy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Treatment Outcome; Young Adult

2014
[Gastrointestinal stromal tumours bigger than 20 cm: experience with imatinib chemotherapy in neoadjuvant intention].
    Zeitschrift fur Gastroenterologie, 2014, Volume: 52, Issue:1

    Topics: Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Piperazines; Pyrimidines; Treatment Outcome; Tumor Burden

2014
Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study).
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2014, Volume: 40, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Confounding Factors, Epidemiologic; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Liver Neoplasms; Male; Metastasectomy; Middle Aged; Patient Selection; Peritoneal Neoplasms; Piperazines; Predictive Value of Tests; Prognosis; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Selection Bias; Treatment Outcome

2014
Complete pathological response in advanced extra-gastrointestinal stromal tumor after imatinib mesylate therapy: a case report.
    Anticancer research, 2014, Volume: 34, Issue:2

    Topics: Aged; Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mesentery; Omentum; Peritoneal Neoplasms; Piperazines; Pyrimidines; Rectal Neoplasms; Urinary Bladder Neoplasms

2014
CTHRC1 acts as a prognostic factor and promotes invasiveness of gastrointestinal stromal tumors by activating Wnt/PCP-Rho signaling.
    Neoplasia (New York, N.Y.), 2014, Volume: 16, Issue:3

    Topics: Benzamides; Cell Movement; Extracellular Matrix Proteins; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prognosis; Proto-Oncogene Proteins; Pyrimidines; rac1 GTP-Binding Protein; rhoA GTP-Binding Protein; Wnt Proteins; Wnt Signaling Pathway; Wnt-5a Protein

2014
Evaluating new therapies in gastrointestinal stromal tumor using in vivo molecular optical imaging.
    Cancer biology & therapy, 2014, Volume: 15, Issue:7

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Biomarkers, Tumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Heterografts; Imatinib Mesylate; Magnetic Resonance Imaging; Mice, Nude; Molecular Imaging; Molecular Probes; Neoplasm Transplantation; Piperazines; Pyrimidines; Tomography, Optical

2014
[Treatment strategy for recurrent and metastatic gastrointestinal stromal tumors].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2014, Volume: 17, Issue:4

    Topics: Benzamides; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indazoles; Indoles; Liver Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Recurrence; Sulfonamides; Sunitinib

2014
[Drug resistance mechanism and new therapy strategy progression in targeted treatment of gastrointestinal stromal tumors].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2014, Volume: 17, Issue:4

    Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Quality of Life; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib

2014
[A multicentre retrospective cohort study of patients with gastrointestinal stromal tumors in Shandong Province].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2014, Volume: 17, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Cohort Studies; Combined Modality Therapy; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Piperazines; Prognosis; Proportional Hazards Models; Pyrimidines; Retrospective Studies; Survival Rate; Young Adult

2014
[Clinical analysis of 156 patients with gastrointestinal stromal tumors receiving imatinib therapy].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2014, Volume: 17, Issue:4

    Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Prognosis; Pyrimidines; Retrospective Studies; Survival Rate

2014
Treatment patterns, prescribing decision drivers, and predictors of complete response following disease recurrence in gastrointestinal stromal tumor patients-a chart extract-based approach.
    Journal of gastrointestinal cancer, 2014, Volume: 45, Issue:4

    Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Retrospective Studies; Treatment Outcome

2014
Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome.
    BMC gastroenterology, 2014, Jun-07, Volume: 14

    Topics: Antineoplastic Agents; Area Under Curve; Benzamides; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mitotic Index; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Piperazines; Prognosis; Proportional Hazards Models; Pyrimidines; Risk Factors; Treatment Outcome

2014
Hepatitis B viral reactivation secondary to imatinib treatment in a patient with gastrointestinal stromal tumor.
    Anticancer research, 2014, Volume: 34, Issue:7

    Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatitis B virus; Humans; Imatinib Mesylate; Liver Failure, Acute; Liver Transplantation; Male; Middle Aged; Piperazines; Pyrimidines; Virus Activation

2014
A ruptured recurrent small bowel gastrointestinal stromal tumour causing hemoperitoneum.
    Frontiers of medicine, 2015, Volume: 9, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Cytoreduction Surgical Procedures; Disease Progression; Dissection; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hemoperitoneum; Humans; Imatinib Mesylate; Intestine, Small; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Postoperative Complications; Pyrimidines; Risk Assessment; Rupture, Spontaneous

2015
Preoperative imatinib facilitates complete resection of locally advanced primary GIST by a less invasive procedure.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Preoperative Period; Pyrimidines; Retrospective Studies; Treatment Outcome

2014
Unexpected DOG-1 immunoreactivity in sarcomatous carcinoma of the liver: a diagnostic pitfall.
    Pathology, 2014, Volume: 46, Issue:6

    Topics: Aged; Anoctamin-1; Antineoplastic Agents; Autopsy; Bile Duct Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Chloride Channels; Diagnosis, Differential; Fatal Outcome; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver; Liver Neoplasms; Male; Neoplasm Proteins; Sarcoma; Tomography, X-Ray Computed; Ultrasonography

2014
A multicenter long-term study of imatinib treatment for Japanese patients with unresectable or recurrent gastrointestinal stromal tumors.
    Journal of surgical oncology, 2014, Volume: 110, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Retrospective Studies

2014
Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
    Anticancer research, 2014, Volume: 34, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Drug Substitution; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Retreatment; Sunitinib; Treatment Outcome; Young Adult

2014
microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome.
    British journal of cancer, 2014, Nov-25, Volume: 111, Issue:11

    Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; MicroRNAs; Mutation; Piperazines; Protein Tyrosine Phosphatases, Non-Receptor; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha

2014
Gastrointestinal stromal tumor: 15-years' experience in a single center.
    BMC surgery, 2014, Nov-18, Volume: 14

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lymphatic Metastasis; Male; Middle Aged; Mitotic Index; Neoplasm Grading; Neoplasm Invasiveness; Piperazines; Proportional Hazards Models; Pyrimidines; Risk Factors; Tumor Burden; Young Adult

2014
Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1

    Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genetic Association Studies; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Proteins; Piperazines; Polymorphism, Single Nucleotide; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Republic of Korea; Retrospective Studies; Survival Analysis

2015
Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour.
    ANZ journal of surgery, 2014, Volume: 84, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines; Retrospective Studies; Survival Analysis; Treatment Outcome

2014
Gastrointestinal stromal tumor of the adrenal gland:a case report and review of the literature.
    Endocrine pathology, 2015, Volume: 26, Issue:1

    Topics: Adrenal Gland Neoplasms; Adult; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Biopsy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Piperazines; Positron-Emission Tomography; Pyrimidines

2015
Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor.
    Clinics (Sao Paulo, Brazil), 2014, Volume: 69, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Preoperative Care; Preoperative Period; Pyrimidines; Reproducibility of Results; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden

2014
Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib: case report.
    Future oncology (London, England), 2014, Volume: 10, Issue:15

    Topics: Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pleural Effusion, Malignant; Pyrimidines; Radiography; Treatment Outcome

2014
Augmentation of multiple protein kinase activities associated with secondary imatinib resistance in gastrointestinal stromal tumors as revealed by quantitative phosphoproteome analysis.
    Journal of proteomics, 2015, Feb-06, Volume: 115

    Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Neoplasm Proteins; Phosphoproteins; Piperazines; Protein Kinases; Proteome; Proteomics; Pyrimidines

2015
[The importance of mutational status in prognosis and therapy of GIST].
    Recenti progressi in medicina, 2015, Volume: 106, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Phenylurea Compounds; Piperazines; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sensitivity and Specificity; Sunitinib

2015
Assessment of early response to imatinib 800 mg after 400 mg progression by ¹⁸F-fluorodeoxyglucose PET in patients with metastatic gastrointestinal stromal tumors.
    Future oncology (London, England), 2015, Volume: 11, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Image Interpretation, Computer-Assisted; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome

2015
Long term experience of patients with unresectable or metastatic KIT positive gastrointestinal stromal tumours.
    Bratislavske lekarske listy, 2015, Volume: 116, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Czech Republic; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Time Factors

2015
[Molecular-genetic methods for diagnostics of tumour growth].
    Klinicheskaia meditsina, 2014, Volume: 92, Issue:7

    Topics: Aged; Antineoplastic Protocols; Benzamides; Biomarkers, Tumor; Digestive System Surgical Procedures; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Genetic Testing; Humans; Imatinib Mesylate; Male; Middle Aged; Molecular Diagnostic Techniques; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Treatment Outcome

2014
Prognostic Relevance of p53 Overexpression in Gastrointestinal Stromal Tumors of the Small Intestine: Potential Implication for Adjuvant Treatment with Imatinib.
    Annals of surgical oncology, 2015, Volume: 22 Suppl 3

    Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Cohort Studies; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Intestinal Neoplasms; Intestine, Small; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Tumor Suppressor Protein p53; Young Adult

2015
Familial and multiple gastrointestinal stromal tumors with fair response to a half-dose of imatinib.
    Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:7

    Topics: Aged; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Exons; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Germ-Line Mutation; Humans; Imatinib Mesylate; Male; Middle Aged; Pedigree; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Siblings

2015
Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
    Cancer research, 2015, May-15, Volume: 75, Issue:10

    Topics: Anilides; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Inhibitory Concentration 50; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Piperazines; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-met; Pyridines; Pyrimidines; Pyrroles; Signal Transduction; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays

2015
[Neoadjuvant therapy of imatinib in gastrointestinal stromal tumors and the timing of surgery].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2015, Volume: 18, Issue:4

    Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy

2015
[Clinical management of advanced gastrointestinal stromal tumors after failure of at least both imatinib and sunitinib targeted therapy].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2015, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Pyrroles; Sunitinib

2015
Survival After Resection of Gastrointestinal Stromal Tumor and Sarcoma Liver Metastases in 146 Patients.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2015, Volume: 19, Issue:8

    Topics: Abdominal Neoplasms; Adolescent; Adult; Aged; Antineoplastic Agents; Child; Child, Preschool; Databases, Factual; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leiomyosarcoma; Liver Neoplasms; Male; Metastasectomy; Middle Aged; Retroperitoneal Neoplasms; Retrospective Studies; Sarcoma; Survival Rate; Young Adult

2015
Imatinib mesylate treatment in a dog with gastrointestinal stromal tumors with a c-kit mutation.
    The Journal of veterinary medical science, 2015, Volume: 77, Issue:11

    Topics: Animals; Antineoplastic Agents; DNA, Complementary; Dog Diseases; Dogs; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation; Imatinib Mesylate; Mutation; Proto-Oncogene Proteins c-kit

2015
A Case of Disseminated Intra-abdominal Gastrointestinal Stromal Tumor Managed with Low Dose Imatinib.
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2015, Volume: 65, Issue:6

    Topics: Aged; Antineoplastic Agents; Exanthema; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Proto-Oncogene Proteins c-kit; Tomography, X-Ray Computed

2015
Treatment and Prognoses in Patients With Primary Gastrointestinal Stromal Tumors ≥10  cm: A Single-Institution Experience in China.
    Medicine, 2015, Volume: 94, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; China; Digestive System Surgical Procedures; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Retrospective Studies

2015
Prognostic factors after imatinib secondary resistance: survival analysis in patients with unresectable and metastatic gastrointestinal stromal tumors.
    International journal of clinical oncology, 2016, Volume: 21, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Retrospective Studies; Survival Analysis; Survival Rate

2016
Gastrointestinal stromal tumour metastatic to the epididymis.
    BMJ case reports, 2015, Sep-23, Volume: 2015

    Topics: Antineoplastic Agents; Epididymis; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genital Neoplasms, Male; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Pyridines; Scrotum; Tomography, X-Ray Computed

2015
Adjuvant imatinib treatment in gastrointestinal stromal tumor: which risk stratification criteria and for how long? A case report.
    Anti-cancer drugs, 2016, Volume: 27, Issue:1

    Topics: Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Risk; Time Factors

2016
Killing two birds with one stone: a case of GIST and supervening CML.
    BMJ case reports, 2015, Oct-14, Volume: 2015

    Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Male; Middle Aged; Neoplasms, Multiple Primary

2015
KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
    Oncotarget, 2016, Jan-12, Volume: 7, Issue:2

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Mice, Nude; Mutation; NF-kappa B; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Signal Transduction; Time Factors; Transfection; Up-Regulation; Xenograft Model Antitumor Assays

2016
Primary surgery as a frontline treatment for synchronous metastatic gastrointestinal stromal tumors: an analysis of the Kinki GIST registry.
    Surgery today, 2016, Volume: 46, Issue:9

    Topics: Aged; Catheter Ablation; Combined Modality Therapy; Digestive System Surgical Procedures; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Japan; Liver Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Protein Kinase Inhibitors; Registries; Retrospective Studies; Survival Rate; Treatment Outcome

2016
Inhibition effect of Peg-IFNα-2b and Imatinib alone or combination on imatinib-resistant gastrointestinal stromal tumors cell lines.
    International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Phosphorylation; Polyethylene Glycols; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Cells, Cultured

2015
Subdural hematoma in a patient taking imatinib for GIST: a case report and discussion of risk with other chemotherapeutics.
    Anti-cancer drugs, 2016, Volume: 27, Issue:3

    Topics: Antineoplastic Agents; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hematoma, Subdural, Intracranial; Humans; Imatinib Mesylate; Middle Aged; Neoadjuvant Therapy; Risk

2016
Adjuvant Imatinib for GI Stromal Tumors: When and For How Long?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, Jan-20, Volume: 34, Issue:3

    Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged

2016
Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors.
    Anti-cancer drugs, 2016, Volume: 27, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Precision Medicine; Protein Kinase Inhibitors; Treatment Outcome

2016
Detecting Secondary C-KIT Mutations in the Peripheral Blood of Patients with Imatinib-Resistant Gastrointestinal Stromal Tumor.
    Oncology, 2016, Volume: 90, Issue:2

    Topics: Antineoplastic Agents; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Proto-Oncogene Proteins c-kit

2016
Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors.
    Oncotarget, 2016, May-24, Volume: 7, Issue:21

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Treatment Outcome; Young Adult

2016
Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 57

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Monitoring; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestine, Small; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Stomach; Treatment Outcome

2016
Clinico-pathological characteristics and prognostic factors of gastrointestinal stromal tumors among a Chinese population.
    International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:12

    Topics: Aged; Antineoplastic Agents; Asian People; Biomarkers, Tumor; Chemotherapy, Adjuvant; China; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Mitotic Index; Multivariate Analysis; Neoplasm, Residual; Predictive Value of Tests; Proportional Hazards Models; Risk Factors; Time Factors; Treatment Outcome; Tumor Burden; Tumor Suppressor Protein p53

2015
RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor.
    Oncotarget, 2016, Mar-22, Volume: 7, Issue:12

    Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptors for Activated C Kinase; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2016
Long-term outcome of molecular subgroups of gastrointestinal stromal tumour patients treated with standard-dose imatinib in the BFR14 trial: The wild-type gastrointestinal stromal tumours are not a single group yet.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 58

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit

2016
Role of surgery in patients with focally progressive gastrointestinal stromal tumors resistant to imatinib.
    Scientific reports, 2016, Mar-07, Volume: 6

    Topics: Adult; Aged; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Survival Analysis; Treatment Outcome

2016
PIK3C2A is a gene-specific target of microRNA-518a-5p in imatinib mesylate-resistant gastrointestinal stromal tumor.
    Laboratory investigation; a journal of technical methods and pathology, 2016, Volume: 96, Issue:6

    Topics: 3' Untranslated Regions; Adult; Aged; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Imatinib Mesylate; Male; MicroRNAs; Middle Aged; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; RNA, Neoplasm

2016
Neoadjuvant imatinib treatment and laparoscopic anus-preserving surgery for a large gastrointestinal stromal tumor of the rectum.
    World journal of surgical oncology, 2016, Mar-08, Volume: 14

    Topics: Anal Canal; Antineoplastic Agents; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Organ Sparing Treatments; Prognosis; Rectal Neoplasms

2016
Effective Downsizing of a Gastroesophageal GIST Using Neoadjuvant Imatinib Mesylate: a Case Report.
    Journal of gastrointestinal cancer, 2017, Volume: 48, Issue:2

    Topics: Antineoplastic Agents; Esophagogastric Junction; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Prognosis

2017
Endoscopic full-thickness resection of esophagogastric junction gastrointestinal stromal tumor assisted by laparoscopy after neoadjuvant therapy.
    Endoscopy, 2016, Volume: 48 Suppl 1

    Topics: Aged, 80 and over; Antineoplastic Agents; Dissection; Endoscopy, Digestive System; Esophagogastric Junction; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Neoadjuvant Therapy; Surgery, Computer-Assisted; Treatment Outcome

2016
Resection of liver metastases in patients with gastrointestinal stromal tumors in the imatinib era: A nationwide retrospective study.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2016, Volume: 42, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Liver Neoplasms; Male; Metastasectomy; Middle Aged; Netherlands; Proportional Hazards Models; Retrospective Studies; Survival Rate

2016
[A case of a gastrointestinal stromal tumor of the rectum effectively treated with continuously-administered regorafenib after failure of imatinib and sunitinib].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2016, Volume: 113, Issue:4

    Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Phenylurea Compounds; Pyridines; Pyrroles; Rectal Neoplasms; Sunitinib

2016
Synchronous Large Gastrointestinal Stromal Tumor and Adenocarcinoma in the Stomach Treated with Imatinib Mesylate Followed by Total Gastrectomy.
    Anticancer research, 2016, Volume: 36, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Combined Modality Therapy; Gastrectomy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Protein Kinase Inhibitors; Radiography

2016
Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
    Oncotarget, 2016, May-24, Volume: 7, Issue:21

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; DNA Mutational Analysis; Drug Resistance, Neoplasm; Exons; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Sequence Analysis, DNA; Tissue Array Analysis

2016
Molecular cytology genotyping of primary and metastatic GI stromal tumors by using a custom two-gene targeted next-generation sequencing panel with therapeutic intent.
    Gastrointestinal endoscopy, 2016, Volume: 84, Issue:6

    Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Cytogenetic Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genotyping Techniques; High-Throughput Nucleotide Sequencing; Histone-Lysine N-Methyltransferase; Humans; Imatinib Mesylate; Neurofibromin 1; Precision Medicine; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Radiology, Interventional; ras Proteins; Receptor, Platelet-Derived Growth Factor alpha; Succinate Dehydrogenase; Tomography, X-Ray Computed

2016
Circulating tumor cells as a prognostic and predictive marker in gastrointestinal stromal tumors: a prospective study.
    Oncotarget, 2016, Jun-14, Volume: 7, Issue:24

    Topics: Anoctamin-1; Antineoplastic Agents; Biomarkers, Tumor; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Prognosis; Prospective Studies

2016
Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib.
    Oncotarget, 2016, Jul-05, Volume: 7, Issue:27

    Topics: Apoptosis; Cell Line, Tumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Inhibitor of Apoptosis Proteins; Molecular Targeted Therapy; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Signal Transduction

2016
Role of metastasectomy for recurrent/metastatic gastrointestinal stromal tumors based on an analysis of the Kinki GIST registry.
    Surgery today, 2017, Volume: 47, Issue:1

    Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Japan; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Registries; Retrospective Studies; Survival Rate; Time Factors

2017
Lichenoid drug eruption caused by imatinib mesylate in a Chinese patient with gastrointestinal stromal tumor.
    International journal of clinical pharmacology and therapeutics, 2016, Volume: 54, Issue:9

    Topics: Aged; Antineoplastic Agents; Asian People; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lichenoid Eruptions; Male

2016
Giant Gastric Gastrointestinal Stromal Tumor (GIST).
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2017, Volume: 21, Issue:1

    Topics: Antineoplastic Agents; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Neoadjuvant Therapy; Tomography, X-Ray Computed

2017
Skin lesions in patients treated with imatinib mesylate: a 5-year prospective study.
    Cutis, 2016, Volume: 97, Issue:6

    Topics: Antineoplastic Agents; Carcinoma, Basal Cell; Dermatitis, Seborrheic; Dermatomycoses; Drug Eruptions; Eczema; Edema; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Histiocytoma, Benign Fibrous; Humans; Imatinib Mesylate; Keratosis, Actinic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nail Diseases; Orbital Diseases; Prospective Studies; Pruritus; Psoriasis; Skin Neoplasms

2016
Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure.
    Clinical pharmacokinetics, 2017, Volume: 56, Issue:3

    Topics: Aged; Antineoplastic Agents; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Orosomucoid; Prospective Studies

2017
Clinicopathologic features and prognosis of primary gastrointestinal stromal tumor patients under 35 years of age: A 10-year retrospective study.
    Journal of surgical oncology, 2016, Volume: 114, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestine, Small; Male; Prognosis; Retrospective Studies; Young Adult

2016
Proteogenomics for the Study of Gastrointestinal Stromal Tumors.
    Advances in experimental medicine and biology, 2016, Volume: 926

    Topics: Antineoplastic Agents; Culture Media, Conditioned; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Protein Kinase Inhibitors; Proteogenomics; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Tumor Cells, Cultured

2016
Detection and Quantification of KIT Mutations in ctDNA by Plasma Safe-SeqS.
    Advances in experimental medicine and biology, 2016, Volume: 924

    Topics: Antineoplastic Agents; DNA Mutational Analysis; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Outcome Assessment, Health Care; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Pyrroles; Reproducibility of Results; Sunitinib

2016
Computed tomography features and predictive findings of ruptured gastrointestinal stromal tumours.
    European radiology, 2017, Volume: 27, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Ascites; Disease Progression; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hematoma; Hemoperitoneum; Humans; Imatinib Mesylate; Indoles; Intestine, Small; Male; Middle Aged; Necrosis; Peritonitis; Pyrroles; Rupture, Spontaneous; Sensitivity and Specificity; Sunitinib; Tomography, X-Ray Computed; Young Adult

2017
A case of multiple gastrointestinal stromal tumors caused by a germline KIT gene mutation (p.Leu576Pro).
    Familial cancer, 2017, Volume: 16, Issue:2

    Topics: Adult; Antineoplastic Agents; Asthenia; Biopsy; DNA Mutational Analysis; Endoscopy, Gastrointestinal; Exons; Female; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Germ-Line Mutation; Humans; Imatinib Mesylate; Interstitial Cells of Cajal; Intestine, Small; Neoadjuvant Therapy; Neoplasms, Multiple Primary; Proto-Oncogene Proteins c-kit; Rare Diseases; Stomach; Tomography, X-Ray Computed; Young Adult

2017
Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
    Oncotarget, 2016, Nov-29, Volume: 7, Issue:48

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Binding Sites; Cell Line, Tumor; Cell Survival; Cilia; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Interstitial Cells of Cajal; Mutation; Nerve Tissue Proteins; Nuclear Proteins; Oxides; Promoter Regions, Genetic; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; RNA Interference; RNA, Messenger; Signal Transduction; Transfection; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2; Zinc Finger Protein Gli3

2016
The Therapeutic Response of Gastrointestinal Stromal Tumors to Imatinib Treatment Assessed by Intravoxel Incoherent Motion Diffusion-Weighted Magnetic Resonance Imaging with Histopathological Correlation.
    PloS one, 2016, Volume: 11, Issue:12

    Topics: Animals; Cell Line, Tumor; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Xenograft Model Antitumor Assays

2016
[Current status of surgical treatment of gastric gastrointestinal tumors: a national multi-center retrospective study].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2016, Nov-25, Volume: 19, Issue:11

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; China; Combined Modality Therapy; Female; Gastrectomy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Laparotomy; Male; Middle Aged; Postoperative Period; Prognosis; Retrospective Studies; Splenectomy; Stomach Neoplasms; Survival Rate; Young Adult

2016
Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate.
    Oncotarget, 2017, Jan-17, Volume: 8, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; RNA, Small Interfering; Tissue Array Analysis

2017
Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors.
    Genes, chromosomes & cancer, 2017, Volume: 56, Issue:4

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; Humans; Imatinib Mesylate; Mutation; Prognosis; Proto-Oncogene Proteins c-kit; Tumor Cells, Cultured

2017
Gain of TP53 Mutation in Imatinib-treated SDH-Deficient Gastrointestinal Stromal Tumor and Clinical Utilization of Targeted Next-generation Sequencing Panel for Therapeutic Decision Support.
    Applied immunohistochemistry & molecular morphology : AIMM, 2018, Volume: 26, Issue:8

    Topics: Adult; Clinical Decision-Making; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Mutation, Missense; Succinate Dehydrogenase; Tumor Suppressor Protein p53

2018
Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.
    Oncotarget, 2017, Feb-07, Volume: 8, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; China; Disease Progression; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome

2017
Familial gastrointestinal stromal tumors, lentigines, and café-au-lait macules associated with germline c-kit mutation treated with imatinib.
    International journal of dermatology, 2017, Volume: 56, Issue:2

    Topics: Adult; Antineoplastic Agents; Cafe-au-Lait Spots; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Germ-Line Mutation; Humans; Imatinib Mesylate; Lentigo; Male; Pedigree; Proto-Oncogene Proteins c-kit

2017
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.
    JAMA oncology, 2017, Jul-01, Volume: 3, Issue:7

    Topics: Aged; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins c-kit; Randomized Controlled Trials as Topic; Receptor, Platelet-Derived Growth Factor alpha; Succinate Dehydrogenase; Survival Rate; Treatment Outcome

2017
Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors.
    American journal of clinical oncology, 2009, Volume: 32, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Embolization, Therapeutic; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatic Artery; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Survival Rate; Treatment Outcome

2009
Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate.
    Cancer, 2010, Jan-01, Volume: 116, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Cells, Cultured; Echocardiography; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Heart Failure; Humans; Imatinib Mesylate; Incidence; Male; Middle Aged; Myocytes, Cardiac; Piperazines; Pyrimidines; Young Adult

2010
Imatinib treatment of metastatic GIST: don't stop (believing).
    The Lancet. Oncology, 2010, Volume: 11, Issue:10

    Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Multicenter Studies as Topic; Neoplasm, Residual; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome

2010
Unusual presentation of gastrointestinal stromal tumor with early cerebral involvement.
    Irish journal of medical science, 2011, Volume: 180, Issue:3

    Topics: Benzamides; Brain Neoplasms; Disease Progression; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tomography, X-Ray Computed

2011
Response to nilotinib as a first-line treatment for metastatic gastrointestinal stromal tumors.
    Journal of gastrointestinal cancer, 2012, Volume: 43, Issue:2

    Topics: Adult; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Peritoneal Neoplasms; Piperazines; Positron-Emission Tomography; Pyrimidines

2012
[The role of pathologists in the target therapy of gastrointestinal tumors].
    Zhonghua bing li xue za zhi = Chinese journal of pathology, 2010, Volume: 39, Issue:7

    Topics: Anoctamin-1; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Chloride Channels; Drug Delivery Systems; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Membrane Proteins; Neoplasm Proteins; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib; Vascular Endothelial Growth Factor A

2010
Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors.
    International journal of clinical oncology, 2011, Volume: 16, Issue:6

    Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Radiography; Sunitinib

2011
Long-term exposure of gastrointestinal stromal tumor cells to sunitinib induces epigenetic silencing of the PTEN gene.
    International journal of cancer, 2012, Feb-15, Volume: 130, Issue:4

    Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Sunitinib

2012
Biliary excretion of imatinib and its active metabolite CGP74588 during severe hepatic dysfunction.
    Journal of clinical pharmacology, 2012, Volume: 52, Issue:7

    Topics: Aged; Antineoplastic Agents; Benzamides; Bile; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Diseases; Male; Piperazines; Pyrimidines; Severity of Illness Index

2012
The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Sep-01, Volume: 17, Issue:17

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Cell Line, Tumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Mice; Mice, Nude; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Stem Cell Factor; Sunitinib; Xenograft Model Antitumor Assays

2011
CT scan is not everything in the evaluation of a patient with gastrointestinal tumors (GIST) under imatinib therapy.
    Pathology oncology research : POR, 2012, Volume: 18, Issue:4

    Topics: Adult; Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Histocytochemistry; Humans; Imatinib Mesylate; Male; Piperazines; Pyrimidines; Tomography, X-Ray Computed

2012
Bone marrow necrosis secondary to imatinib usage, mimicking spinal metastasis on magnetic resonance imaging and FDG-PET/CT.
    Journal of neurosurgery. Spine, 2012, Volume: 16, Issue:1

    Topics: Aged; Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Diseases; Diagnosis, Differential; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Multimodal Imaging; Necrosis; Piperazines; Positron-Emission Tomography; Pyrimidines; Spinal Neoplasms; Tomography, X-Ray Computed

2012
Survivin expression and its potential clinical significance in gastrointestinal stromal sarcoma.
    International immunopharmacology, 2011, Volume: 11, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Inhibitor of Apoptosis Proteins; Male; Middle Aged; Mitosis; Piperazines; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survivin; Treatment Outcome

2011
Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
    Annals of surgical oncology, 2012, Volume: 19, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Risk Factors; Serum Albumin; Sorafenib; Sunitinib; Survival Rate; Young Adult

2012
Characterization of novel germline c-kit gene mutation, KIT-Tyr553Cys, observed in a family with multiple gastrointestinal stromal tumors.
    Laboratory investigation; a journal of technical methods and pathology, 2012, Volume: 92, Issue:3

    Topics: Adult; Aged; Amino Acid Substitution; Animals; Benzamides; Cell Line; Cell Proliferation; DNA Mutational Analysis; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Imatinib Mesylate; Male; Mice; Pedigree; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor Protein-Tyrosine Kinases

2012
[Clinical analysis of 79 gastrointestinal tract stromal tumor cases].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2011, Volume: 33, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines

2011
Renal dysfunction in a renal transplant patient treated concurrently with cyclosporine and imatinib.
    Investigational new drugs, 2012, Volume: 30, Issue:6

    Topics: Aged; Antineoplastic Agents; Benzamides; Cyclosporine; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunosuppressive Agents; Kidney Diseases; Kidney Transplantation; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines

2012
[Curative resection for bulky gastrointestinal stromal tumor with conversion therapy by imatinib].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:12

    Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines

2011
Pediatric gastrointestinal stromal tumor.
    Seminars in pediatric surgery, 2012, Volume: 21, Issue:1

    Topics: Adolescent; Adult; Benzamides; Child; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Young Adult

2012
KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Mar-15, Volume: 18, Issue:6

    Topics: 3T3 Cells; Aged; Animals; Benzamides; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genes, ras; HEK293 Cells; Humans; Imatinib Mesylate; Male; MAP Kinase Signaling System; Mice; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrimidines

2012
Neoadjuvant and adjuvant therapy with imatinib for locally advanced gastrointestinal stromal tumors in eastern Indian patients.
    Asian Pacific journal of cancer prevention : APJCP, 2011, Volume: 12, Issue:8

    Topics: Adult; Aged; Asian People; Benzamides; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Prospective Studies; Pyrimidines; Treatment Outcome

2011
Gastrointestinal stromal tumors: case series of 29 patients defining the role of imatinib prior to surgery.
    World journal of surgery, 2012, Volume: 36, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines

2012
Updates on the management of gastrointestinal stromal tumors.
    Surgical oncology clinics of North America, 2012, Volume: 21, Issue:2

    Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pedigree; Piperazines; Pyrimidines; Radiotherapy, Adjuvant; Receptor, Platelet-Derived Growth Factor alpha; Risk Assessment

2012
Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry.
    BMC cancer, 2012, Mar-19, Volume: 12

    Topics: Adolescent; Adult; Age Factors; Age of Onset; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Child; Child, Preschool; DNA Mutational Analysis; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prognosis; Proportional Hazards Models; Pyrimidines; Retrospective Studies; Sex Factors; Survival Analysis; Young Adult

2012
The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.
    BMC cancer, 2012, Mar-22, Volume: 12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Multivariate Analysis; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Young Adult

2012
Gastrointestinal stromal tumors (GIST): a single center experience.
    Acta chirurgica Belgica, 2012, Volume: 112, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Length of Stay; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies

2012
Optimal duration of adjuvant therapy for patients with resected gastrointestinal stromal tumors.
    JAMA, 2012, Mar-28, Volume: 307, Issue:12

    Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Piperazines; Pyrimidines

2012
Involvement of signaling molecules in the prediction of response to imatinib treatment in metastatic GIST patients.
    The Journal of surgical research, 2012, Volume: 178, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Phosphatidylethanolamine Binding Protein; Piperazines; Predictive Value of Tests; Protein Kinase C; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor Cross-Talk; Receptor, IGF Type 1; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Signal Transduction

2012
Prospective observational study of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors: long-term follow-up and second malignancy.
    Japanese journal of clinical oncology, 2012, Volume: 42, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Second Primary; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Time Factors; Treatment Outcome

2012
Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST).
    BMC cancer, 2012, May-21, Volume: 12

    Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Liver Cirrhosis; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Pyrimidines

2012
Intervention in gastrointestinal stromal tumour with a high risk of malignancy and associated with thalassaemia minor.
    Anti-cancer drugs, 2012, Volume: 23 Suppl

    Topics: Aged; Antineoplastic Agents; Benzamides; beta-Thalassemia; Chemotherapy, Adjuvant; Diagnosis, Differential; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Treatment Outcome; Vitamin B 12; Vitamin B 12 Deficiency

2012
Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors.
    Future oncology (London, England), 2012, Volume: 8, Issue:5

    Topics: Antineoplastic Agents; Asian People; Benzamides; China; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome

2012
Evaluation of malignancy using Ki-67, p53, EGFR and COX-2 expressions in gastrointestinal stromal tumors.
    World journal of gastroenterology, 2012, May-28, Volume: 18, Issue:20

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Cyclooxygenase 2; ErbB Receptors; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Ki-67 Antigen; Male; Middle Aged; Mitotic Index; Neoplasm Grading; Piperazines; Prognosis; Proportional Hazards Models; Pyrimidines; Tumor Suppressor Protein p53

2012
p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors.
    PloS one, 2012, Volume: 7, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; DNA-Binding Proteins; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Heterogeneous-Nuclear Ribonucleoprotein K; Humans; Imatinib Mesylate; Imidazoles; Mutation; Nuclear Proteins; Phosphorylation; Piperazines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-mdm2; Pyrimidines; Sequence Analysis, DNA; Signal Transduction; Transcription Factors; Transcription, Genetic; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins

2012
Tumor rupture exposes the patient to an increased risk of relapse, regardless of the size and number of mitoses.
    Anti-cancer drugs, 2012, Volume: 23 Suppl

    Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intraoperative Complications; Mitotic Index; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Risk; Rupture, Spontaneous

2012
Haemoperitoneum as an indicator of GIST.
    Anti-cancer drugs, 2012, Volume: 23 Suppl

    Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hemoperitoneum; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Pyrimidines; Rupture, Spontaneous; Tomography, X-Ray Computed; Treatment Outcome

2012
Congestive heart failure in a 77-year-old woman receiving adjuvant treatment with imatinib for a large gastric gastrointestinal stromal tumour.
    Anti-cancer drugs, 2012, Volume: 23 Suppl

    Topics: Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Heart Failure; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Rupture; Treatment Outcome

2012
Patient with high-risk GIST not associated with c-KIT mutations: same benefit from adjuvant therapy?
    Anti-cancer drugs, 2012, Volume: 23 Suppl

    Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neurofibromatosis 1; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Risk; Tomography, X-Ray Computed

2012
A rare case of gastrointestinal stromal tumor presenting with closed perforation of the small intestine.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2012, Volume: 23, Issue:3

    Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Perforation; Intestine, Small; Male; Middle Aged; Piperazines; Pyrimidines; Tomography, X-Ray Computed

2012
[Establishment and pathologic analysis of imatinib-resistant gastrointestinal stromal tumor xenografts].
    Zhonghua bing li xue za zhi = Chinese journal of pathology, 2012, Volume: 41, Issue:3

    Topics: Animals; Antineoplastic Agents; Benzamides; Cell Differentiation; Cell Line, Tumor; Desmin; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Myogenin; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Rhabdomyosarcoma; Xenograft Model Antitumor Assays

2012
Length of adjuvant imatinib therapy in GIST: weighing benefits, side effects and costs.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2012, Volume: 18, Issue:3

    Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Costs; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Medication Adherence; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic; Time Factors

2012
Treatment response monitoring in patients with gastrointestinal stromal tumor using diffusion-weighted imaging: preliminary results in comparison with positron emission tomography/computed tomography.
    NMR in biomedicine, 2013, Volume: 26, Issue:2

    Topics: Antineoplastic Agents; Benzamides; Diffusion Magnetic Resonance Imaging; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multimodal Imaging; Pilot Projects; Piperazines; Positron-Emission Tomography; Prognosis; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome

2013
Role of operative therapy in treatment of metastatic gastrointestinal stromal tumors.
    The Journal of surgical research, 2012, Volume: 177, Issue:2

    Topics: Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Minnesota; Neoplasm Metastasis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib

2012
Patterns of extension of gastrointestinal stromal tumors (GIST) treated with imatinib (Gleevec®) by 18F-FDG PET/CT.
    Revista espanola de enfermedades digestivas, 2012, Volume: 104, Issue:7

    Topics: Aged; Antineoplastic Agents; Benzamides; Drug Monitoring; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome

2012
The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use.
    Japanese journal of clinical oncology, 2012, Volume: 42, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Genotype; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Piperazines; Proportional Hazards Models; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult

2012
Imatinib mesylate (Gleevec) induced unilateral optic disc edema.
    Optometry and vision science : official publication of the American Academy of Optometry, 2012, Volume: 89, Issue:10

    Topics: Aged; Antineoplastic Agents; Benzamides; Diagnosis, Differential; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Optic Disk; Papilledema; Piperazines; Protein-Tyrosine Kinases; Pyrimidines

2012
Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management.
    Drugs, 2012, Oct-22, Volume: 72, Issue:15

    Topics: Animals; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease Management; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic

2012
[Responses to treatment and switching tyrosine kinase inhibitors in gastrointestinal stromal tumor(GIST)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:9

    Topics: Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome

2012
Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23 Suppl 7

    Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Management; DNA Mutational Analysis; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Staging; Piperazines; Prognosis; Pyrimidines; Risk Assessment; Treatment Outcome

2012
Inactivation of Patched1 in mice leads to development of gastrointestinal stromal-like tumors that express Pdgfrα but not kit.
    Gastroenterology, 2013, Volume: 144, Issue:1

    Topics: Animals; Benzamides; Cell Transformation, Neoplastic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression; Genotype; Hedgehog Proteins; Humans; Imatinib Mesylate; Integrases; Intestinal Mucosa; Kruppel-Like Transcription Factors; Leiomyosarcoma; Mice; Muramidase; Nerve Tissue Proteins; Patched Receptors; Patched-1 Receptor; Piperazines; Promoter Regions, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptors, Cell Surface; Signal Transduction; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2; Zinc Finger Protein Gli3

2013
Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2013, Volume: 39, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Administration Schedule; Female; Gastrectomy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Netherlands; Piperazines; Pyrimidines; Retrospective Studies; Time Factors; Treatment Outcome

2013
Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy.
    Pharmacological research, 2013, Volume: 68, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease Progression; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Male; Middle Aged; Organic Cation Transport Proteins; Piperazines; Polymorphism, Genetic; Protein Kinase Inhibitors; Pyrimidines; Solute Carrier Family 22 Member 5; Symporters; Young Adult

2013
Tumor volume as an alternative response measurement for imatinib treated GIST patients.
    PloS one, 2012, Volume: 7, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Automation; Benzamides; Cohort Studies; Disease Progression; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imaging, Three-Dimensional; Imatinib Mesylate; Male; Medical Oncology; Middle Aged; Neoplasm Metastasis; Observer Variation; Piperazines; Pyrimidines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome

2012
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Salvage Therapy; Sorafenib; Sunitinib; Treatment Outcome; Young Adult

2013
Evaluation of regorafenib in colorectal cancer and GIST.
    Lancet (London, England), 2013, Jan-26, Volume: 381, Issue:9863

    Topics: Antineoplastic Agents; Benzamides; Colorectal Neoplasms; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sunitinib

2013
Prognostic factors in surgically managed gastrointestinal stromal tumours.
    The Journal of international medical research, 2012, Volume: 40, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Piperazines; Prognosis; Pyrimidines; Retrospective Studies; Young Adult

2012
Clinicopathological study of 113 gastrointestinal stromal tumors.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2013, Volume: 32, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Retrospective Studies

2013
A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Feb-01, Volume: 19, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Indazoles; Mice; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays

2013
ESMO: regorafenib improved PFS for GIST in post-imatinib/sunitinib setting.
    Oncology (Williston Park, N.Y.), 2012, Volume: 26, Issue:11

    Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sunitinib

2012
Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
    Digestion, 2013, Volume: 87, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome

2013
[Targeted treatment of cancers with imatinib mesylate (STI571, Gleevec): results of Asco 2002].
    Bulletin du cancer, 2002, Volume: 89, Issue:6

    Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Florida; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma; Skin Neoplasms

2002
Imatinib provides lasting treatment for patients with advanced GISTs.
    Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:7

    Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Multicenter Studies as Topic; Piperazines; Prognosis; Pyrimidines; Stromal Cells; Survival; Treatment Outcome

2002
Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour.
    The British journal of dermatology, 2002, Volume: 147, Issue:2

    Topics: Benzamides; Colonic Neoplasms; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Omentum; Peritoneal Neoplasms; Piperazines; Protein-Tyrosine Kinases; Psoriasis; Pyrimidines; Splenic Neoplasms

2002
A molecular star in the wars against cancer.
    The New England journal of medicine, 2002, Aug-15, Volume: 347, Issue:7

    Topics: Benzamides; Gastrointestinal Neoplasms; Genes, src; Humans; Imatinib Mesylate; Myeloproliferative Disorders; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta

2002
GIST 1, chemotherapy 0, with a brand new hitter up next.
    Cancer investigation, 2002, Volume: 20, Issue:5-6

    Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leiomyosarcoma; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor Protein-Tyrosine Kinases

2002
Testing for KIT (CD117) in gastrointestinal stromal tumors: another HercepTest?
    Applied immunohistochemistry & molecular morphology : AIMM, 2002, Volume: 10, Issue:3

    Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Immunohistochemistry; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; United States; United States Food and Drug Administration

2002
Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function.
    Anti-cancer drugs, 2002, Volume: 13, Issue:8

    Topics: Aged; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Stromal Cells

2002
U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.
    The oncologist, 2002, Volume: 7, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bone Neoplasms; Cystitis; Diphosphonates; Drug Approval; Gastrointestinal Neoplasms; Hematuria; Hemorrhage; Humans; Ifosfamide; Imatinib Mesylate; Imidazoles; Mesna; Multiple Myeloma; Orphan Drug Production; Piperazines; Protective Agents; Pyrimidines; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Zoledronic Acid

2002
[A patient with diffuse peritoneal metastases of GIST who was administered STI571].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:12

    Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Intestinal Neoplasms; Middle Aged; Peritoneal Neoplasms; Piperazines; Pyrimidines

2002
Complete remission of a metastatic gastrointestinal stromal tumour with the tyrosine kinase inhibitor imatinib (STI 571): effect of low dosage in an advanced tumour with exon 11 mutation.
    European journal of gastroenterology & hepatology, 2003, Volume: 15, Issue:3

    Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Mesenchymoma; Middle Aged; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction

2003
[Gastrointestinal stromal tumors: open problems].
    Il Giornale di chirurgia, 2002, Volume: 23, Issue:10

    Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Mutation; Neoplasms, Connective Tissue; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Terminology as Topic

2002
An FDG positron emission tomographic study in a case of gastrointestinal stromal tumor.
    Clinical nuclear medicine, 2003, Volume: 28, Issue:4

    Topics: Appendiceal Neoplasms; Benzamides; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Jejunal Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Radionuclide Imaging; Radiopharmaceuticals; Treatment Outcome

2003
Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT.
    Cancer chemotherapy and pharmacology, 2003, Volume: 51, Issue:3

    Topics: Adult; Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Frameshift Mutation; Gastrointestinal Neoplasms; Gene Expression Regulation; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Stromal Cells

2003
Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors.
    International journal of cancer, 2003, May-20, Volume: 105, Issue:1

    Topics: Animals; Antineoplastic Agents; Benzamides; Cell Division; Cell Line; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Imatinib Mesylate; Immunoblotting; MAP Kinase Signaling System; Mice; Mice, Nude; Mutation; Phosphorylation; Piperazines; Precipitin Tests; Proto-Oncogene Proteins c-kit; Pyrimidines; Time Factors; Transfection

2003
Mycosis fungoides-like reaction in a patient treated with Gleevec.
    Journal of cutaneous pathology, 2003, Volume: 30, Issue:4

    Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Middle Aged; Mycosis Fungoides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Skin; Stromal Cells

2003
Images in pathology. Morphologic features of response to Gleevec (Imatinib) treatment of GIST.
    International journal of surgical pathology, 2003, Volume: 11, Issue:2

    Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Piperazines; Pyrimidines

2003
A successful case of oral molecularly targeted therapy with imatinib for peritoneal metastasis of a gastrointestinal stromal tumor.
    International journal of clinical oncology, 2003, Volume: 8, Issue:3

    Topics: Administration, Oral; Benzamides; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Immunohistochemistry; Magnetic Resonance Imaging; Middle Aged; Neoplasm Staging; Peritoneal Neoplasms; Piperazines; Pyrimidines; Risk Assessment; Stromal Cells; Treatment Outcome

2003
[A case of primary small intestinal gastrointestinal stromal tumor: an intraperitoneal bleeding from greater omentum metastasis caused by administration of imatinib mesylate].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2003, Volume: 100, Issue:7

    Topics: Aged; Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Hemorrhage; Humans; Imatinib Mesylate; Intestine, Small; Male; Omentum; Peritoneal Diseases; Peritoneal Neoplasms; Piperazines; Pyrimidines; Stromal Cells

2003
F-18 FDG PET imaging in gastrointestinal stromal tumor.
    Clinical nuclear medicine, 2003, Volume: 28, Issue:8

    Topics: Antineoplastic Agents; Benzamides; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Liver Neoplasms; Piperazines; Pyrimidines; Radiopharmaceuticals; Stromal Cells; Tomography, Emission-Computed; Whole-Body Counting

2003
Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors.
    Molecular cancer therapeutics, 2003, Volume: 2, Issue:8

    Topics: Antineoplastic Agents; Benzamides; Biopsy, Needle; Cell Line; Down-Regulation; Gastrointestinal Neoplasms; Gene Expression Regulation; Gene Targeting; Genetic Markers; Imatinib Mesylate; Muscle Proteins; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; SKP Cullin F-Box Protein Ligases; Stromal Cells

2003
Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.
    Gastroenterology, 2003, Volume: 125, Issue:3

    Topics: Amino Acid Substitution; Benzamides; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Mutation; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha

2003
OncoloGIST, BioloGIST, RadioloGIST: the big impact on the field of oncology of a molecularly-targeted therapy designed to treat a rare disease.
    European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:14

    Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Medical Oncology; Molecular Biology; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines

2003
[FDG-PET and CT in gastrointestinal stromal tumor treated with imatinib].
    Ugeskrift for laeger, 2003, Sep-08, Volume: 165, Issue:37

    Topics: Antineoplastic Agents; Benzamides; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Pyrimidines; Radiopharmaceuticals; Stromal Cells; Tomography, Emission-Computed; Tomography, X-Ray Computed

2003
Imatinib administration in two patients with liver metastases from GIST and severe jaundice.
    British journal of cancer, 2003, Oct-20, Volume: 89, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Jaundice; Liver Neoplasms; Male; Piperazines; Pyrimidines; Stromal Cells; Treatment Outcome

2003
Treatment with STI571, a tyrosine kinase inhibitor, for gastrointestinal stromal tumor with peritoneal dissemination and multiple liver metastases.
    Journal of gastroenterology, 2003, Volume: 38, Issue:9

    Topics: Adult; Benzamides; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Neoplasm Invasiveness; Neoplasms, Connective Tissue; Peritoneum; Piperazines; Protein-Tyrosine Kinases; Pyrimidines

2003
Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era.
    Surgery, 2003, Volume: 134, Issue:4

    Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Mitosis; Mortality; Necrosis; Neoplasm Recurrence, Local; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Retrospective Studies; Staining and Labeling; Stromal Cells; Tomography, X-Ray Computed

2003
[Several patients with a metastasised gastrointestinal stroma-cell tumor for whom the tide turned by the introduction of imatinib].
    Nederlands tijdschrift voor geneeskunde, 2003, Oct-18, Volume: 147, Issue:42

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Stromal Cells; Treatment Outcome

2003
[New oncological treatment principle with imatinib].
    Nederlands tijdschrift voor geneeskunde, 2003, Oct-18, Volume: 147, Issue:42

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dermatofibrosarcoma; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms; Stromal Cells; Treatment Outcome

2003
Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?
    American journal of surgery, 2003, Volume: 186, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiography; Retrospective Studies

2003
The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c-Kit positive gastrointestinal stromal tumors (GIST).
    Neoplasma, 2003, Volume: 50, Issue:6

    Topics: Adult; Aged; Benzamides; Combined Modality Therapy; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Hepatectomy; Humans; Imatinib Mesylate; Intestinal Neoplasms; Liver Neoplasms; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Reoperation; Retrospective Studies; Stomach Neoplasms; Time Factors; Tomography, X-Ray Computed

2003
Isolated abdominal wound metastasis from a gastrointestinal stromal tumor.
    International journal of gastrointestinal cancer, 2003, Volume: 33, Issue:2-3

    Topics: Abdominal Wall; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Digestive System Surgical Procedures; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Laparoscopy; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Postoperative Complications; Pyrimidines; Stromal Cells; Surgical Wound Dehiscence

2003
Advanced gastrointestinal stromal tumors successfully treated with imatinib mesylate: a report of two cases.
    Journal of the National Medical Association, 2003, Volume: 95, Issue:12

    Topics: Aged; Antineoplastic Agents; Benzamides; Black People; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Stromal Cells

2003
Molecular response of gastrointestinal stromal tumour after treatment with tyrosine kinase inhibitor imatinib mesylate.
    Journal of clinical pathology, 2004, Volume: 57, Issue:2

    Topics: Adult; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Neoplasm Metastasis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Stromal Cells; Treatment Outcome

2004
Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma.
    The British journal of surgery, 2004, Volume: 91, Issue:2

    Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Immunoassay; Piperazines; Platelet Count; Prospective Studies; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Vascular Endothelial Growth Factor A

2004
Gastrointestinal stromal tumours (Br J Surg 2003; 90: 1178-1186).
    The British journal of surgery, 2004, Volume: 91, Issue:2

    Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Mitoxantrone; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Stromal Cells

2004
Metastatic gastrointestinal stromal tumor with an exon 11 c-kit mutation responding to the tyrosine kinase inhibitor imatinib.
    Digestive surgery, 2004, Volume: 21, Issue:1

    Topics: Benzamides; Exons; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Immunohistochemistry; Middle Aged; Mutation; Neoplasm Invasiveness; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Stromal Cells

2004
Downstaging of an advanced gastrointestinal stromal tumor by neoadjuvant imatinib.
    Digestive surgery, 2004, Volume: 21, Issue:1

    Topics: Adult; Benzamides; Cholera Toxin; Combined Modality Therapy; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Radiography; Remission Induction; Stromal Cells

2004
Neo-adjuvant STI571 therapy for high-risk gastrointestinal stromal tumour.
    ANZ journal of surgery, 2004, Volume: 74, Issue:4

    Topics: Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Neoplasms, Connective Tissue; Piperazines; Pyrimidines

2004
[Gastrointestinal stromal tumor].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:3

    Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Mutation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha

2004
Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation.
    British journal of cancer, 2004, Jun-01, Volume: 90, Issue:11

    Topics: Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Stromal Cells

2004
A pilot study of imatinib mesylate (STI571) on gastrointestinal stromal tumors in Japanese patients.
    Journal of gastroenterology, 2004, Volume: 39, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Japan; Male; Middle Aged; Pilot Projects; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Stromal Cells; Treatment Outcome

2004
Imatinib in patients with metastatic gastrointestinal stromal tumours relapsing after hepatic transplantation.
    European journal of cancer (Oxford, England : 1990), 2004, Volume: 40, Issue:9

    Topics: Antineoplastic Agents; Benzamides; Connective Tissue Diseases; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Immunosuppressive Agents; Liver Transplantation; Neoplasm Recurrence, Local; Piperazines; Pyrimidines

2004
Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor.
    Anti-cancer drugs, 2004, Volume: 15, Issue:6

    Topics: Benzamides; Biopsy; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Follow-Up Studies; Gastrectomy; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Intestinal Polyps; Israel; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Piperazines; Postoperative Period; Pyrimidines; Remission Induction; Splenectomy; Stromal Cells; Tomography, Spiral Computed; Treatment Outcome

2004
Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jun-15, Volume: 10, Issue:12 Pt 1

    Topics: Benzamides; Blotting, Western; Gastrointestinal Neoplasms; Gene Expression Regulation; Humans; Imatinib Mesylate; Immunohistochemistry; Isoenzymes; Mesoderm; Neoplasms; Oligonucleotide Array Sequence Analysis; Piperazines; Protein Isoforms; Protein Kinase C; Protein Kinase C-theta; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Sarcoma; Stromal Cells; T-Lymphocytes; Transcription, Genetic

2004
Different inhibitory effect of imatinib on phosphorylation of mitogen-activated protein kinase and Akt and on proliferation in cells expressing different types of mutant platelet-derived growth factor receptor-alpha.
    International journal of cancer, 2004, Sep-01, Volume: 111, Issue:3

    Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Benzamides; Cell Division; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Kinetics; Mice; Mitogen-Activated Protein Kinases; Models, Animal; Phosphorylation; Piperazines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Recombinant Proteins; Stromal Cells; Time Factors

2004
KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications.
    The American journal of surgical pathology, 2004, Volume: 28, Issue:7

    Topics: Adult; Aged; Benzamides; Chromosomes, Human, 13-15; DNA Mutational Analysis; Epithelial Cells; Exons; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Immunoblotting; Immunohistochemistry; Karyotyping; Male; Middle Aged; Monosomy; Mutation, Missense; Oncogene Proteins; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Stromal Cells

2004
Other malignant neoplasms in patients with gastrointestinal stromal tumors (GIST).
    Medical science monitor : international medical journal of experimental and clinical research, 2004, Volume: 10, Issue:8

    Topics: Adult; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasms; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines

2004
Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects.
    The Journal of clinical investigation, 2004, Volume: 114, Issue:3

    Topics: Animals; Antineoplastic Agents; Benzamides; Case-Control Studies; Coculture Techniques; Dendritic Cells; Enzyme Inhibitors; Female; Gastrointestinal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Interferon-gamma; Killer Cells, Natural; Leukocytes, Mononuclear; Longitudinal Studies; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, SCID; Mutation; Neutrophil Activation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Stromal Cells

2004
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.
    Cancer research, 2004, Sep-01, Volume: 64, Issue:17

    Topics: Alleles; Antineoplastic Agents; Base Sequence; Benzamides; Clinical Trials, Phase III as Topic; Disease Progression; Drug Resistance, Neoplasm; Exons; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Mutation, Missense; Piperazines; Protein Structure, Tertiary; Proto-Oncogene Proteins c-kit; Pyrimidines; Randomized Controlled Trials as Topic; Stromal Cells

2004
[Target-oriented tumor therapy -- proof of the principle].
    Deutsche medizinische Wochenschrift (1946), 2004, Oct-01, Volume: 129, Issue:40

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Drug Delivery Systems; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Pyrimidines

2004
KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumors.
    The Journal of molecular diagnostics : JMD, 2004, Volume: 6, Issue:4

    Topics: Amino Acid Sequence; Base Sequence; Benzamides; Binding Sites; Chromatography, High Pressure Liquid; DNA; DNA, Complementary; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Deletion; Homozygote; Humans; Imatinib Mesylate; Introns; Molecular Sequence Data; Mutation; Piperazines; Polymerase Chain Reaction; Prognosis; Protein Isoforms; Proto-Oncogene Proteins c-kit; Pyrimidines; Sequence Analysis, DNA; Treatment Outcome

2004
[Two cases of postoperative recurrence of gastric GIST treated by imatinib].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:10

    Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Drug Administration Schedule; Female; Gastrectomy; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leiomyosarcoma; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Stomach Neoplasms; Thyroid Neoplasms

2004
Targeted therapy with imatinib: hits and misses?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jan-01, Volume: 23, Issue:1

    Topics: Benzamides; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines

2005
Giant malignant gastrointestinal stromal tumors: recurrence and effects of treatment with STI-571.
    World journal of gastroenterology, 2005, Jan-14, Volume: 11, Issue:2

    Topics: Adult; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Retrospective Studies; Stromal Cells; Survival Analysis; Time Factors

2005
Clinical benefit of intermittent administration of imatinib in a patient with metastatic gastrointestinal stromal tumour.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2005, Volume: 17, Issue:2

    Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Liver Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines

2005
Multidrug resistance proteins in gastrointestinal stromal tumors: site-dependent expression and initial response to imatinib.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Nov-01, Volume: 11, Issue:21

    Topics: Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Blotting, Western; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gastrointestinal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunohistochemistry; Leiomyosarcoma; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Risk

2005
Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.
    Journal of surgical oncology, 2006, Mar-15, Volume: 93, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Piperazines; Prognosis; Pyrimidines; Remission Induction

2006
STI571 (Glivec) suppresses the expression of vascular endothelial growth factor in the gastrointestinal stromal tumor cell line, GIST-T1.
    World journal of gastroenterology, 2006, Feb-07, Volume: 12, Issue:5

    Topics: Antineoplastic Agents; Base Sequence; Benzamides; Cell Line, Tumor; Cell Survival; DNA; Gastrointestinal Neoplasms; Gene Expression; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imatinib Mesylate; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Vascular Endothelial Growth Factor A

2006
Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour.
    Oncology reports, 2006, Volume: 16, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Biopsy; Drug Resistance, Neoplasm; Exons; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Sequence Analysis, DNA; Stromal Cells

2006
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib.
    Clinical pharmacology and therapeutics, 2006, Volume: 80, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Alleles; ATP-Binding Cassette Transporters; Benzamides; Biological Transport, Active; Carrier Proteins; Cell Line, Tumor; Cohort Studies; Cytochrome P-450 Enzyme System; Female; Gastrointestinal Neoplasms; Gene Frequency; Genotype; Humans; Imatinib Mesylate; Isoenzymes; Male; Middle Aged; Pharmaceutical Preparations; Phenotype; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Stromal Cells

2006
Treatment of advanced gastrointestinal stromal tumor: a marriage of targeted therapy and surgery?
    Annals of surgical oncology, 2007, Volume: 14, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Protein-Tyrosine Kinases; Pyrimidines

2007
Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response.
    Japanese journal of clinical oncology, 2006, Volume: 36, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prospective Studies; Pyrimidines; Treatment Outcome

2006
Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
    Annals of surgical oncology, 2007, Volume: 14, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome

2007
Outcome of metastatic GIST in the era before tyrosine kinase inhibitors.
    Annals of surgical oncology, 2007, Volume: 14, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Survival Rate

2007
Central nervous system metastases from imatinib mesylate resistant gastrointestinal stromal tumor.
    Journal of neuro-oncology, 2007, Volume: 82, Issue:2

    Topics: Antineoplastic Agents; Benzamides; Brain Neoplasms; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Middle Aged; Piperazines; Pyrimidines

2007
Somatostatin analogues, a series of tissue transglutaminase inducers, as a new tool for therapy of mesenchimal tumors of the gastrointestinal tract.
    Amino acids, 2007, Volume: 32, Issue:3

    Topics: Adult; Aged; Benzamides; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Induction; Female; Gastrointestinal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leiomyoma; Leiomyosarcoma; Male; Mesoderm; Middle Aged; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Somatostatin; Somatostatin; Transglutaminases

2007
[Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
    Zhonghua yi xue za zhi, 2006, Nov-21, Volume: 86, Issue:43

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Premedication; Preoperative Care; Pyrimidines; Retrospective Studies

2006
Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - implications for treatment with imatinib mesylate.
    Journal of cutaneous pathology, 2007, Volume: 34, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Carcinoma, Merkel Cell; Child; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Mutation; Piperazines; Polymerase Chain Reaction; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines

2007
Metastatic gastrointestinal stromal tumor with long-term response after treatment with concomitant radiotherapy and imatinib mesylate.
    Anti-cancer drugs, 2007, Volume: 18, Issue:8

    Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Piperazines; Pyrimidines; Tomography, X-Ray Computed

2007
Current management of GIST.
    Clinical advances in hematology & oncology : H&O, 2004, Volume: 2, Issue:5

    Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease Management; Drug Delivery Systems; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor

2004
Successful resection of a giant recurrent gastrointestinal stromal tumour with imatinib mesylate as neoadjuvant therapy.
    Scandinavian journal of gastroenterology, 2007, Volume: 42, Issue:9

    Topics: Adult; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Piperazines; Pyrimidines

2007
[Chemotherapy and target-therapy of gastrointestinal tumors call for development of pathology].
    Zhonghua bing li xue za zhi = Chinese journal of pathology, 2007, Volume: 36, Issue:7

    Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; ErbB Receptors; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Staging; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A

2007
Locally advanced GISTs need aggressive therapy pending the results of trials.
    Annals of surgical oncology, 2008, Volume: 15, Issue:5

    Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Piperazines; Pyrimidines

2008
Researchers optimistic about sea change in cancer treatment.
    JAMA, 2001, Jun-13, Volume: 285, Issue:22

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Medical Oncology; Neoplasms; Piperazines; Pyrimidines; Receptor Protein-Tyrosine Kinases

2001
Gleevec (STI-571) for chronic myeloid leukemia.
    The Medical letter on drugs and therapeutics, 2001, Jun-11, Volume: 43, Issue:1106

    Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fees, Pharmaceutical; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines

2001
Gastrointestinal stromal tumor workshop.
    Human pathology, 2001, Volume: 32, Issue:6

    Topics: Benzamides; Cytogenetic Analysis; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Piperazines; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Stromal Cells

2001
Cancer treatment. New drugs, new hope.
    Harvard health letter, 2001, Volume: 26, Issue:9

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Sarcoma

2001
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.
    Oncogene, 2001, Aug-16, Volume: 20, Issue:36

    Topics: Apoptosis; Benzamides; Cell Division; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Mutation; Oncogene Proteins; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Stromal Cells; Tumor Cells, Cultured

2001
Cancer treatment in the STI571 era: what will change?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Sep-15, Volume: 19, Issue:18 Suppl

    Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Evidence-Based Medicine; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Patient Selection; Piperazines; Pyrimidines; Stromal Cells

2001
[New target-aimed molecular cancer treatment of chronic myeloid leukemia and gastrointestinal stromal tumor].
    Ugeskrift for laeger, 2001, Aug-27, Volume: 163, Issue:35

    Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines

2001
[STI571: the resistance organizes!].
    Bulletin du cancer, 2001, Volume: 88, Issue:9

    Topics: Antineoplastic Agents; Benzamides; Drug Design; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gastrointestinal Neoplasms; Gene Amplification; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines; Recurrence

2001
Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours.
    Annals of medicine, 2001, Volume: 33, Issue:7

    Topics: Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Sensitivity and Specificity; Treatment Outcome

2001
Challenges in oncology. Case 4. Response of metastatic gastrointestinal stromal tumor including CNS involvement to imatinib mesylate (STI-571).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Feb-01, Volume: 20, Issue:3

    Topics: Aged; Antineoplastic Agents; Benzamides; Brain Neoplasms; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Piperazines; Pyrimidines

2002
[The tyrosine kinase antagonist imatinib mesylate].
    Medizinische Monatsschrift fur Pharmazeuten, 2002, Volume: 25, Issue:1

    Topics: Animals; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia; Piperazines; Protein-Tyrosine Kinases; Pyrimidines

2002
Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec).
    Medizinische Klinik (Munich, Germany : 1983), 2002, Jan-15, Volume: 97 Suppl 1

    Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma; Stromal Cells; Treatment Outcome

2002
From the Food and Drug Administration.
    JAMA, 2002, Mar-06, Volume: 287, Issue:9

    Topics: Adult; Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Second-Generation; Antineoplastic Agents; Arthritis, Psoriatic; Benzamides; Chemical and Drug Induced Liver Injury; Cyclohexanones; Enzyme Inhibitors; Etanercept; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Immunoglobulin G; Infant; Liver Failure; Nitrobenzoates; Orphan Drug Production; Piperazines; Pyrimidines; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Triazoles; Tyrosinemias; United States; United States Food and Drug Administration

2002
Systemic therapy for advanced soft-tissue sarcomas.
    Current oncology reports, 2002, Volume: 4, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Doxorubicin; Gastrointestinal Neoplasms; Humans; Ifosfamide; Imatinib Mesylate; Piperazines; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Survival Rate

2002
Clinical management of gastrointestinal stromal tumors: before and after STI-571.
    Human pathology, 2002, Volume: 33, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma; Stromal Cells; Survival Analysis; Survival Rate

2002